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Chapter 1 
Introduction and aim of this thesis 
In recent years the disease entity of COPD has become accepted widely. One of the 
major steps forward has been the publication by the American and the European 
Societies of their statements on the diagnosis and management of COPD in 1995 
(1,2). This was accompanied orfollowed by national standards (eg, British Thoracic 
Society) and recommendations or guidelines for specific groups of health-care 
workers, for instance the family doctors 'NHG-standaard COPD: behandeling' (3). 
Although differences exist with regard to the management of patients with COPD, 
the definitions of COPD have become quite uniform. Initially, COPD was 
considered as composed of two diseases, which often occurred concomitantly: 
chronic bronchitis and emphysema. Chronic bronchitis is defined as "the presence 
of chronic or recurrent increases in bronchial secretions sufficient to cause 
expectoration. The secretions are present on most days for a minimum of 3 months 
a year, for at least two successive years and cannot be attributed to other pulmonary 
or cardiac causes". Emphysema is defined not by clinical characteristics, but 
anatomically by "a permanent, destructive enlargement of airspaces distal to the 
terminal bronchioles, without obvious fibrosis". Nowadays, a more comprehensive 
definition has gained popularity: COPD is defined as "a disorder characterized by 
reduced expiratory flow and slow forced emptying of the lungs, which does not 
change markedly in time". This defmition also reminds of the classical work of 
Fletcher and Peto, who found that FEV! gradually falls over lifetime and clinically 
significant airflow obstruction occurs in a small group of susceptible smokers (4,5). 
In daily practice, for establishing the diagnosis of COPD, the physician combines 
the results from the patient's history, physical examination, chest X-ray and lung 
function data. If necessary, additional investigations, such as allergy tests and high 
resolution computed tomography (HRCT) scan are completed. Still, it may be 
difficult in some cases to differentiate COPD from asthma. This is particularly true 
for older patients with more or less stable expiratory flow limitation and significant 
increases of their FEV! after inhalation of a beta-adrenergic or an anticholinergic 
drug. Terms like "chronic asthma", "chronic asthmatic bronchitis" and "asthma 
with persistent airflow limitation" have been applied for categorizing these patients. 
A popular way of clarifYing the interface of asthma and chronic 
bronchitis/emphysema is a picture with three overlapping circles. Nowadays, there 
is a tendency to depict the relation of asthma and COPD as a flat ellipse with on the 
one side COPD and on the other asthma. On the one side there is "classical COPD" 
interpreted as a disease with airflow limitation that is (in a stable state) impossible 
to be influenced by any kind of intervention, and on the other side, asthma is 
depicted as a disorder with (fully) reversible airways obstruction. 
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In this introduction three items are discussed which are important for the 
intervention study that we will describe in this thesis: COPD and bronchial 
hyperresponsiveness, inflammation in COPD, and glucocorticoid therapy in COPD. 
COPD and bronchial hyperresponsiveness 
Excessive airways narrowing by allergens, pharmacological agents and physical 
stimuli is most extensively investigated in asthma. Those patients who have 
experienced this phenomenon tend to avoid these stimuli, of which cigarette smoke 
is the most notorious. Not only subjects with asthma but also COPD patients, even 
those who have been categorized as emphysematous, have this health problem. 
Provocative airway narrowing by means of inhalation of a variety of substances has 
been applied extensively, both for purposes of research and patient care. In 1921, 
Alexander and Paddock noted that subcutaneous injections of pilocarpine produced 
asthmatic attacks in patients with asthma (6). In 1946, Curry presented a study in 
which the effects of histamine on vital capacity were recorded after nebulization 
(7). In nine patients with 'bronchitis, emphysema and asthma' bronchoconstriction 
was noticed, while there was no effect on vital capacity in normal subjects and in 
patients with a history of allergy. Responses to inhaled pharmacological stimuli like 
histamine and methacholine appeared to be highly reproducible (8). 
Later on, the FEV, was accepted as the standard outcome measure. PC20 is the 
provocative concentration that causes a 20% fall of the FEV" and a PC20 below or 
at a concentration of 8 mg/ml histamine or methacholine in a two-minute 
provocation test is considered abnormal: bronchial hyperresponsiveness (BHR) (9, 
10). The establishment of a low PC20 is considered to be a confirmation of the 
diagnosis of asthma. From epidemiologic studies it appears that the positive and 
negative predictive values of the PC20 in the absence of respiratory symptoms are 
low (11, 12). A PC20 below 2 mg/ml is a strong predictor for the diagnosis of 
asthma, but was also present in "chronic bronchitis" and "respiratory 
symptoms"(II). 
The highest chance of finding BHR was in patients with upper or lower respiratory 
tract symptoms (12-14). BHR was found in approximately 20% of apparently 
normal (non-asthmatic) children (IS). 
Orie and co-workers proposed in 1961 that BHR is a genetically determined risk 
factor for the development of COPD (16). This 'Dutch hypothesis' has been a 
subject of debate for many years (17). 
There is some evidence that BHR is related to smoking (18-20). However, this 
relationship is complex (20-22). 
With regard to COPD it was estimated in one study that approximately half of the 
subjects with COPD in a general population have BHR (23). In the Lung Health Study, 
BHR was noted in 85.1 % of the women and 58.9% of the men with mild to moderate 
airflow limitation and cigarette smoking (21). Clinical studies suggest that BHR in 
COPD differs from BHR in asthma (24-26). In COPD patients with 
hyperresponsiveness for pharmacological agents (e.g. histamine), bronchoconstriction 
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could usually not be provocated by physiologic stimuli (eg, cold air), whereas in 
asthma both types of stimuli cause bronchoconstriction (25). Increased diurnal 
variation of peak expiratory flow is related to BRR in patients with asthma, but this 
relation is less clear in patients with chronic bronchitis and airflow obstruction (27). 
Contrary to patients with asthma, smokers with mild airflow limitation are 
significantly less responsive to methacholine than to equimolar doses of histamine 
(28). Usually the degree of BRR, with respect to both PC20 and maximal 
bronchoconstriction, is less in chronic bronchitis as compared to asthma (28,29). 
In COPD, contrary to mild asthma, there is a relationship between baseline FEV, 
and the level of PC20 (13,23,24,26,30-33). In accordance with this, the change of 
PCzo in smokers over a period offour years was related to the change of FE V, (32). 
The presence of obstructed airways leading to a low FEV, makes a provocative fall 
in FEV, more likely to occur (34). This provides a mathematical problem. This has 
not yet been investigated in detail. 
The explanation for the differences between asthma and COPD with regard to BHR 
might be found in the different pathologic changes in the airways and in the lung 
parenchyma of asthma and COPD patients (35). This subject will be discussed in 
more detail in the next paragraph. The main and most clear functional difference is 
based on the destruction of lung parenchyma in COPD, leading to emphysema and 
loss of lung elasticity (36). Decrease of parenchymal elastic recoil pressure is one of 
the mechanisms leading to enhanced bronchoconstriction (table I) (37,38). In one 
study, in patients with ex -I-antitrypsine deficiency, it was demonstrated that elastic 
recoil indeed influenced maximal airways narrowing (39). 
Otherwise, it is possible that the presence of BHR in COPD is a reflection of a 
different inflammatory infiltrate. In asthma, BHR has been associated with 
eosinophil cell infiltrates of bronchial walls (41, 42). Patients with COPD and BHR 
could have eosinophilic airways inflammation and therefore constitute "hidden 
asthmatics". Studies concerning the inflammatory characteristics ofBRR in patients 
with COPD will be discussed in the next paragraph. 
In a general population, smoking in combination with respiratory symptoms 
constitutes a worse prognosis (43,44). Several epidemiologic studies have shown 
that patients with COPD and BRR (particularly those who continue smoking) are 
prone to an even more accelerated decline of their FEV, as compared to those 
without (45-51). This could indicate a more severe or a different inflammatory 
infiltrate andlor higher levels of markers of inflammation. 
The presence of BHR in patients with COPD predicts a worse prognosis, especially 
if these patients continue smoking. Cessation of smoking is important as an attempt 
to improve the prognosis in COPD, but also for reducing symptoms and reducing 
the other risks of health associated with smoking. However, whether BRR in COPD 
can be influenced by either smoking cessation or therapy, and thereby improve the 
prognosis, is uncertain. In parallel with the findings in asthma it is tempting to 
speculate that anti-inflammatory therapy can modulate BRR and subsequently 
improve life expectancy of patients with COPD. The need for intervention studies 
10 
addressing this idea was proposed for instance by O'Connor et aL (48) .. Data from 
earlier intervention studies concerning BHR in COPD will be discussed later on. 
Table 1. 
Mechanisms that are potentially involved in bronchial hyperresponsiveness 
(adapted from 38 and 40): 
A: amplified stimulation by bronchoconstrictor stimuli, "pre-synaptic mechanisms", 
leading to a leftward shift of the dose-response curve: 
1. defects of epithelium: malfunction, epithelial shedding, open tight junctions 
2. inflanunation: increased number of cells, increased cell cytokine/mediator 
release 
3. neural control: cholinergic activity, excitatory nonadrenergic noncholi-
nergic 
4. reduced breakdown or removal of stimuli 
B: amplified bronchoconstrictor response, "post-synaptic mechanisms", leading to 
an increased plateau value of the dose-response curve: 
I. increased smooth muscle contractility and/or hyperplasia! hypertrophy 
2. swelling of the submucosal and/or adventitial layer 
3. increased collagen in the subepithelial reticular layer 
4. reduced mucosal folding 
5. intraluminal exudates and secretion 
6. decreased parenchymal elastic recoil pressure (reduced alveolar attach-
ments) 
7. uncoupling of forces of interdependence between parenchyma and airway 
wall 
Inflammation in COPD 
Initially it was believed that obstuction of the small airways by mucus caused a 
mechanical damage to the alveoli resulting in enlarged airspaces (52). Mucus 
hypersecretion is related to both an increased number of glands in the bronchial 
wall and in the epithelial layer, and to an increased secretory activity. Additionally, 
the composition of mucus is abnormal (53). Mechanisms involved in mucus 
hypersecretion are autonomic nervous system imbalance, local inflanunation and 
exogenous stimuli from cigarette smoke. 
Cigarette smoking is by far the most important factor in the pathogenesis of COPD 
(4,5,54,55). Smoking induces many changes of inflanunatory cell number and 
function (56-62). Smokers with airflow obstruction have higher numbers of cells in 
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their BAL fluid as compared to smokers without airflow obstruction (63). 
Interestingly, there are several studies, which were unable to demonstrate 
significant differences with regard to inflammation between patients with COPD 
who continue smoking and patients with COPD who stopped smoking (64-66). 
Figure 1. Biopsy from one of the patients with COPD and BHR described in tbis thesis. 
Epithelium is intact at the top of the specimen. In the submucosal layer, at the right, mucous 
secreting glands are visible. Preparation of the biopsy specimen is described in Chapter 4. 
Picture taken by Joost Hegmans. 
The oldest observations on pathologic changes in chronic bronchitis showed 
hypertrophy of submucosal glands and an increased number of Goblet cells (68-
73). The volume of expectorated sputum correlates with the proportion of mucous 
glands (74). The number of serous acini of the submucosal glands is reduced, unlike 
in to asthma (68). Increased numbers of monocytes were found in the mucosa of 
airways with a diameter greater than 2 millimeter and in surrounding glands and 
gland ducts of bronchi larger than 4 millimeter, indicating markedly inflamed 
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airways (75). Neutrophil and mast cell proteases could be involved in the 
pathogenesis of mucous secretion (76). 
In young smokers there is an increased number of intraluminal macrophages in the 
respiratory bronchioles (77). In BAL fluid the number of inflammatory cells is 
raised five- to tenfold, especially alveolar macrophages and neutrophilic 
granulocytes (78-80). Functional characteristics of cells from smokers are different. 
Macrophages from smoking COPD patients released higher levels of elastase 
(81,82) or had higher elastinolytic activity (83). 
-~ 
Figure 2. The positively staining cells (in red) in the submucosal layer express BMK-13 
(eosinophils). Picture taken by Joost Hegmans. 
A large number of neutrophils was found in the lungs of patients with COPD who 
smoke (84), especially during COPD exacerbation (85). Neutrophils in BAL fluid 
are found predominantly in the first lavage aliquot, suggesting their presence in 
airways rather than in the alveolar compartment (78,79). Also in induced sputum 
the percentage of neutrophils and the levels of their activation markers are increased 
(86). Even in patients with COPD who have never smoked the percentage of 
neutrophils in BAL was increased (87). In the lamina propria increased numbers of 
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neutrophils, monocytes/macrophages as well as plasma cells and sporadically 
eosinophils were found (68,71). In biopsies taken from lobar bronchi significant 
increases were reported in the numbers of macro phages, total leukocytes (CD45+), 
T lymphocytes (CD3+) and activated T-cells (CD25+ and VLA-1+) (88). In another 
biopsy study there was an increased expression of E-selectin on vessels and of 
ICAM-l on basal epithelial cells (89). Levels of circulating ICAM-\ and E-selectin 
were also increased in serum and BAL fluid of patients with COPD (90). These 
adhesion molecules are involved in neutrophil recruitment. The expression of 
several adhesion molecules appears to be influenced rather by (heavy) smoking than 
by the disease process ofCOPD (9\). 
The function of circulating neutrophils is different in patients with COPD as 
compared to normals: for instance, the number of formyl-peptide receptors 
expressed on their surface is significantly increased (92). 
Figure 3. Above the thickened basement membrane the epithelium has almost completely 
disappeared, due to epithelial shedding andlor mechanical damage. Picture taken by Joost 
Hegmans. 
14 
The central airways of smokers with chronic bronchitis have a higher number of 
lymphocytes (93,94). In the submucosa, greater than normal lymphocyte numbers 
were counted (95). Increased numbers of B lymphocytes were present in the 
adventitia of smokers, with a positive correlation with the number of smoked 
cigarettes (96). T lymphocytes are present in both the epithelial and the 
subepithelial layer, and the predominant type is the CD8+ (cytotoxic/suppressor) 
lymphocyte (97). CD8+ T -cells are also more abundant in the lung parenchyma and 
in pulmonary arteries (98). In BAL fluid the CD4/CD8 ratio was lower in smokers 
with or without chronic bronchitis, compared with healthy individuals (58). The 
number of CD8+ T -cells is negatively correlated with FEV [, and positively 
correlated with mucus-secreting cells (97-99). Furthermore, the number of T 
lymphocytes has a negative correlation with the degree of alveolar destruction 
(100). Circulating CD4+ T-Iymphocytes in patients with COPD produce 
predominantly TNFa and less Interieukin-4, pointing to a THI-like immune 
response (101). 
Figure 4. A detailed view showing metaplasia and dysplasia of the epithelial layer in a 
bronchial biopsy of a patient with COPD and BRR. Staining is positive (red) for CD8+ T-
lymphocytes. Picture taken by Joost Hegmans. 
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Eosinophilic granulocytes are present in slightly increased numbers, and do not 
seem to degranulate (80,1 02). Their numbers increase markedly during an 
exacerbation (103,104). The presence of eosinophilia seems to be an early sign of 
larger declines of lung function as compared to those chronic bronchitis patients 
without eosinophilia (55). 
Several studies indicate that mast cells are involved in COPD as their number is 
increased (95,105-107). Perhaps the higher proportion of mast cells in airway 
epithelium is related to smoking (108). 
An increased total amount of airway smooth muscle was noted in small bronchi 
and bronchioli of COPD patients (109,110). In the small airways « 3 rum 
diameter), there may be, next to smooth muscle hypertrophy, mural edema, 
peribronchiolar fibrosis, peribronchiolar inflammation and loss of alveolar 
attachments (77,110-115). These peripheral airways are the major site of airflow 
resistance in patients with obstructive airways disease (116,117). The airflow 
limitation in small airways seems to be caused to a larger extent by airway 
pathology than by decreased elastic recoil or a check-valve in the small airways 
(118-122). Surprisingly, there is at least one study showing a relation between the 
severity of airway inflammation in biopsies from large bronchi and the severity of 
airflow limitation (123). 
It should be noted that airflow is also limited by intraluminal material such as 
mucus, inflammatory cells and shedded epithelial cells. 
The inflammatory infiltrate in the bronchioli and in the alveoli consists mainly of 
pigmented macrophages, neutrophils, and CD8+ T-Iymphocytes (77,110,111,115, 
124). These inflammatory changes lead to expiratory airflow limitation and 
disturbance of the protease-antiprotease balance. Next to a possible direct cytotoxic 
activity of T cells, secretory products from inflammatory cells (eg, neutrophil 
elastase) and an excessive oxidant burden, all of which contribute to the protease-
antiprotease imbalance with subsequent destruction of alveolar walls (125-127). 
The immunopathology of BHR in COPD has not been studied as extensively as in 
asthma. Several studies in asthma have shown a correlation between severity of BRR 
and inflammatory changes in the bronchial walls (128,129). In asthma the most 
prominent inflammatory cell types are eosinophils, lymphocytes and mast cells 
(41,42,68,95,128). Especially eosinophilic inflammation seems to be involved in the 
pathogenesis of BRR in asthma (130,131). In patients with chronic bronchitis, the 
level of airways hyperresponsiveness was not correlated with blood or sputum 
eosinophilia (131). In one study of patients with COPD undergoing lung surgery, pre-
operative PC20 was correlated with the severity of inflammation in bronchioli and not 
with changes in airways containing cartilage (75). In the same study, PC20 was 
correlated with cigarette consumption (pack years). 
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In COPD, the most prominent cell types are monocytes/macrophages, neutrophils and 
CD8+ lymphocytes. If BHR in COPD, as in asthma, is related to inflammation, than 
BHR can be associated with different inflammatory processes. It is also possible that 
we will find yet a different inflammatory profile in well-defined patients with COPD 
andBHR. 
Another potential causative mechanism of BHR is epithelial shedding. In asthma the 
surface epithelial layer of the bronchi is fragile and parts have been lost (133). The 
extent of such loss shows negative correlation with BHR (134-136). Loss of epithelial 
cells occurs also in patients with COPD (72,95). One study describes the mucosal 
permeability of aerosol radioactive particles in smokers and in nonsmokers (137). 
Mucosal permeability was increased in smokers, but there was no relation to BHR. 
Taylor et a1. investigated airway responsiveness in another way. They tested bronchial 
smooth muscle strips from surgical specimens of patients with COPD and a wide 
range of PC20 values, and were unable to find correlations with several contractile or 
relaxation mechanisms (138). Their conclusion was that in vivo airway responsiveness 
was not solely due to changes of in vitro smooth muscle function. 
In summary, the pathologic and immunologic changes of COPD are an increase of 
mucus secreting cells, loss of alveolar walls, and the presence of increased numbers of 
neutrophils, monocytes/macrophages and CD8+ lymphocytes, with altered cell 
properties (139). The pathologic basis of airflow limitation consists of reduced airway 
lumen due to inflammation of small airway walls, increased collapsibility of small 
airways due to loss of alveolar attachments, and the presence of intraluminal secretions 
(140). The presence of BHR in COPD may be due to an increased severity of 
inflammation, to a more asthma-like inflammatory profile or to defects of the epithelial 
layer. 
Glucocorticoid therapy in COPD 
There is a large discrepancy between daily practice and guidelines with regard to 
glucocorticoid therapy in COPD. In most guidelines the institution of glucocorticoid 
therapy has been discouraged. In those guidelines in which inhaled glucocorticoids 
are not rejected, the importance of a thorough evaluation of a trial with oral or 
inhaled glucocorticoids is emphasized. 
The percentage of patients with COPD enrolled in bronchodilator studies being 
treated with inhaled glucocorticoids has grown from 13.2% in 1987 to 41.4% in 
1995 (141). In an American study the percentages of patients with unstable and 
stable COPD admitted to hospital who had a current prescription of inhaled 
glucocorticoids were 48 and 26, respectively (142). In the Netherlands, the number 
of COPD patients receiving inhaled glucocorticoid therapy is approximately 70%. 
Apparently clinicians are inclined to a "benefit of the doubt" strategy when being 
confronted with patients who experience therapy-resistant symptoms and 
limitations. Certainly, the successes of inhaled glucocorticoids in asthma, together 
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with negligible side effects, may contribute to this way of prescribing. It is also 
possible that "asthmatic features" are more frequent in patients with COPD than 
generally assumed. It is somewhat surprising that patients with COPD adhere to 
therapy that provides little or no subjective improvement in the short term. This is 
especially true if one takes into account that the compliance to inhaled therapy is 
low. 
Perhaps the earliest study on glucocorticoid effects in COPD was published in 1978 
by Shim et aI (143). They found that oral prednisone caused improvement of FE V, 
in 7 out of 24 patients with chronic bronchitis. Remarkably, these seven patients 
showed eosinophils in their sputum. The same author reported in a later study that 
effects of oral steroids could not be reproduced by inhaled beclomethasone (144). 
Mendella et al reported that 8 out of 46 patients with COPD responded to a short 
course of prednisolone (145). The response to prednisolone was present in those 
patients who also responded significantly to a bronchodilator, suggesting that these 
patients had asthmatic features (145). In one other study, eight of 29 patients with 
COPD had an improved FEV, and FVC after oral steroid treatment (146). The 
amount of steroid responsive patients with COPD was, however, inversely related 
to FEV, suggesting that patient selection markedly influenced the results (147). 
Oral prednisolone did not improve exercise performance of patients with COPD 
(148). One study showed an increase of the protease inhibitora-I-antichymotrypsin 
in sputum after oral steroid treatment (149). 
The earliest studies on the effect of glucocorticoids on FEV, decline showed that 
prednisolone at doses above 7.5 mg/day could slow down the progression of the 
disease (\50,151). A meta-analysis showed that a minority of patients with stable 
COPD benefit slightly from oral corticosteroid treatment (152). Three separate 
studies have shown that a beneficial effect of an oral glucocorticoid might occur in 
a subset of patients with COPD and with features of asthma, particularly larger 
numbers of eosinophils and higher levels of eosinophil-derived cationic protein in 
BAL fluid or the presence of sputum eosinophilia (153-155). 
There are several short-term studies with inhaled glucocorticoids, looking at 
different parameters of treatment effect. These are summarized in tables 2 and 3. 
Overall, these results give the impression that inhaled glucocorticoids have at least 
some effect, due to their ability to modulate the inflanunatory process in COPD. 
Recently, the results of four large multicenter trials have been reported. The aim of 
these studies was to examine whether inhaled glucocorticoids could reduce, in 
patients with COPD, the FEV, decline in the long term and thereby improve 
prognosis. The EUROSCOP trial showed that the use of inhaled budesonide in 
patients with mild COPD gave a small improvement of the FEV, in the first three 
months, but the long-term decline was not influenced (171). The Copenhagen study 
was unable to show clinical benefit from inhaled budesonide treatment in patients 
with mild COPD (172). Results from the ISOLDE study indicate that patients with 
COPD and moderate or severe airflow obstruction benefit from high-dose inhaled 
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fluticasone, mainly because of a decreased frequency of exacerbations (173). Also, 
quality of life scores showed a significant beneficial effect of inhaled fluticasone in 
these patients with COPD (173). 
Table 2: 
Summary of placebo-controlled trials with inhaled glucocorticoids in COPD. 
Studylfirst author Parameter Beneficial No effect 
(reference number) 
I [number ofpatients*] 
effect 
Engel (156) Symptom scores ~ 
[8vs 10] Ventilatory capacity ~ 
PC20 histamine ~ 
Weir (157) FEV], FVC, PEF ~ 
1[34 vs 351 
Auffarth (158) Dyspnoea ~ 
[12 vs 12] Other symptom scores ~ 
Spirometry, PC20 
Thompson (159) FVC, FEF25. 75 ~ 
[20 vs 10] FEV, ~ 
BAL cells (bronchial sample) ~ 
Lactoferrin, lysozyme ~ 
Llewellyn-Jones (160) Sputum: chemotactic activity ~ 
[8 vs 8] Sputum: elastase inhibitory 
activity ~ 
Superoxide "eneration ~ 
Renkema (161) Drop outs ~ 
[21 vs 18] Symptoms ~ 
FEV, decline ~ 
Bourbeau (162) FEV], PEF, exercise capacity, ~ 
[39 vs 40] dyspnoea, Quality of Life, ~ 
respiratory symptoms ~ 
Confalonieri (163) Sputum cells ~ 
1[17 vs 17] Spirometry ~ 
Van Grunsven (164) FEV, decline ~ 
1[144 vs 88] Exacerbation rate ~ 
* number of actively treated patients versus placebo 
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If patients with COPD were included in the ISOLDE study and their inhaled 
glucocorticoids were discontinued, 38% experienced an exacerbation, whereas in 
those without previous inhaled glucocorticoid therapy, there was an exacerbation 
rate of 6% (174). The Lung Health Study on inhaled triamcinolone in patients with 
mild-to-moderate COPD showed no effect on FEV j decline and on quality of life 
scores (175). Beneficial effects of triamcinolone inhalation were improvement of 
airway reactivity, less dyspnea and a reduction of unscheduled medical respiratory 
care. 
Table 3: 
Summary of crossover and other trials with inhaled glucocorticoids in COPD 
Studylfirst author Parameter Beneficial No effect 
(reference number) effect 
r number of patients 1 
Watson FEV!, VC, PC20 '" (165) 
.114, crossoverl 
Weiner FEV j '" (25%) '" (75%) 
(166) 
r30, crossover] 
Culpitt Sputum cells 
'" (167) Sputum proteases '" 
, [13, crossover] 
Llewellyn-Jones Neutrophil functions 
'" (168) Superoxide production 
'" I [8, ex vivo tests] 
Keatings Lung function 
'" (169) Symptom scores 
'" [131 Cells and cell activation markers '" 
Balbi IL-8, MPO, cells in BAL 
'" (170) Symptoms, bronchitis index 
'" I r81 
One of the conclusions that can be drawn from the results of these four studies is 
that, overall, patients with COPD do not seem to benefit from inhaled 
glucocorticoid therapy, but there is a strong indication that patients with a worse 
FEV j experience a beneficial effect. Remarkably, the findings of the inhaled 
glucocorticoid studies are similar to the older oral glucocorticoid trials. In these 
trials there was also a higher chance of a beneficial effect in those patients with a 
worse lung function (147). The multicentre trial of Paggiaro et al demonstrated 
significant beneficial effects of inhaled f1uticasone with regard to a reduction of 
20 
moderate or severe exacerbations, with regard to several functional parameters as 
well as cough and sputum volume (176). 
Analysis of these studies leads to the conclusion that there are at least some patients 
with COPD for whom inhaled glucocorticoid therapy is usefuL It is not yet possible 
to specifY with certainty which subgroups of COPD patients should be prescribed 
inhaled glucocorticoids. It may be that those patients with "asthmatic 
characteristics" and those with a low FEY j benefit from inhaled glucocorticoid 
therapy. 
Aim of this thesis 
We intended to study in detail a well-defined group of patients with COPD, those 
with bronchial hyperresponsiveness. They attracted our attention for two reasons. 
First was the fact that these patients with COPD had an even more accelerated 
decline of their FEY J, and that might offer the opportunity to detect an effect of an 
anti-inflammatory therapy on lung function parameters. Those patients with COPD 
who had a steep decline of their FEY j showed indeed an improvement of lung 
function after inhaled glucocorticoid therapy (177). From a Dutch multicenter trial 
it appeared that one of the parameters predicting a beneficial effect of an inhaled 
glucocorticoid was bronchial hyperresponsiveness: the lower the PC20, the greater 
the chance of improvement (178,179). The second reason for studying BHR in 
COPD is that this phenomenon has not been studied in detail before. Whereas BHR 
in asthma improves after glucocorticoid.therapy (180, 181), most studies in COPD 
indicate that PC20 was not influenced by anti-inflammatory therapy (156,158,165). 
One of our approaches involves taking into account not only the PC20, as well as 
also other parameters from a dose-response curve (182), which could well be be 
influenced by anti-inflammatory therapy. Furthermore, we wanted to investigate in 
detail the inflammatory processes in this particular group of patients, before and 
after anti-inflammatory therapy, in order to gain insight in the pathogenetic 
mechanisms underlying this disease. Therefore, we examined cell numbers in 
bronchial biopsies, in bronchoalveolar lavage fluid and in blood, and also 
determined concentrations of mediators of inflammation, and the capability of cells 
to produce reactive oxygen species. 
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Abstract 
Study objectives: The interpretation of nonspecific bronchial provocation dose-
response curves in COPD is still a matter of debate. Bronchial hyperresponsiveness 
(EHR) in COPD could be influenced by the destruction of the parenchyma and the 
augmented mechanical behavior of the lung. Therefore, we studied the 
interrelationships between indexes of BHR, on the one hand, and markers of lung 
parenchymal destruction, on the other. 
Patients and methods: COPD patients were selected by clinical symptoms, evidence 
of chronic, nonreversible airways obstruction and BHR, which was defined as a 
provocative dose of a substance (histamine) causing a 20% fall in FEV 1 (PC20) of::; 
8 mg/ml. BHR was subsequently studied by methacholine dose-response curves to 
which a sigmoid model was fitted for the estimation of plateau values and reactivi-
ty. Model fits of quasi-static lung pressure-volume (PV) curves yielded static 
compliance (Cstat), the exponential factor KE and elastic recoil at 90% of total lung 
capacity (P90TLC). Carbon monoxide (CO) transfer was measured with the 
standard single-breath method. 
Results: Twenty-four patients were included in the study, and reliable PV data 
could be obtained from 19. The following mean values (±SD) were taken: FEV" 65 
±12% of predicted; reversibility, 5.6 ±3.1 % of predicted; the PC20 for methacholine, 
4.3 ±5.2 mg/mL; reactivity, 11.0 ±5.6% FEVl/doubling dose; plateau, 48.8 ±17.4% 
FEV,; transfer factor, 76.7 ±17.9% of predicted; transfer coefficient for carbon 
monoxide (KCO), 85.9 ±22.6% of predicted; Cstat, 4.28 ±2.8 LlkPa; shape factor 
(KE) 1.9 ±1.5 kPa·1; and P90TLC, 1.1 ±0.8 kPa. We confirmed earlier reported 
relationships between Cstat, on the one hand, and KE (p<0.0001), P90TLC 
(p=0.0012), and KCO percent predicted (p = 0.006), on the other hand. The indexes 
of the methacholine provocation test were not related to any parameter of lung 
elasticity and CO transfer. 
Conclusion: BHR in COPD patients who smoke most probably is determined by 
airways pathology rather than by the augmented mechanical behavior caused by 
lung parenchymal destruction. 
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Introduction 
Bronchial hyperresponsiveness (BHR) is present in patients with asthma and COPD 
(1). Approximately half of the subjects with COPD in a general population have 
BHR (2). In the Lung Health Study, BHR was noted in 85.1% of the women and 
58.9% of the men with mild-to-moderate airflow limitation (3). The estimation of 
BHR is important for the diagnosis of asthma and for determining asthma severity, 
whereas the meaning of BHR for the clinical management of COPD is still unclear 
(4). COPD patients with BHR appear to be prone to a more rapid decline of their 
FEV! (5). 
Clinical studies suggest that BHR in patients with COPD differs from BHR in 
patients with asthma (6-9). For example, in patients with COPD, BHR for 
physiologic stimuli (eg, cold air) usually is not found in the presence of BHR for 
pharmacologic agents (eg, histamine). In patients with asthma, both types of stimuli 
cause bronchoconstriction (6,7). The explanation for these differences might be 
found in the different pathologic changes in the airways and in the lung parenchyma 
of asthma and COPD patients (I). The main and clearest difference between asthma 
and COPD is destruction of the lung parenchyma in COPD, leading to emphysema 
and loss of lung elasticity. In patients with COPD, compared to those with asthma, 
there is a relationship between baseline FEV! and the level ofBHR (8,9). The FEV! 
is, however, not a good predictor of the amount of parenchymal destruction and loss 
of elastic recoil (10-13). The most reliable test for lung elasticity is the direct 
estimation of quasi-static esophageal pressure-volume (PV) curves (10,11,14). The 
destruction of parenchymal tissue also is shown by impairment of carbon monoxide 
(CO) transfer (15-18). We performed these lung function tests in COPD patients 
who smoked, who fulfilled the established clinical and functional criteria for 
COPD, and who also had a provocative concentration of a substance (histamine) 
causing a 20% fall in FEV I (PC20) of S 8 mg/mt In subsequent methacholine dose-
response curves, not only PC20 (sensitivity) but also maximal bronchoconstriction 
(plateau) and the slope of the curve (reactivity) were estimated, because these 
factors should yield additional information on the causative mechanisms of BHR 
(19). 
The aim of our study was to investigate the influence of the impairment of lung 
parenchymal structure on BHR by the estimation of the interrelationships between 
indexes related to lung parenchymal destruction (lung elasticity and CO transfer) 
and indexes from methacholine log-dose response curves. 
Materials and methods 
Patients 
COPD patients were recruited according to generally accepted clinical and 
functional criteria (20). The inclusion criteria were the following: chronic 
productive cough; age between 40 and 70 years; current smokers; negative skin 
tests for standard inhalation allergens; FEV I or FEV /inspiratory vital capacity 
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(lVC) ratio::; 70% of the predicted nonnal value; reversibility of FEV1 of <10% 
predicted after 750 Ilg terbutaline administered by metered-dose inbalation; and 
nonspecific BHR, defined by a PC20 for histamine of::; 8 mg/ml. Exclusion criteria 
were the following: a history of asthma; complaints of wheezing; radiographic signs 
of bullous emphysema; recent respiratory tract infection; and recent or concurrent 
usage of anti-inflammatory drugs. Eligible patients refrained from oral anti-
inflammatory medication at least 3 months and from inhaled glucocorticoids at least 
6 weeks before the start of the study. 
The study was approved by the Medical Ethics Committee of the University 
Hospital Dijkzigt, and written infonned consent was obtained from all participants. 
Lung/unction tests 
Functional tests included the following: spirometry (total lung capacity [TLC], 
functional residual capacity [FRC], RV, lVC, FEV1); reversibility test (FEV1 
percent predicted); single-breath CO transfer (transfer factor of the lung for CO 
[T LCO] and transfer coefficient for CO [KCO]; and PV curves. Spirometry was 
measured with the multiple-breath, closed Helium wash-in method, using a water-
sealed spirometer (model D35R; Lode; Groningen, The Netherlands) and with the 
patient in sitting position. The lung volumes were corrected to body temperature 
and ambient pressure, saturated with water vapor. All reference values were derived 
from the standards ofthe European Community for Steel and Coal (21,22). 
Bronchial provocation tests 
Histamine and methacholine provocation tests were perfonned according to the 2-
min tidal breathing method that was first described by Cockcroft et al (23,24). The 
PC20 for histamine was used as an inclusion criterion. Because of lesser side effects, 
methacholine was used for obtaining as complete as possible dose-response curves 
(25). After inhalation of an isotonic saline solution, doubling concentrations of 
histamine-sulphate or acetyl-~-methy1choline-bromide were administered, starting 
with doses of 0.03 mg/mL. Methacholine was prepared by our hospital pharmacy 
department. Solutions were stored at 4°C and were used at room temperature. 
Aerosols were generated by a nebulizer (model 646; DeVilbiss Co; Somerset, PAl 
(measured output 0.13 mL/min) and were inhaled by tidal breathing over a 2-min 
period at 5-min intervals. The response to methacholine or histamine was measured 
as the change in FEV 1 expressed as a percentage of the initial value. The histamine 
provocation test was interrupted if a 20% fall in FEV 1 occurred before or at a dose 
of 8 mg/mL. The methacholine tests were continued up to a concentration of 256 
mg/mL but were interrupted if the FEV1 fell by > 60% or if unpleasant side effects 
occurred. 
From the methacholine provocation tests, the log2 concentration and the measured 
percentage of changes in FEV 1 were imported to a computer program that fitted a 
sigmoid function (cumulative Gaussian distribution) to the data (26). Reactivity (the 
slope of the curve), and plateau values (maximal bronchoconstriction) were taken 
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from this model fit, whereas the PCzo was calculated from the measured data by 
linear interpolation of adjacent data points. 
Pressure-volume curves 
The lung elasticity measurements were performed immediately after the reversi-
bility test. This sequence was chosen for reasons of standardization and in order to 
minimize the potential disturbing effect of airway closure on lung elasticity. Quasi-
static deflation exercises were performed according to the method that has been 
described before (27). In short, the transpulmonary pressure was measured via a 
transducer (model P45; Validyne Engineering Corp; Northridge, CAl coupled to a 
balloon that was positioned in the lower third of the esophagus. The simultaneous 
recording of volume changes was obtained during a slow expiration (ie, expiration 
not exceeding 0.3 Lis). Selected curves were smoothed by drawing a line by hand 
through katacrotic points of the cardiac pulsations on the curve. Volume data were 
obtained at equal transpulmonary pressure intervals, yielding an average IOta 30 
data points up to the TLC level. A linear-exponential (LE) and an exponential 
model were fitted to the measured data. The LE model gave the most accurate fit to 
experimental curves and was, therefore, used for the estimation of static lung 
compliance (Cstat) and volume- dependent recoil pressures (27,28). For this fit, the 
curve was considered to be composed of a linear part, from the first data points on 
starting at the FRC level, and an exponential part, starting at the higher volume 
level. Cstat was obtained from the linear part if four or more data points contributed 
to that part. In a minority of cases, we calculated Cstat by hand as the slope between 
FRC and FRC + 0.5 L. The elastic recoil pressure at 90% of TLC (p90TLC) also 
was derived from the LE model fit. This pressure index was considered to be the 
elastic recoil index with the lowest variation coefficient (29). Additionally, we 
prefer to use the P90TLC values above the recoil pressure at TLC because P90TLC 
is less dependent on inspiratory muscle force. The shape factor KE was determined 
from the following generally used exponential equation: 
V = Vmax {I - exp [KE (P - PO)]} 
where Vmax is the asymptotic value (in liters) and PO is the intercept with the P 
axis at V = 0 kPa. 
KE can be considered as an elasticity index, independent of lung size (28). For the 
fit with the exponential model, we used the same (measured) input data as for the 
LE model fit. KE was considered as an additional elasticity index. 
Statistics 
Linear regression analysis between variables, pairwise multivariate correlation, and 
statistical significance were calculated with the use of a package of statistical 
software (Statistical Graphics Corp; Rockville, MD). Test results were considered 
statisticallY significant at p < 0.05. 
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Results 
Baseline characteristics 
Twenty-four patients were included in the study. From 19 patients, we obtained 
reliable PV curves; the remaining patients did not tolerate the esophagus balloon 
long enough or showed effects of swallowing that hampered an accurate 
interpretation of the data. The mean age of the patients was 56 years (Table I). The 
mean FEV, was 65% of predicted. One patient had an FEV, > 70% of predicted, 
but was included because his FEV,IIVC ratio was 0.51. The mean reversibility of 
FEV, after terbutaline inhalation was 5.6%. Four patients showed no reversibility at 
all. 
Table 1. 
Smoking habits, FEV" reversibility, BRR, CO transfer and lung elasticity data. 
n Mean±SD median Range 
Age, yr 24 55.5 ±8.5 54 42 - 69 
Actual smoking, cigarettes/d 24 15.6 ±6.8 13 6 - 30 
Pack-years 24 23 ±10.5 23 5 - 50 
FEV" % predicted 24 64.5 ±11.9 65 34 - 93 
Reversibility, % predicted 24 6.8±4.0 7.3 0-13.8 
PC20 
Histamine 24 1.66 ±2.00 0.87 0.11 - 8 
Methacholine 24 4.27 ±5.2 1.46 0.4-17.4 
log2 PC20 methacholine 24 1.07 ±1.74 0.53 -1.3 -4.1 
Reactivity, %FEV/doubling dose 24 11.0 ±5.6 8.98 3.9 - 26.8 
Plateau, %FEV, 24 48.8 ±17.4 48.3 20.8 - 95.7 
Cstat, LlkPa 19 4.6 ±2.8 4.1 1.1 - 10.5 
KE, kPa-' 19 2.5 ±1.5 2.2 0.7 - 6.3 
P90TLC, kPa 19 1.1 ±O.8 0.8 0.4 - 2.7 
T Leo, % predicted 24 76.7 ±17.9 75 34 - 106 
KCO, % predicted 24 85.9 ±22.6 86 43 - 139 
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Figure 1. Two examples of sigmoid fitting of the methacholine provocation tests. 
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The patients had moderate or severe BHR (Table I). The mean PC20 for 
methacholine was higher than that for histamine (4.3 vs 1.7 mg/mL, respectively). 
This difference was also reported in an earlier study of smokers with mild chronic 
airflow limitation (30). After correction for the difference in molecular weight 
(1 mg of the bromide compound is equivalent to 0.82 mg of the chloride com-
pound), the corrected mean bromide value of the PCzo became 3.5 mg/mL. 
The mean plateau value was 48.8 % of the FEV,. In Figure 1, we present a curve in 
which the fitted plateau is almost equal to the measured data (Fig. I , top) and a 
curve in which the plateau value is derived from extrapolation (Fig. 1 , bottom). If 
the experimental plateau estimate was defined by the mean value of the last two 
provocative concentrations with a variation of <5%, we observed that the fitted 
plateau was almost equal to the experimental plateau estimate in 13 of the 24 dose-
response curves. 
Cstat ranged from 1.06 to 10.52 LlkPa, which indicates a range from moderately 
low to clearly increased if a normal range of 1.5 to 2.5 LlkPa is taken into account 
(21). Mean Cstat was 4.6 LlkPa (Table 1). 
TLCO was between 34% of predicted to 106% of predicted and Kco ranged from low 
(43% of predicted) to higher than normal (139% of predicted). 
Table 2. Correlations of the indexes of the PV curves, CO transfer, and smoking by 
pairwise multivariate analysis. 
Variable 1 Variable 2 Number of RValue p Value 
patients 
Cstat KE 19 0.821 <0.0001 
Cstat P90TLC 19 -0.687 0.0012 
T LCO, % predicted Cstat 19 -0.290 0.23 
T LCO, % predicted KE 19 -0.254 0.29 
T LCO, % predicted P90TLC 19 0.123 0.62 
KCO, % predicted Cstat 19 -0.604 0.006 
KCO, % predicted KE 19 -0.414 0.077 
KCO, % predicted P90TLC 19 0.438 0.061 
KE Act smoking* 19 0.534 0.019 
* Act smoking = actual smoking (cigarettes/day). 
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Correlation studies 
Pressure-volume curves 
Statistically significant correlations existed among all the parameters of the PV 
curve (Table 2). The strongest correlation was between Cstat and KE (R = 0.81; p < 
0.0001). 
The KCO percent predicted correlated strongly with Cstat (R = -0.60; p = 0.006; 
Table 2) but not with KE and P90TLC. The T LCO percent predicted showed no 
significant correlation with Cstat, KE or P90TLC. 
Bronchial hyperresponsiveness 
The indexes ofBHR (pC20, reactivity, and plateau value) were tested for correlation 
with the indexes of the PV curve (Cstat, KE, P90TLC), CO transfer (TLCO and 
KCO), and FEV1• In Table 3, we present the correlations between Cstat and the 
BHR indexes. No significance was found and no significance was found for the 
additional elasticity indexes and diffusion parameters. 
Table 3. Correlations of the indexes ofBHR with quasi-static compliance and FEV1 
by pairwise multivariate analysis. 
Variable I Variable 2 No. of RValue p Value 
patients 
PC20 histamine Cstat 19 0.282 0.24 
PC20 methacholine Cstat 19 0.061 0.82 
Reactivity Cstat 19 0.291 0.24 
Plateau Cstat 19 0.321 0.19 
PC20 histamine FEV], % predicted 24 0.483 om 
PC20 methacholine FEV], % predicted 24 0.470 0.02 
Reactivity FEV], % predicted 24 -0.522 0.0075 
Plateau FEV], % predicted 24 -0.194 0.35 
There was a significant correlation between the FEV1 percent predicted, on the one 
hand, and log2PC2o for histamine and log2PC2o for methacholine, on the other hand 
(R = 0.44; P = 0.024; and R = 0.46, P = 0.023, respectively; Table 3). There was 
also a significant (negative) correlation between the FEV1 percent predicted and 
reactivity (R = -0.52; p = 0.008; Table 3). The correlation between the FEV1 percent 
predicted and plateau value was not significant (Table 3). 
38 
Because smoking is the most important risk factor for emphysema, we looked at 
paired correlations among smoking data, CO transfer and indexes of the PV curve. 
There was a significant correlation only between KE and the actual number of 
cigarettes smoked per day (R = 0.53; P = 0.019; Table 2). 
Discussion 
The aim of our investigations was to study the interrelationships among indexes 
describing BHR, lung elasticity, and CO transfer in patients with COPD. For the 
estimation of BHR and the degree of impairment of lung mechanics, detailed infor-
mation was obtained by fitting models of methacholine dose-response curves and 
quasi-static PV curves. 
Several mechanisms have been proposed for explaining enhanced bronchoconstric-
tion as a reaction to inhaled stimuli (1,19,31). Detailed analysis of methacholine 
log-dose response curves is supposed to offer additional information on the 
causative mechanisms of BHR (19). PC20 and reactivity are considered to be 
determined by pre junctional mechanisms, and the plateau value is more dependent 
on postjunctional mechanisms (19). In patients with COPD, both prejunctional (ie, 
epithelial damage, neural control, and inflammation) and postjunctional mecha-
nisms (ie, loss of lung elasticity, swelling of airway wall, and intraluminal 
secretions) can be responsible for the occurrence ofBHR. Because lung elasticity in 
stable patients with asthma is not appreciably disturbed, this would be an attractive 
explanation for the occurrence ofBHR in COPD and to relate it to the loss of elastic 
recoil. Theoretically, a decrease in lung elasticity can facilitate an amplified 
bronchomuscular response (31). 
PV-curves and lung parenchyma impairment 
First, we have studied the functional indexes of lung parenchymal destruction. 
Some degree of emphysema, which is present in patients with mild COPD, already 
influences the PV relationships (10,11,14). A PV curve can be obtained with relati-
vely simple techniques but has the disadvantage of being an invasive test. The 
reproducibility of estimates, especially of KE, was reported to be good, at least for 
healthy adults (29,32,33). KE was found to be a good indicator for the presence of 
mild emphysema (10,15,32). We found that Cstat and P90TLC from the LE model 
fit and KE from the exponential model fit correlated well with each other, 
indicating that these indexes were linked to elastic properties of the lung (Table 2). 
Elasticity and CO diffosion 
An additional index of lung parenchymal destruction is CO diffusion. Berend et al 
were the first to report a correlation between CO transfer and severity of 
emphysema (16). Others have confirmed the relationship between emphysema and 
KCO (15,17,18). We found also a significant correlation of Cstat with KCO (Table 
2). KCO can be considered as an index, related to structural aspects of lung 
parenchyma, whereas T LCO is a measure of overall gas transport. 
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Lung elasticity and smoking 
In this study, we also tested the indexes of the impairment of lung patenchymal 
structure for correlation with cigatette smoke exposure, pack-yeats and actual 
smoking. There was a significant correlation ofKE only with actual smoking (Table 
2). There ate few data about the correlation of smoking with patenchyma 
impairment. In one study, there was no detectable effect of smoking on lung recoil 
in healthy men (34). Other investigators have reported a quantitative relationship 
between the total exposure to cigatette smoke and both a1veolat and airway 
pathologic features in a necropsy study (35). So, although the assumption is 
plausible that there is a relationship between cigatette smoke exposure and loss of 
elastic recoil, it is not yet cleat how this influences the derivatives of the PV curve. 
We have assumed that differences in vulnerability of the lung patenchyma to 
cigatette smoke influence the measured loss of elastic recoil more than the amount 
of cigatette smoke exposure. 
Impairment of lung parenchymal structure and bronchial hyperresponsiveness 
In patients with u I-antitrypsine deficiency, Cheung et al found a relationship 
between the loss of elastic recoil and maximal airway natrowing (plateau) (36). It 
should be noted that their patient group was selective; five of eight patients had an 
FEV1 >80% of predicted, patients were clinically stable, and patients were ex-
smokers or nonsmokers. These patients seemingly had only patenchymal disease. 
The effect of the involvement of airways disease was shown in a study by Eidelman 
et aI (13). They described different patterns of mechanical abnormalities between 
smoking and nonsmoking patients with u I-antitrypsine deficiency. In COPD 
patients, especially in those who smoke, it is likely that there ate both patenchymal 
and airway changes. In our study and in the study by Koyama et al (37), nO 
significant correlations were found among indexes of the PV curve, on the one 
hand, and BHR, on the other hand. This means either that PV curves do not repre-
sent elastic recoil changes or that BHR is also influenced by airway pathology. 
There ate several atguments that support the last mechanism. First, as discussed 
above, indexes of PV curves have been found to correlate with pathologic 
assessment of lung patenchyma. Second, the significant correlations among the 
different indexes of the PV curve, and between elasticity and KCO, indicate that our 
results ate a good reflection of the loss of elastic recoil of the lung. Third, there 
were significant relationships between the determinant of airways obstruction 
(FEV1) and PC20 (Table 3). 
Relationship of FEV/ and the indices of BHR 
In the present study, not only were the PC20 for histamine and the PC20 for 
methacholine correlated with the FEV1 percent predicted, but also with reactivity. 
The first correlation was reported elsewhere (2,8,9) and was found also by Cheung 
et aI (36) and Koyama et al (37). This indicates that the definition ofPC2o as a 20% 
fall of the starting FEV 1 makes the outcome highly dependent on measurements of 
FEV 1 in patients with a low FEV I. Our finding that reactivity (the slope of the 
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dose-response curve) is steeper at lower FEV 1 percent predicted, indicates that 
reactivity also was hampered by the way in which the response is expressed. This 
appeared to be distinct for the plateau value, which was not correlated with the 
starting FEV l (Table 3). The clinical significance of the level of a plateau value is 
that it is a measure of the maximal acute bronchoconstriction that can be provoked 
in an individual. The application of the plateau value in combination with the PC20 
for methacholine has been suggested for the distinction between asthma and COPD 
(1). While BHR Can be found both in patients with asthma and patients with COPD 
when considering PC20, the plateau value is usually not reached in patients with 
moderately severe or severe asthma. In our study of patients with COPD who have 
moderately severe BHR, the plateau was reached in the majority of the patients, but 
not in all. It appears, therefore, that the estimation of the plateau does not always 
provide a clear distinction between asthma and COPD. 
BHR and airway pathology in COPD 
Because none of the indexes of BHR is related to any of the functional data of lung 
elasticity or CO transfer in COPD patients who smoke, airway pathology determi-
nes the response to methacholine at least to such an extent that it overrules a 
possible correlation with parenchymal destruction. The nature and extent of airways 
disease seem to be more important for the occurrence of BHR in patients with 
COPD than does parenchymal pathology. Taylor et al have compared PC20 for 
methacholine in vivo with the function of bronchial smooth muscle strips from 
surgical specimens (38). No correlation was found, which led to their conclusion 
that smooth muscle pathophysiologic changes were not responsible for BHR in 
COPD. One other study provided evidence that BHR in patients with emphysema is 
related to differences among types of emphysema and to the cell infiltrate in the 
airway walls (39). 
In conclusion, we found no relationship between the impairment of lung 
parenchymal structure, either from PV curves or CO diffusion, and indexes ofBHR. 
Nonspecific BHR in COPD patients who smoke is determined by small airway 
pathology to such an extent that it overrules a possible correlation with 
parenchymal impairment. The combination of our findings with those from 
clinicopathologic studies suggest that the plateau value (maximal airway 
constriction) is a better indicator of small airways pathologic changes than are PC20 
and reactivity. 
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'Normalized' PC,. values are unrelated to baseline FEV1 but correlate with 
eosinophilic airways inflammation in patients with Chronic Obstructive 
Pulmonary Disease 
Joachim G.J. V. Aerts, Gert T. Verhoeven, Joost P.J.J Hegmans, Jan-Bas Prins, 
Henk C. Hoogsteden, Jan M. Bogaard 
Department of Pulmonary and Intensive Care Medicine, Erasmus University Medical Center 
Rotterdam, The Netherlands. 
(Submitted for publication) 
Abstract 
Study objectives: The interpretation of bronchial provocation tests in COPD is 
hampered by the correlation oflog2PC20 with the baseline FEV, (FEV,pre): a lower 
FEV, makes the patient more prone to an abnormal test result. To avoid the 
influence of FEV,pre on 10g2PC2o we expressed the response by an alternative 
expression (Iog2nPC20) based on FEV, response as percent predicted and compared 
the relationships between log2PC2o and log2nPC zo with eosinophilic airways 
inflammation. 
Patients and methods: 21 patients with COPD were included. Mean (±SD) FEV" 
65 ± 11 % of predicted, mean 10g2PC2o for methacholine equalled 1.1 ±l. 7. 
Log2PC20 was calculated as log dose of the percentage change of the FEV,pre 
(FEV,pre - FEV,post / FEV,pre), and log2nPC2o as the log dose of the quotient of 
the absolute decrease in FEV, and the FEV,pred (FEV,pre - FEV,post! FEV,pred). 
Bronchial biopsy specimens were stained with monoclonal antibodies for major 
basic protein (MBP), and immunostained areas were measured with an image 
analysis system. Correlation studies were performed with linear regression analysis. 
Results: Log2PC20 was positively correlated to FEV,pre (p =.04), whereas 
log2nPC2o did not correlate. Log2nPC20 was correlated to MBP count (p=.004), 
while 10g2PC2o failed to reach significance. 
Conclusions: Log2nPC20 was not correlated to baseline FEV, but related to 
eosinophilic airways inflammation both in contrast to 10g2PC2o . Log2nPC20 may, 
therefore, be a more adequate indicator of inflammation in patients with COPD. 
44 
Introduction 
In patients with asthma, bronchial hyperresponsiveness is related to eosinophilic 
airways inflammation. Bronchial hyperresponsiveness (BRR) is usually defined as a 
20% decrease in FEV, from the baseline value (log2PC20) at a provocative 
concentration lower than 8 mglmL histamine or methacholine (1). In asthma, 
corticosteroids are known to have a beneficial effect on eosinophilic airways 
inflammation and consequently on bronchial hyperresponsiveness (2,3). It is therefore 
generally accepted as standard therapy in these patients (2,3). The use of 
corticosteroids, either inhaled or oral, in patients with stable COPD is controversial. It 
is suggested that those patients with COPD who have eosinophilic airways 
inflammation would benefit from corticosteroid therapy (4-7). In others, the use of 
corticosteroids may be detrimental (8). Consequently, it is of great value to properly 
establish the level of eosinophilic airways inflammation in patients with COPD. Until 
now only measures like bronchoscopy and induced sputum could be used to determine 
the level of eosinophilic airways inflammation. 
In patients with COPD, similar to patients with asthma, bronchial provocation tests are 
performed to diagnose BHR. In patients with COPD, a positive correlation between 
the baseline FEV, and PC20 has been described (9-12). This indicates that at a lower 
FEV" due to the mathematical expression of log2PC2o, patients are prone to be 
indicated as hyperresponsive, while for the purpose of a clinical estimate of 
eosinophilic airways inflammation, the significance of the 10g2PC2o is unknown. 
We tested whether a deduced variable from the bronchial provocation test was 
independent of FE V, but related to airways inflammation. Log2PC20 was estimated in 
patients with COPD and related to baseline FEV, values, and eosinophilic airways 
inflammation. Eosinophilic airways inflammation was determined as the number of 
eosinophils in the lamina propria present in bronchial biopsy specimens from these 
patients. 
We also calculated an alternative expression of log2PC2o: the provocative 
concentration at which a 20% decrease in FEV, predicted values was obtained. This 
'log2nPC2o' was also tested for correlation with the baseline FEV, and the number 
of eosinophils in the airway wall. 
Patients and Methods 
Patients 
Patients with COPD were included according to the following criteria: chronic 
productive cough, age between 40 and 70 yrs, current smokers, negative skin tests 
for inhalation allergens, FEV, < 70% of predicted normal value (pred) or FEV,NC 
<0.70, reversibility of FEV, <10% pred after 750 fig terbutaline inhalation and 
BHR defined as PC20 for histamine < 8 mglmL (Table 1). Exclusion criteria were a 
history of asthma, complaints of wheezing, recent respiratory tract infection and 
recent or concurrent usage of anti-inflammatory drugs. Oral anti-inflammatory 
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medication was discontinued for at least 3 months and inhaled glucocorticoids at 
least 6 weeks before the start of the study. 
The study was approved by the Medical Ethics Committee of the Erasmus 
University Medical Center Rotterdam, and written informed consent was obtained 
from all participants. 
Methacholine provocation tests 
Methacholine provocation tests were performed according to the 2-min tidal 
breathing method at S-min intervals (1,13). A nebulizer (model 646; DeVilbiss Co; 
Somerset PA, USA) was used to generate aerosols at a measured output of 0.13 
mL/min. Methacholine provocation tests were continued up to a concentration of 
128 mglmL or when the FEVl fell by more than 60% of the baseline value, or when 
a plateau was reached (defined as a no further decline in FEVl (± S%) at two 
consecutive concentrations of methacholine). 
Processing of methacholine provocation tests 
Log2PC2o was calculated by linear intrapolation of the log2 dose of methacholine 
before and after a 20% decrease in the baseline value of the FEV 1 (FEV lpre). 
In formula: 
10g2PC2o = 10g2 
Log2nPC2o was calculated by linear extrapolation of the log2 dose of methacholine 
before and after 20% decrease in predicted FEV 1 values. 
In formula: 
10g2nPC2o = 10g2 
Predicted FEV 1 values were obtained from published data (European Community 
for Coal and Steel [14]). When a plateau was reached at FEVl values lower than 
20% of predicted values patients were excluded. When bronchial provocation tests 
were interrupted either because of a decline in FEVl of more than 60% of the 
baseline value, or when the maximal provocation dose was reached, the log2nPC2o 
was extrapolated from a cumulative Gaussian distribution curve fitting to the 
measured data, which we have described earlier (IS). 
Bronchoscopy 
All patients received 0.5 mg atropine intramuscularly. Pulse rate and oxygen saturation 
was monitored by pulse-oxymetry. Lidocaine spray was used to anaesthetize the 
pharynx. Oxybuprocaine solution (SmglmL) was nebulized to anaesthesize vocal 
cords, trachea and bronchial tree (maximum 20mL). Bronchoscopy was performed 
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with an Olympus BF ITIO. At least 6 biopsies were taken from the bronchi of the right 
and the left upper and lower lobes using a fenestrated forceps (FB-ISC or FB-20C). 
All according to published guidelines (16). 
Estimation of eosinophilic airways inflammation 
Bronchial biopsies were snap-frozen in Tissue-Tek II OCT embedding medium 
(Miles, Naperville, Illinois, USA) in liquid nitrogen within 10 minutes after 
collection, and stored at -SO°C. Once all biopsy specimens were collected, 6 ).Lm 
serial tissue sections were cut on a cryostat (model HM-560, Microm, Heidelberg, 
Germany). At least two sections from one biopsy specimen, 120 ).!Ill apart, were 
placed on a poly-L-Iysine-coated microscopic slide (Sigma Diagnostics; St.Louis, 
MO, USA). Next, sections were air dried for 30 min and stored at -SO°C until use. 
Immunostaining was carried out with a monoclonal antibody directed against Major 
Basic Protein (MBP) (BMK13 from Dako, Glostrup, Denmark). Binding of the 
antibodies was detected by the immuno-alkaline phosphatase anti-alkaline 
phosphatase (AP AAP) method (Dako). 
Immunostained sections were analyzed with an image analysis system by an 
investigator unaware of the other subject information (JPJlli). The image analysis 
hardware consisted of a 3CCD (charge-coupled device) color video camera (DXC-
950; Sony, Tokyo, Japan) mounted on a microscope (DM RBE, Leica, Rijswijk, 
The Netherlands) and connected to a Matrox Meteor frame grabber in a Pentium 
200 MHz personal computer. Illumination was provided by a halogen light-source, 
connected to a stabilized adjustable power supply (12V/IOOW). Images were taken 
at 10xlO magnification. 
The image analysis software consisted of the QWin Standard software (Leica) 
running under Microsoft Windows environment. Images were analyzed by 
interactively setting the reticular basement membrane. The program was set to 
analyze 100 ).Lm deep into the lamina propria. The outer perimeter of the intact 
epithelium was interactively set. Detection of the color of interest was done by 
setting thresholds for hue, saturation and intensity. During the image analysis 
procedure, hue, saturation and intensity were kept constant during the analysis of 
the entire study population. This approach allows for a densitometric analysis. The 
immunostained areas (mm3) were divided by the field measurement (mm\ 
Statistics 
Results are expressed as means ±standard deviations, unless otherwise mentioned. 
Linear regression analysis between variables and statistical significance were 
calculated with the use of a package of statistical software (Statistical Graphics 
Corp; Rockville, MD). Test results were considered statistically significant at p < 
0.05. 
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Results 
Twenty-one patients were included in the study. From all participants lung function 
tests and bronchial biopsy specimens were obtained. They had moderate-to-severe 
COPD and moderate or severe bronchial hyperresponsiveness (Table I). The mean 
age of the patients was 54 ± 8 years (17 male, 4 female). The mean FEV, equalled 
2.07 ±0.47 L. MBP count equalled 0.86 ±1.l6 (mm3/mm3). 
Table 1. Patient characteristics. 
N mean±SD median Range 
Age, yrs 21 56.3 ±8.9 60 42-69 
Actual smoking, cigarettes/day 21 15.4 ±7.4 13 6-30 
Pack-years 21 25.3 ±11.2 21 5 -50 
FEV 10 % predicted 21 62.5 ±12.9 65 34-93 
Reversibility, % predicted 21 5.3 ±3.1 5 0-9.0 
PC20, mglmL 
For histamine 21 1.7 ±2.1 0.87 0.11 - 8 
For methacholine 21 4.6 ±5.5 1.72 0.6 - 17.4 
Eosinophils, MBP count, 18 0.86 ±1.l6 0.39 0.03 -4.46 
mm3/mm3 
In three patients no 10g2nPC2o could be calculated because in these patients a 
plateau of the measured decline in FEV, was reached below the level necessary to 
obtain a 20% decrease in predicted FEV,. These patients were excluded from 
further analysis. 
Mean (±SD) log2PC2o for methacholine was 1.1 ±1.7. A positive correlation 
between log2PC2o and FEV, starting value was obtained (Figure I, R = 0.53, P = 
0.04). There was no significant correlation between log2PC2o and MBP count 
(p >.2). 
Log2nPC20 for methacholine equalled 3.9 ±1.9. No correlation between log2nPC2o 
and FEV, was obtained (p >.1). A statistically significant negative correlation was 
found between MBP count and log2nPC2o (Figure 2, R = -0.58, P = 0.04). 
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Figure 1. Correlation of log2PC2o and FEV1 in percentage of predicted normal 
values (FEVlpred) in 21 patients with COPD; R = 0.53, P = 0.04. 
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This study confirms the earlier described relationship between baseline FEV1 and 
the provocative concentration at which a 20% decrease of the baseline FEV1 is 
reached (Iog2PC20), in patients with COPD (2-5). An alternative expression of 
bronchial hyperresponsiveness, the concentration of a provocative agent at which a 
20% decrease in predicted FEV 1 was reached (10g2nPC2o), was found to be 
irrespective of the baseline FEV I. This log2nPC20 was found to be correlated with 
eosinophilic airways inflanunation whereas log2PC2o was not. 
Three patients were excluded from further analysis as no iog2nPC20 could be 
measured. A plateau of the decline in FEV1 during the test was reached at a level 
below a 20% decrease in predicted values. In all three patients low levels of 
eosinophilic airways inflanunation were found which is another indication for the 
relationship between eosinophilic airways inflanunation and log2nPC2o• 
Low (iog2)PCzo values were found in more than half of the subjects with chronic 
airflow limitation, who were current smokers (6,9,16). Due to the known positive 
correlation between FEV1 and log2PCzo, the level of log2PCzo could be influenced 
to a greater extent by the baseline FEV 1, than by the contractility of smooth muscles 
in the walls of the small airways. Small absolute changes become large percentage 
changes in subjects with a low baseline FEV1• This problem is comparable to the 
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difficulties in the interpretation of the measurements of reversibility (17). The 
relation between FEY 1 and log2PC zo, and the lack of studies regarding this subject 
are the reasons why the clinical meaning of a low log2PC zo in patients with COPD 
is still unclear (18). 
Figure 2. Correlation of log2nPCzo and the number of eosinophils in bronchial 
biopsies in 18 patients with COPD; R = -0.58, P = 0.04. 
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Bronchial hyperresponsiveness, established with pulmonary function testing with a 
provocative agent (log2PCzo), is one of the keystones for the diagnosis of asthma. In 
patients with asthma, BHR is related to eosinophilic airways inflammation. The 
standard estimate ofBHR, log2PC2o, was related to the number of eosinophils in the 
airway wall (19,20), although there also have been published negative results (21). 
As far as we know, no study has been published concerning the relationship 
between eosinophilic airway inflammation and 10g2PCzo in patients with COPD. 
Several recent studies in patients with COPD show a relationship between 
eosinophilic airways inflammation and beneficial effects of glucocorticosteroids (4-
7). 
In these studies the level of eosinophilic airways inflammation was determined by 
using induced sputum. Induced sputum is now regarded as a minimal-invasive 
technique for the estimation of the number of eosinophils involved in the 
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inflammatory process in the lungs. This technique has some major drawbacks (22). 
It has an invasive character and is not suitable in every patient. In patients with 
BHR, the inhalation of hypertonic saline may lead to uncontrolled and dangerous 
levels of bronchoconstriction. Next to the difficulties with obtaining a proper 
specimen, the laboratory work on determining eosinophil counts is complex (22). 
Bronchial provocation testing, using either methacholine or histamine, is a 
uniformly used technique for establishing BHR. If we could obtain from this test 
information regarding the level of eosinophilic airways inflammation, it may be 
possible to identify those patients with stable COPD who benefit from long-term 
glucocorticosteroid therapy and, even so important, to preclude glucocorticosteroid 
therapy in others. 
In this study we have normalized log2PC2o measurements by taking into account 
predicted FEVl values. This log2nPC20 was irrespective of baseline FEVl and was 
related to eosinophilic airways inflammation as analyzed in bronchial biopsy 
specimens, both in contrast to log2PC2o. Additional studies are needed for 
establishing whether COPD patients with low log2nPC2o levels are more prone to 
benefit from long-term glucocorticosteroid therapy. 
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Abstract 
Background - Treatment of chronic obstructive pulmonary disease (COPD) with 
inhaled glucocorticoids does not appear to be as effective as similar treatment of 
asthma. It appears tbat only certain subgroups of patients witb COPD benefit from 
steroid treatment. Therefore, we examined whetber inhaled fluticasone propionate 
(PP) had an effect on lung function and on indices of inflammation in a subgroup of 
COPD patients, witb bronchial hyperresponsiveness (BHR) in particular. 
Methods - We included 23 patients witb COPD based on tbe following criteria, 
chronic productive cough, forced expiratory volume in one second (FEV l) :s; 70% of 
tbe predicted normal value (%pred), reversibility of FEVl < 10% predicted after 
inhalation of 750 meg terbutaline, negative serology (phadiatop test) and negative 
skin prick test for standard inhaled allergens. Patients had to be persistent current 
smokers between 40 and 70 years of age. Nonspecific BHR was defined by a PC20 
for histamine of:s; S mg/mi. Patients received either 2 x 500 meg FP or placebo for 
6 montbs. Expiratory volumes were measured at montbly visits, BHR was 
determined at tbe start, after 3 and after 6 months, bronchial biopsies were taken at 
tbe start and after 6 months. Biopsies from healthy smokers served as controls. 
Results - Unlike in asthma, indexes of BHR were not significantly influenced by FP 
treatment. There was a steep decline of tbe FEVl in the placebo group, while tbe 
FEVl in the FP treated patients remained stable. FEVlIFVC, MEF50 and MEF25 
were significantly increased in the FP treated patients compared to tbe control 
group, while FVC and PEF were not affected. Biopsy specimens were analyzed for 
tbe presence of CD3+, CD4+, CDS+, MBP+, CDI5+, CD6S+, CDla+ and tryptase+ 
cells. After FP treatment, tbe numbers of CDS+, MBP+ and CD6S+ cells were 
significantly reduced in tbe lamina propria. In tbe epithelium, tbe number of 
tryptase + cells was significantly reduced. 
Conclusion - In patients witb COPD and BHR, FP compared to placebo, has a 
positive effect on indexes of lung function while bronchial inflammation as 
analyzed in bronchial biopsy specimens is reduced. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a disorder characterized by 
reduced maximum expiratory flow and slow forced emptying of the lungs. About 
15% of the smoking population develops COPD. The airways in COPD are 
markedly inflamed. However, the predominant types of inflammatory cells and the 
main anatomical site of the lesions appear to differ from those in asthma (1-3). 
Inhaled glucocorticoids (GCs) are the most prominent medication used in the 
treatment of asthma and COPD. However, while treatment with GCs is the potent 
therapy available for patients with asthma, the beneficial effects of steroid treatment 
in COPD are subject of debate. The improvements of lung function parameters, 
which are characteristic in case of steroid treatment in asthma, have not been 
unequivocally found in COPD (4-7). It has been postulated that if steroids are 
important in the treatment of COPD, they act via down- regulation of cytokine and 
adbesion molecule expression, with a consequent reduction in cell migration and 
activation (8). To date, the number of studies reported dealing with the effect of 
steroid treatment on inflammation in COPD is limited. 
Approximately 25% of patients with stable COPD could, however, benefit from 
continuous steroid treatment (9). Earlier, it was suggested that inhaled 
glucocorticoids were more likely to have beneficial effects in patients with COPD 
when asthmatic features were present (10). Most recently, a beneficial effect of 
prednisolone was shown in patients with COPD who had increased numbers of 
sputum eosinophils (11). In a large .multicenter trial with patients with respiratory 
symptoms, the effect of an inhaled steroid on the course of FEV l was found to be 
most prominent in patients with more severe bronchial hyperresponsiveness (BHR) 
(12). BHR is usually regarded as a distinguishing characteristic of asthma, but is 
surprisingly often found in patients with COPD and in smokers (13,14). The 
features of BHR, however, differ between asthma and COPD. In COPD, the 
presence of BHR is associated with more severe disease, leading to an even more 
accelerated decline of lung function (FEV l ) resulting in reduced life expectancy 
(15-18). It could be an indicator ofa more serious and/or a different inflammatory 
process in the airways of these patients with COPD (19-21). 
Therefore, we speculated that patients with COPD and BHR would benefit from 
inhaled steroid treatment. We analyzed indexes of lung function and markers of 
inflammation in the larger airways before and after treatment in this group of 
patients. Indexes of lung function were determined at the start and at four weeks 
intervals up to 6 months into the study during which the patients received either FP, 
twice daily 500 mcg, or placebo. Bronchial biopsies were obtained at the start and 6 
months later at the end of the study. Immunohistochemical analysis of biopsy 
specimens was performed to identifY and quantifY markers of inflammation. 
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Participants, materials and methods 
Patients 
Patients with COPD (n = 23) were selected according to generally accepted criteria 
(22). In short, these criteria were chronic productive cough, FEV j ,;; 70% of the 
predicted normal value (%pred), reversibility ofFEV j of < 10 % predicted after 750 
Ilg terbutaline administered by metered-dose inhalation, negative serology 
(phadiatop test) and negative skin prick tests for standard inhaled allergens. Also, 
patients with an FEV/inspiratory vital capacity (IVC) ratio';; 0.70 were included, 
provided their TLC was greater than the predicted value plus 1.64 SD. Reference 
values were obtained from EGKS standards (23). Participants had to be current and 
persistent smokers between 40 and 70 years of age. Nonspecific BHR was defined 
by a PC20 for histamine';; 8 mg/mL. FEV j had to be > 1.2 L to ensure complete 
safety in view of the bronchial provocation tests. Patients' characteristics are listed 
in table 1. 
Subjects were excluded if they had a history of asthma characterized by attacks of 
dyspnoea, chest tightness or wheezing; respiratory tract infection in the four weeks 
preceding the first visit or were suffering from serious or unstable concomitant 
disease. 
Eligible patients using anti-inflammatory therapy including NSAIDs were asked to 
refrain from oral prescriptions for at least three months and from inhaled 
glucocorticoids, sodium cromoglycate or nedocromil sodium for at least six weeks 
prior to the start of the study. Also, longacting ~2-agonists, xanthine derivatives and 
anti-histamine drugs had to be stopped at least six weeks before the start of the study. 
If after discontinuation of drug therapy deterioration of symptoms or lung function 
occurred, patients were excluded from the study. 
Asymptomatic smokers with a normal maximal expiratory flow-volume (MEFV) 
curve, PCzo for histamine> 8 mglmL and absence of allergy (negative Phadiatop 
test) were selected and served as control group (n = 6; Table I). 
After an overnight fast, blood was drawn for measurement of circulating cortisol 
levels early in the morning prior to lung function tests. The concentration of cortisol 
was determined using kits supplied by Diagnostics Products Corporation (Los 
Angeles, California, USA) at the Department of Internal Medicine of our University 
Hospital (24). 
The hospital's Medical Ethics Committee approved the study. Written informed 
consent was obtained from all participants. 
Study design 
We performed a double blind, placebo-controlled study with a treatment period of 
six months. The design is schematically presented in figure I. 
During the two-weeks' run-in period, subjects underwent lung function tests. 
Eligible patients were randomly allocated to either the treatment group (n = 10), 
which received twice-daily 500 Ilg FP via a diskhaler, or the placebo group (n = 
13), which received their prescription via a similar device. Salbutarnol via diskhaler 
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was given as rescue medication. Inhalation of ipratropium bromide was allowed at 
constant dosages. At the start of the treatroent period and after 6 months, bronchial 
biopsies were collected. Every four weeks, participants visited our outpatient clinic 
for a follow-up, to have their used and unused medication of the preceding period 
taken in, and to have their MEFV curve determined, before and after inhalation of 
750 )lg terbutaline. BHR was tested with methacholine at the start, three months 
into and at the end of the treatroent period. 
Figure 1. Study design 
Two-week run-in period 
months 0 
lung function test * 
methacholine provocation test * 
bronchoscopy * 
Lung jUnction tests 
2 x 500 "Fluticasone ro ionate 
2 x 1 dose placebo 
I 2 3 4 5 
* * * * * 
* 
6 
* 
* 
* 
At baseline, spirometry and the closed circuit Helium wash-in method were used to 
obtain spirometric volumes and lung capacities (total lung capacity [TLC], 
functional residual capacity [FVC], IVC, FEV1). At the start and at each fourth 
week visit, MEFV curves were recorded with a heated pneumotachometer (Jaeger, 
Wurzburg, Germany). From the MEFV curve, the forced vital capacity (FVC), the 
peak expiratory flow (PEF), the maximal expiratory flow at 50% ofFVC (MEF50), 
and the maximal expiratory flow at 25% of FVC (MEF25), were derived. All 
MEFV curves were recorded at the same time of the day. Patients were instructed 
not to take any bronchodilators at least 8 hours prior to lung function tests. 
Histamine and methacholine provocation tests were performed according to the 2-
min tidal breathing method. Histamine was used to determine PC20 (inclusion 
criterion), while methacholine was used to establish a full dose-response curve. 
Solutions of histamine-sulphate and acetyl-B-methylcholinebromide were prepared 
at the hospital's Pharmacy Department. Solutions were stored at 4°C and were used 
at room temperature. Aerosols were generated by a nebulizer (model 646; 
DeVilbiss Co; Somerset, PA, USA) (measured output 0.13 mLl min) and were 
inhaled by tidal breathing over a 2-min period at 5-min intervals. After inhalation of 
an isotonic saline solution, doubling concentrations (0.03 - 256 mg/ml) of 
histamine or methacholine were administered. The response to methacholine or 
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histamine was measured as the change in FEV, expressed as a percentage of the 
initial value. FEV, was derived from the pneumotachograph readings. PC20 was 
calculated from these data. Histamine provocation tests were interrupted if a 20% 
fall of FEV, was achieved at a histamine concentration::; 8 mg/mL. Methacholine 
tests were interrupted if the FEV, fell by more than 60%, or if unpleasant side 
effects occurred. After the test, the patient inhaled a bronchodilator to restore the 
FEV, to the initial value. 
From the methacholine provocation tests, the log2 concentration and the measured 
percentage changes in FEV, were imported to a computer program that fitted a 
sigmoid function (cumulative Gaussian distribution) to the data (2S). Reactivity (the 
slope of the curve), plateau values (maximal bronchoconstriction), and ECso (the 
concentration of the stimulus causing SO% of maximal bronchoconstriction) were 
taken from this model fit. 
Bronchoscopy 
The procedure was carried out essentially as described in the ATS guidelines (26). 
At the start of the procedure, the patient received 0.5 mg atropine intramuscularly. 
A pulse-oxymeter was applied to a fingertip of the patient to monitor pulse rate and 
oxygen saturation. Mouth and pharynx were anaesthetized with a lidocaine spray. 
Next the vocal cords, trachea and bronchial tree were anaesthetized with aerosolized 
oxybuprocaine-solution (S mg/mL) up to a maximum of20 mL. Bronchoscopy was 
performed with the Olympus BF I TI O. At least 6 biopsies were taken from the 
subcarinae of both the right and the left upper and lower lobes with a fenestrated 
forceps (FB-18C or FB-20C). Sedative drugs and/or oxygen were administered 
whenever thought necessary by the physician or requested by the patient. 
Processing of the bronchial biopsies 
Bronchial biopsies were snap-frozen in Tissue-Tek II OCT embedding medium 
(Miles, Naperville, Illinois, USA) in liquid nitrogen within 10 min after collection, 
and stored at -80°C. Once all biopsy specimens were collected, 6 11m serial tissue 
sections were cut on a HM-S60 cryostat (Microm, Heidelberg, Germany). At least 
two sections 120 11m apart from one biopsy specimen were placed on a poly-L-
lysine-coated microscopic slide (Sigma Diagnostics, St.Louis, MO, USA). Next, 
sections were air dried for 30 min and stored at -80°C until use. Immunosta~ning 
was carried out with: aCD3 (UCHTI), aCD4 (MT310), aCD8 (DK2S), and 
aCD2S (ACT-I) (Becton Dickinson, San Jose, CA, USA); aCDla (NA1I34), 
aCDIS (C3D-I), aCD68 (EMBlI), and aMBP (BMKI3) (Dako, Glostrup, 
Denmark); a-tryptase (Chemicon Brunschwig Chemie, Temecula, CA, USA); 
aEG2 (pharmacia). 
Binding of the antibodies was detected by the immuno-alkaline phosphatase anti-
alkaline phosphatase (APAAP) method. Sections were fixed in acetone for 10 min 
at RT, rinsed in phosphate buffered saline (PBS) pH 7.2 and placed in a semi-
automatic stainer (Shandon, Pittsburgh, P A, USA). Slides were sequentially 
incubated with bovine serum albumin (BSA) 2% in PBS for 10 min, incubated with 
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10% nonnal rabbit serum in PBS (Central Laboratory of the Netherlands Red Cross 
Blood Transfusion Service, Amsterdam, The Netherlands) for 10 min. Next, they 
were incubated with the appropriate mAbs for 60 min at RT. Subsequently, sections 
were rinsed twice in PBS for 5 min and incubated with a rabbit anti-mouse (RaM) 
(1 :50) immunoglobulin serum for 30 min. Next, slides were rinsed twice in PBS, 
incubated with AP AAP (I :50) (Dako, Glostrup, Denmark) for 30 min at 20°C, 
rinsed in PBS and Tris buffer (PH 8.0), and incubated for 30 min with New Fuchsin 
substrate (Chroma, Stuttgart, Gennany) as chromogen. Sections were 
counterstained with Mayers hematoxylin. 
Immunostained sections were analyzed with an image analysis system. The image 
analysis hardware consisted ofa 3CCD (charge-coupled device) color video camera 
(model DXC-950; Sony, Tokyo, Japan) mounted on a microscope (model DM 
REE; Leica, Rijswijk, The Netherlands) and connected to a Matrox Meteor frame 
grabber in a Pentium 200 MHz personal computer. Illumination was provided by a 
halogen light-source, connected to a stabilized adjustable power supply 
(l2VIl00W). Since the emission of light-sources and the noise and sensitivity of 
CCD cameras are known to vary with temperature, all hardware was allowed a I 
hour warming-up period to minimize unwanted thennal effects. Images were taken 
at 10xi0 magnification. 
The image analysis software consisted of the QWin Standard software (Leica) 
running under Microsoft Windows environment. Images were analyzed by 
interactively setting the reticular basement membrane. The program was set to 
analyze 100 llm deep into the lamina propria. The outer perimeter of the intact 
epithelium was interactively set. Detection of the color of interest was done by 
setting thresholds for hue, saturation and intensity. During the image analysis 
procedure, hue, saturation and intensity were set for each immunohistochemical 
staining and kept constant during the analysis of the entire study population for that 
particular staining. This approach allows for a densitometric analysis. However, this 
makes a comparison between marker molecules impossible. 
The immunostained areas were divided by the field measurement, which consisted 
of the total area, either of the epithelium or the lamina propria. If the total area 
studied was less than 100.000 llm2 for a given subject, this subject was excluded 
from further analysis of that particular inflammatory marker. 
Statistics 
Results are expressed as mean ± SD, unless otherwise mentioned. Differences 
between groups were analyzed with the unpaired Student's t test or the Marm-
Whituey U-test where appropriate. Paired data were tested for significance with the 
paired Student's t test or, after In-transfonnation, the Wilcoxon matched pairs test 
where appropriate. A rmANOV A was perfonned for the dependent variables FEV] 
(as percent predicted), FVC, FEV/FVC, PEF, MEF50 and MEF25, after In-
transfonnation. From each of these variables, one baseline measurement at the start 
of the intervention and 6 repeated measurements during treatment were available. In 
the rmANOVA model, the independent variables are time (a within-subject 
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categorical factor with 6 levels), treatment (a between-subjects factor with 2 levels), 
and the baseline measurement of the outcome variable considered as a between-
subjects continuous and constant variable. The within-subject residual covariance 
structure is assumed to be of the type "compound synnnetry". Interest is in the 
effect of treatment and its interaction with time. The question of interest is whether 
there is a difference between the two treatment groups and whether this difference 
changes over time. Significance is accepted ifp < 0.05. 
Results 
Patients 
Participants of the study had a mild to moderate degree ofCOPD according to ERS 
criteria and moderately to severe BHR. At baseline, characteristics were not 
significantly different between the FP and placebo group. Asymptomatic smokers 
and patients with COPD could be discriminated based on a significantly different 
FEV l and FEV/ FVC (Table I). 
Compliance with study medication was high. Percentages of returned used blisters 
were not different between the groups, 92.5 in the FP group and 90.7 in the placebo 
group. 
During the treatment period, no subjects dropped out of the study. Periodically, 
several participants noticed worsening of disease-related symptoms, like coughing 
and production of sputum. In all cases, these symptoms could be resolved with 
rescue medication while not violating the inclusion criteria. 
Adverse events were reported 25 times in the FP treated group and 28 times in the 
placebo group (p > 0.05). Adverse events related to airways' disease and/or study 
medication were reported more often by patients receiving placebo as compared to 
FP treated patients (18 vs 7, p = 0.02). These adverse events included candidiasis of 
mouth (in the FP treated group), stomatitis, throat pain, irritation of pharynx, upper 
respiratory tract infection, acute bronchitis without decrease in FEV" and mild 
increase of airways' obstruction. 
The use of rescue medication was not different between the two groups of patients 
(p > 0.05). The mean numbers of used salbutarnol dosages were 32.5 ±27 and 40.4 
±42.7 per month in the FP group and in the placebo group, respectively. The mean 
numbers of used ipratropium bromide dosages were 2.2 ±4.7 and 9.6 ±3.0 per 
month in the FP group and in the placebo group, respectively. 
Levels of circulating cortisol were monitored. At the start of the study, mean levels 
were 360.9 ±112 and 335 ±87 nMollL in the FP and the placebo group, 
respectively. After 6 months, mean levels were 414.6 ±156 and 430 ±104 nMollL. 
Levels were not significantly different between groups at a given time-point, nor 
were they significantly different between time-points. 
Lungfonction 
During the treatment period of six months, the mean PC20 for methacholine had 
increased in the FP treated patients relative to the placebo group (Fig. 2). This 
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increase was, however, not statistically significant. No significant changes of 
reactivity, maximal bronchial constriction (plateau) and ECso were detected either 
(Fig. 3). 
Table 1. Subject characteristics (mean ±SD) 
Asymptomatic Fluticasone Placebo 
smokers propionate 
(n= 6} (n = 10} (n = 13} 
Male! female ratio 3/3 8/2 ll/2 
Age (yrs) 44±9 54±8 56 ±8 
Actual smoking 21 ±10.0 15 ±8.2 16 ±6.7 
Pack years 23 ±12.4 25.2 ±12.3 26±9.7 
Serum 19E (UIL) N.D. 72±64 81 ±127 
Blood eosinophils (xl031L) N.D. 163 ±98 195 ±91 
FEV! (L) 2.78 ±O.48* 2.09 ±D.45 2.02 ±0.48 
FEV! (%pred) 93 ±1111 66±13 61 ±12 
Reversibility (%pred) 4.0 ±3.0 5.3 ±3.7 5.6±2.7 
FEV/FVC 0.79±O.03 0.56 ±0.12 0.56 ±D.I0 
PC20 for histamine (mg! mL) >8 2.6 ±2.4 0.8 ±0.6 
PC20 methacholine (mg! mL) N.D. 6.3 ±5.9 2.6 +4.3 
* p = 0.02 and 11 p = om (asymptomatic smokers vs COPD patients), N.D. = not 
done. 
Changes of mean FEV! after bronchodilation are shown (Fig. 4A). A significant 
decline of the FEV! was detected in the placebo group while the FEV! in the FP 
treated group remained almost unchanged. The mean decline of the FEV! in the 
placebo group compared to the FP treated patients was 6.92 %pred before 
bronchodilation and 7.97 %pred after bronchodilation. The course of the pre- and 
that of the post-bronchodilator FEV! were significantly different between the FP 
treated patients and the placebo group (pre-bronchodilator, p = 0.015; post-
bronchodilator, p = 0.0002 (rrnANOV A); Fig. 4B). The starting values were taken 
as co-variants for the rmANOVA tests. The FEV!/ FVC ratio (pre-bronchodilator) 
showed a similar pattern of change, mean difference was 0.065, p = 0.024 
(rmANOVA). There were significant changes of MEF50 from the second month 
onwards [0.29 ±0.07 L (mean ±SD)], and of MEF25 from the third month onwards 
[0.32 ±0.09 L (mean ±SD)] (t-test for equality of mean changes) (Fig. 5). Both FVC 
and PEF were not affected and remained unchanged in both groups. 
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Figure 2. Course of the mean log2PC2o for methacholine during the treatment 
period of 6 months with either Fluticasone propionate (closed circles) or placebo 
(open circles). P > 0.05 (rmANOVA). 
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Figure 3. Fitted methacholine dose-response curves, mean of the Fluticasone 
propionate treated patients, at the start of the treatment (------), 3 months into the 
treatment ( --), 6 months into the treatment (end of study, ----). 
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Bronchial inflammation 
Bronchial biopsy specimens were analysed for the presence of inflanrmatory cells 
characterized by cell surface molecules and/or cytoplasmic proteins. 
First, COPD patients were compared with 'healthy' smoking controls. Inflanrmation 
was analyzed separately in the bronchial epithelium and 100 11m deep into the 
lamina propria. None of the marker molecules were significantly increased or 
decreased in the patients with COPD as compared to 'healthy smoking' control 
subjects. There was, however, less CD3 detectable in the lamina propria in COPD 
patients compared with the control group (Table 2). 
Next, the effects of six months' treatment with FP or placebo were analyzed (Table 
3). CD8 was significantly decreased in the lamina propria in both placebo (p = 
0.006) and FP treated (p = 0.028) patients. In contrast, MBP (p = 0.015) and CD68 
(p = 0.021) were significantly decreased in the FP treated patients only. In the 
epithelial layer, levels of tryptase were significantly decreased after FP treatment (p 
= 0.027). Other markers of inflanrmation were not or only marginally affected by 
the treatment regimen. 
Discussion 
We treated mild-to-moderate COPD patients who were hyperresponsive and who 
continued smoking, with FP (500 Ilg twice daily) for 6 months in a double-blind, 
placebo-controlled study. Analysis of the methacholine dose-response curves 
showed that not only PC20, but all other indexes of BHR did not change as a result 
of FP treatment Earlier we have shown that an equal dose of FP in patients with 
asthma with a similar degree of BHR, resulted in a rightward shift of the 
methacholine dose-response curve (27). Studies concerning patients with COPD in 
which PC20 was determined showed that inhaled steroid treatment had no effect on 
BHR (28-30). To our knowledge, we show for the first time that also additional 
indexes of BHR (reactivity, plateau, and ECso) were not affected by steroid 
treatment 
There was, however, a significant reduction of the decline in both pre- and post-
bronchodilator FEV, (%pred) (Fig. 4). Our results are supported by a recent study 
(31). Here, the investigators reported that FP treatment (500 Ilg twice daily for 6 
months) of COPD patients resulted in improvement of FEV, and FVC. The FP 
treated patients had less frequent, but also less severe exacerbations. Clinical 
symptoms improved significantly, while sputum production decreased. Markers of 
inflanrmation were not analysed in that study. Three years treatment with inhaled 
budesonide in subjects with mild COPD who continued smoking (EUROSCOP) 
showed an improvement of FE V, of 17 mL per year, as compared with a decline of 
81 mL per year in the placebo group during the first six months of the study (5). 
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Figure 4. Change of FE VI (A) and the course of FE VI (B) [post-bronchodilationJ, 
expressed as percentages of predicted nonnal values (% pred), during the treatment 
period of 6 months with either Fluticasone propionate (closed squares) or placebo 
(open squares). 
Figure 4A. mean difference: 7.97% pred, p = 0.0002 (rmANOVA) 
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Figure S. Course of MEF50 (A) and MEF25 (B), expressed as percentages of 
predicted nonnal values (% pred) during the treatment period of 6 months with 
either Fluticasone propionate (closed triangles) or placebo ( open triangles). 
Figure SA. P = 0.0006 (rmANOVAj 
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Table 2. Baseline scores of inflammatory markers in epithelium and lamina propria 
of biopsies taken from the central airways of smoking patients with COPD and 
'healthy', smoking control subjects. 
Data are expressed as median (range) ratios of immunostained areas and field measurement, 
which consisted of the total area, either of the epithelium or the lamina propria. Statistical 
analysis by Mann-Whitney U test after log transformation. 
EPITHELIUM LAMINA PROPIA 
Marker Patients with 'healthy', Patients with 'healthy', 
COPD smoking control COPD smoking control 
subjects subjects 
CD3 0.72 0.63 0.36 0.74 
(0.10-4.52) (0.24-0.93) (0.04-5.71) (0.61-1.19) 
CD4 1.07 0.94 0.74 0.64 
(0.14-4.0) (0.40-2.0) (0.07-9.0) (0.27-1.63) 
CD8 0.08 0.05 0.04 0.04 
(0.03-0.60) (0.02-0.09) (0.03-0.42) (0.01-0.13) 
CD25 0.22 0.10 0.15 0.12 
JO.03-3.2~ (0.03-0.22) (0.03-2.39) (0.04-0.26) 
MBP 0.12 0.03 0.38 0.25 
(0.03-5.27) (0.01-0.67) (0.00-6.45) (0.01-5.1~ 
EG2 0.12 0.12 0.25 0.46 
(0.01-1.79) (0.01-0.55) (0.03-0.68) (0.14-8.01) 
CDl5 3.43 3.39 0.62 0.81 
(0.08-17.4) (0.68-8.96) (0.14-4.73) (0.Ql-l.40) 
CD68 1.53 1.09 2.49 2.95 
(0.24-11.4) (0.46-1.98) (0.44-20.1 ) (1.13-4.74) 
CDla 0.12 0.08 0.14 0.07 
(0.04-0.45) (0.03-0.18) (0.04-0.35) (0.02-0.12) 
Tryptase 0.14 0.10 1.30 1.23 
(0.03-0.63) (0.05-0.29) (0.12-4.03) (0.20-2.49) 
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Table 3. Comparison of baseline and post-intervention scores of inflammatory 
markers in epithelium (A) and lamina propria (B) of biopsies taken from the central 
airways of patients with COPD, treated with either Fluticasone propionate or 
placebo. Data are expressed as median ratios (range) of immunostained areas and 
field measurement, which consisted of the total area, either of the epithelium or the 
lamina propria. 
Statistical analysis by paired Wilcoxon test after log transformation. 
Table 3A. 
EPITHELIUM 
Fluticasone propionate Placebo 
Marker Baseline post- Baseline post-
intervention intervention 
CD3 0.57 0.28 0.79 0.45 
(0.10-4.52) (0.10-1.54) (0.35-2.23) (0.147-3.25) 
CD4 1.03 0.70 1.11 1.19 
(0.14-4.0) (0.40-2.03) (0.19-1.79) (0.70-2.17) 
CD8 0.09 0.09 0.07 0.07 
(0.05-0.60) (0.01-0.12) (0.03-0.26) (0.026-0.23) 
CD25 0.16 0.20 0.27 0.15 
(0.07-3.28) (0.03-0.31) (0.03-1.28) (0.004-1.79) 
MBP 0.06 0.03 0.20 0.15 
(0.OH.22) (0.01-0.25) (0.03-5.27) (0.001-1.05) 
EG2 0.16 0.06 0.08 0.07 
(0.01-0.45) (0.02-0.31 ) (0.03-1.79) (0.008-0.47) 
CD15 3.31 2.12 4.32 1.64 
(1.52-17.4) (0.08-8.68) (0.15-14.6) (0.529-27.7) 
CD68 1.42 0.81 1.64 1.19 
(0.24-11.4) (0.23-2.64) (0.39-9.86) (0.368-5.12) 
CDla 0.14 0.13 0.10 0.10 
(0.04-0.45) (0.05-0.29) (0.05-0.30) (0.013-0.19) 
Tryptase 0.10 0.02 0.18 0.097 
(0.03-0.63) (0.00-0.18) ~ (0.03-0.61) (0.023-0.59) 
~ Reduction oftryptase+ cells compared to baseline in FP treated group (p<0.03) 
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Table 38. 
LAMINA PROPIA 
Fluticasone propionate Placebo 
Marker baseline post- baseline post-
intervention intervention 
CD3 0.23 0.20 0.50 0.31 
(0.04-5.71) (0.03-1.58) (0.20-1.40) (0.02-1.97) 
CD4 0.68 0.54 0.80 0.58 
(0.07-5.61) (0.18-1.02) (0.14-9.0) (0.47-1.48) 
CD8 0.06 0.03 0.04 0.02 
(0.03-0.42) (0.01-0.07) * (0.03-0.16) (0.01-0.10) t 
CD25 0.17 0.15 0.13 0.06 
(0.05-2.39) (0.02-0.51) (0.03-0.47) (0.00-0.46) 
MBP 0.29 0.08 0.46 1.87 
(0.05-2.30) (0.01-0.64) :j: (0.03-4.46) (0.00-6.45) 
EG2 0.22 0.28 0.28 0.72 
(0.13-0.68) (0.01-1.01) (0.03-2.5) (0.01-4.69) 
CDl5 0.40 0.90 0.68 0.73 
(0.19-4.73) (0.19-3.73) (0.14-3.95) (0.15-3.98) 
CD68 1.77 0.98 2.67 1.76 
(0.44-20.1) (0.26-2.77) § (0.52-4.35) (0.58-5.64) 
CDla 0.16 0.14 0.12 0.11 
(0.04-0.35) (0.04-0.59) (0.05-0.31) (0.02-0.21) 
Tryptase 0.67 0.44 1.95 
(0.19-3.26) . (0.02-0.74) (0.12-4.03) 
• reduction ofCD8+ cells compared to baseline in FP treated group (p<0.03) 
t Reduction of CD8+ cells compared to baseline in placebo group (p<0.0 1) 
+ Reduction ofMBP+ cells compared to baseline in FP treated group (p<O.02) 
§ Reduction of CD68+ cells compared to baseline in FP treated group (p<0.03) 
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A similar treatment period with FP (ISOLDE) resulted in a significant reduction in 
the fall of FEY1 (32). The rate of decline in FEY1 in the group receiving placebo 
was markedly higher than that of the steroid treated group over the initial 6 months 
of treatment comparable to our findings. In contrast, the Copenhagen City Lung 
Study could not demonstrate an effect of long-term treatment with inhaled steroids 
on decline in lung function in patients with mild to moderate irreversible airflow 
limitation (6). In a recent study, patients with COPD were treated with 
triamcinolone for three years (7). A subgroup of these patients were hyperreactive. 
Among this subgroup the rate of decline in lung function did not slow down when 
evaluated over the entire three years' period. Over the initial six months of the trial, 
however, a beneficial treatment effect of triamcinolone, as compared to placebo, on 
the rate of decline of the FEY 1 can be deduced. This is in line with our results 
showing abolishment of FEY 1 decline in the FP treated group while the placebo 
group had an extrapolated decline of 120 ml per year. During the first 2 months of 
treatment, the decline was most marked and leveled off thereafter. The initial rapid 
decline among the patients receiving placebo may have resulted from the 
withdrawal of steroids. Steroids were withdrawn at least 6 weeks before the actual 
treatment period, which should have been ample time to at least overcome such a 
steroid weaning effect. A more likely explanation for our findings may be found in 
that BHR itself makes the patients subject to a decline in lung function in the 
absence of steroids. The beneficial effect of steroid treatment in this group of 
COPD patients leads to relieving patients from this decline and keeping FEY1 
constant. 
It is unlikely that the treatment period of six months was not long enough to achieve 
a detectable response. Based on results of other studies including EUROSCOP, the 
most marked effects of inhaled steroid treatment should have been achieved during 
this time period (5,6,31,33). Therefore, it is unlikely that an extended FP treatment 
would have resulted in an increase of the FEY1 in the steroid treated patients. On 
the other hand, a meta-analysis of three studies published between 1983 and 1996 
showed a significant beneficial effect of inhaled corticosteroids compared with 
placebo on the course of the pre-bronchodilator FEY1 during two years of treatment 
(34). 
From our analysis of the derivatives of the MEFV curves, we propose that the 
anatomical location of the anti-inflammatory effect of the inhaled steroid is in 
the smaller airways. Significant changes were observed in MEF50 and MEF25. 
In contrast to others, we found FVC and PEF not to be affected (31). This 
discrepancy can be attributed to differences in patient selection criteria. 
Although MEF50 and MEF25 are less accurate parameters of expiratory flow, 
the significance and consistency of this finding indicate that the effect of FP on 
lung function is most probably caused by an effect on the small airways rather 
than by an effect on the larger airways. Bronchial biopsy specimens were taken 
from the central airways. 
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Eosinophils are important in the inflammatory process of asthma and correlate 
with BHR (35). We found eosinophils to be also present in the inflammatory 
infiltrate in COPD comparable with that in asymptomatic smokers. It is likely 
that smoking and other mechanisms that recruit neutrophils into the airways in 
COPD cause a degree of eosinophil influx (36). Recent [mdings show that 
eosinophilic airway inflammation was common among patients who had stable 
moderate and severe COPD (11). In our study, no significant differences in 
changes of cellular indices between treatment groups were detected. However, 
significant changes were detected within groups. Treatment with FP resulted in 
a significant decrease of mast cells in the epithelium and of CDS+ lymphocytes, 
eosinophils (MBPl and macrophages (CD6Sl in the lamina propria. The 
significant treatment effect on CD6S+ cells may be explained by a coincidental 
regression to the mean. In the placebo treated group, an increase in eosinophils 
was detected, which coincided with a decrease of CDS+ cells. The persistent 
inflammation is likely to cause the accelerated decline of the FEV 1 in patients 
withCOPD. 
Previously, we have shown that the number of dendritic cells was elevated in the 
asthmatic airways compared to the airways of healthy control subjects (37). In the 
airway mucosa of COPD patients as well as in that of 'healthy' smoking controls, 
CDla+ dendritic cells were hardly detectable. Consequently, a reduction of the 
number of DCs in airway biopsy specimens from COPD patients as a result of FP 
treatment could not be demonstrated. Our findings are supportive of a limited 
contribution ofDCs to the pathology of CO PD. 
After a two weeks course of oral prednisolone, no changes of inflammatory indexes 
as measured in sputum samples of COPD patients were detected (8). Our study 
. illustrates that FP treatment for 6 months leads to a reduction of cellular infiltrates 
in the bronchial mucosa. This discrepancy may be explained by the fact that sputum 
cell counts have been found to be related to bronchial wash and bronchoalveolar 
lavage fluid, but to a lesser extent to the counts in bronchial biopsies (38). Others 
have reported, that sputum is derived from a different compartment altogether (40). 
We were not able to detect a treatment effect on eosinophil counts in the epithelium. 
In contrast, we observed a significant reduction of eosinophils in the sub-
epithelium. These results are also reflected by the absence of a treatment effect on 
eosinophil numbers in bronchial wash and bronchoalveolar lavage fluid (data not 
shown). This may be explained by the fact that eosinophilic inflammation seemed 
to be much more pronounced in the sub-epithelium than in the epithelium of the 
larger airways in our population of patients with COPD and BHR. 
Overall this study shows that in COPD patients with BHR, FP treatment has a 
positive effect on indexes of airflow limitation. In contrast, indexes of 
hyperresponsiveness were not affected, while inflammation was only marginally 
reduced. Our results suggest that COPD patients with BHR benefit from inhaled 
steroid treatment. 
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ChapterS 
Effects of fiuticasone propionate inhalation on levels of arachidonic acid 
metabolites in patients with chronic obstructive pulmonary disease. 
Gert T. Verhoeven1, Ingrid M Garreldi, Henk C. Hoogsteden1, Freek J. Zijlstra' 
'Department of Pulmonary and Intensive Care Medicine. 'Department of Ph anna co logy, 
University Hospital Dijkzigt and Erasmus University, EMCR, Rotterdam, The Netherlands. 
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Abstract 
Background: In smoking COPD patients the bronchoalveolar lavage (BAL) fluid 
contains high numbers of inflammatory cells. These cells might produce Arachidonic 
Acid (AA) metabolites, which contribute to inflammation and an increased 
bronchomotor tone. 
Aim of the study: investigate levels of AA metabolites in BAL fluid, before and after 
inhaled glucocorticoid therapy: fluticasone propionate (FP) 1 mg per day, or placebo. 
Methods: double-blind placebo controlled trial lasting six months. COPD patients were 
selected by clinical criteria and the presence of bronchial hyperresponsiveness (BHR). 
Lung function was recorded and in BAL fluid we counted cell numbers and measured 
LTB4, LTC.,IDJE4, PGE" 6kPGF,ct,PGF,ct and TxB,. A control group consisted of 
asymptomatic smokers (n=6). 
Results: paired data were obtained from 9 FP treated and II placebo patients. BAL 
cells were almost exclusively alveolar macrophages. In patients and controls both 
cellularity and levels of AA metabolites were equal. Cell numbers did not change after 
treatment. Statistically significant decreases after FP therapy were noticed for PGE, 
(30%), 6kPGF,ct (41%) andPGF,ct (54%). 
Conclusions: in COPD, the capability of inflammatory cells to produce certain AA 
metabolites was decreased after inhaled FP treatment. This result is discussed in its 
relation to clinical effects, the influence of smoking, and the results of an earlier, 
similar study in asthma patients. 
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Introductiou 
. Leukotrienes (LTs) and prostaglandius (P0s) are mediators of inflammation that have 
been investigated almost exclusively in asthma, but not in COPD. These metabolites of 
arachidonic acid (AA) are products of several inflammatory cells and part of the 
mechanisms leading to bronchoconstriction and increased bronchomotor tone. In 
chronic obstructive pulmonary disease (COPD) airway narrowing is caused by several 
mechanisms, including mechanical factors (loss of elasticity of the lung parenchyma), 
increased thickness of the walls of the conducting airways, increased bronchomotor 
tone and intraluminal secretions (1,2). Increased numbers of alveolar macrophages, 
neutrophilic granulocytes and CD8 positive cells constitute the main burden of the 
cellular infiltrate in the airway walls and alveoli. Their secretory products cause 
multiple effects, for instance cell influx and cell activation, but also an increase of the 
contractile status of the smooth muscles in the small bronchi. Among these cell 
products, AA metabolites are known for their potent bronchoconstrictor activity. 
Therefore, we hypothesized that AA metabolites could also be detected in COPD and 
anti-inflammatory treatment could influence their levels. 
Samples of BAL supernatant were collected at the start and after six months of a 
double-blind trial comparing the effect of fluticasone propionate (FP) with placebo, in 
smoking COPD patients. We decided to study a subgroup of COPD patients, 
particularly those with bronchial hyperresponsiveness (BRR), because these patients 
are subject to an even more accelerated decline of their FEVj (3,4). This could indicate 
a severe inflammatory infiltrate, increased levels of AA metabolites and potentially an 
effect of an inhaled glucocorticoid. Smokers without symptoms and with normal lung 
function served as controls. 
Material and methods 
Patients 
COPD patients were selected according to generally accepted clinical and 
functional criteria (5). Inclusion criteria were: age between 40 and 70 years, current 
smoker, FEVj/iVC ratio :90% of predicted normal values (pred), reversibility of 
FEVj <IO%pred after 750 Ilg terbutaline, non-specific BHR - defined by a PC20 his-
tamine ::;8 mglml - and negative skin tests for standard inhaled allergens. Reference 
values were obtained from ECCS standards (6). The main exclusion criteria were a 
history of asthma and recent respiratory tract infection. Any anti-inflammatory 
therapy, including corticosteroids, non-steroidal anti-inflammatory drugs and 
theophyllines, was discontinued. Potential candidates for this study were informed 
about the negative effects of smoking, and we offered them the opportunity to 
participate in a smoking-cessation program. The Hospital's Medical Ethics Com-
mittee approved the study. Written informed consent was obtained from all 
participants. 
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Design of the intervention study 
We perfonned a double blind, placebo-controlled study that lasted for six months. Pa-
tients were randomly assigned to either twice daily 500 Ilg FP or placebo, which were 
delivered via a similar diskhaler. The start of treatment was immediately after the first 
bronchoscopy. Bronchoscopy was repeated at the end of the study. Follow-up visits 
were at intervals of four weeks. 
Bronchoscopy 
The procedure was carried out according to international guidelines (7). For local 
anaesthesia we used lidocaine spray and aerosolised oxybuprocaine. The bronchoscope 
(Olympus BF I nO) was advanced into the lateral segment of the middle lobe, in 
wedge position. Lavage was perfonned successively with I x 40 ml and 4 x 50 ml 
sterile phosphate-buffered saline (PBS) solution (Organon TeiaJ.ika, Boxtel, The Ne-
therlands) at body temperature (3 7°Celsius) and pH 7.4. Aliquots were aspirated in two 
siliconized specimen traps, one for the first 'bronchoalveolar fraction' after 40 ml PBS 
and the second 'alveolar fraction' for the recovery of the 4 x 50 ml PBS. The lavage 
fluid was transported to the laboratory on ice and processed immediately. The recovery 
of the first, bronchoalveolar fraction appeared to be low and insufficient for 
performing the desired experiments. 
ProceSSing of BAL fluid 
After measurement of volume, the BAL fluid was filtered through sterile nylon gauzes 
and centrifuged at 400xg at 4°Celsius for 5 minutes. The cell pellet was washed in PBS 
supplemented with 0.5% bovine serum albumin. The total cell number in the BAL cell 
suspension was counted in a Coulter Counter Model ZM (Coulter Electronics, Hialeah, 
FL, USA) and viability was assessed by cellular exclusion of trypan blue. With 
FACScan flow-cytometry (Becton Dickinson, San Jose, CA, USA) we analysed CD3+ 
T -cells. Immunocytochemistry of cytospins was carried out with the AP AAP (alkaline 
phosphatase anti-alkaline phosphatase) method and the monoclonal antibodies CD68 
(alveolar macrophages), CDl5 (VIM-D5, neutrophils), BMK-13 (eosinophils). Two 
independent observers counted at least 300 cells in each cytospin. 
Determination of concentrations of AA metabolites 
In an earlier publication this has been described in more detail (8). In short: 
immediately after the BAL procedure, 20 ml of supernatant was processed on CI8 
SepPak cartridges (Millipore, Bedford, USA), eluated with 2.5 ml methanol and stored 
at _80° C until analysis. Samples of 200 III BAL eluted fluid were pipetted into 
polypropylene tubes and dried with a Savant sample concentrator. After dissolving in 
300 III assay buffer, levels of thromboxane B2 (TxB2) and L TB4 were determined by 
means of a CH] RIA with antisera from Advanced Magnetics Inc. (Cambridge, Mass.) 
and [3HJlabelled compounds from Amersham Intemational (Buckinghamshire, UK). 
Levels of PGE2 and PGF2u were detennined with commercially available CH] kits 
(Amersharn, UK) and 6kPGF j u with a C25I] RIA kit (Du Pont de Nemours, Dreieich, 
Gennany), according to the manufacturer's instructions. LTC,IDJE4 was measured at 
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room temperature in a microtitre enzyme immunoassay according to protocol (Biotrak, 
Amersham, UK). The cross reactivi1y of the LTC4 antibody with L TD4 was 100% and 
with LTE4, 30%. Cross reactivities for the other assays to related compounds were 
negligible or less than 2% at BlBo 50%. 
Statistics 
Data are expressed as mean ±SD or as median (range), depending on distribution of 
data. Differences between patient groups were tested with either the (unpaired) Student 
t-test or the Mann-Whitney test, depending upon distribution of data. Pre- and post-
intervention data were tested for significant difference with the paired I-test or the 
Wilcoxon signed rank test. Statistical significance was considered at p < 0.05. 
Results 
From the initial 23 participants in the intervention study, paired results were obtained 
from 9 FP patients and from 12 patients with placebo. The reason for missing paired 
data was insufficient recovery of either BAL fluid or BAL cells. Characteristics of 
patients (n=21) and controls are listed in table 1. Baseline characteristics of the FP and 
the placebo group did not differ significantly. The COPD patients had on average 
moderately severe obstructive airways disease and severe BHR. FEV,%predicted and 
PC20 were within the range of normal values in the group of asymptomatic smokers, 
due to selection. 
Table 1. Patient characteristics (mean ±SD). 
Fluticasone Placebo Asymptomatic 
Propionate smokers 
N 9 12 6 
Age, years 54±8 56 ±8 44±9 
Cigarettes! day 15 ±8 16±7 21 ±10 
Pack years 25 ±12 26±10 23 ±12 
FEV, %predicted 66±13 61 ±12 93 ±ll 
FEV, reversibili1y, % 5.3 ±3.7 5.6 ±2.7 4.0±3.0 
PC20 histamine, mg/ml 2.6 ±2.4 0.8±0.6 >8 
Compliance with study medication was high: the percentage of returned used blisters 
(which contained FP or placebo) was 92.5 in the FP and 92.7 in the placebo group. 
In the placebo group, mean FEV, declined from 61.4 %pred at the start of the trial to 
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52.0 %pred after 6 months. On the other hand, in the FP treated patients, lung function 
remained unchanged; mean FEV!: 66A and 68.1 %pred, respectively. This treatment 
effect was statistically significant (p<.05, rmANOV A test), and considered as a 
beneficial effect of FP treatment. Parameters of BRR were not influenced by FP 
treatment. 
Immunocytology 
BAL fluid recovery was higher in controls as compared to the COPD patients (table 
2). 
Mean total cell number of the BAL at the start of the trial was 49 x 106 for FP treated 
patients and 44 x 106 in the placebo group (table 2, no statistical significant difference). 
Small changes were noticed in the BAL cell numbers at the end of the trial, which 
were not significant (table 2). The percentages of fluid recovery, cell viability and cells 
types were not statistically different between both patient groups at baseline, and did 
not change significantly after 6 months of intervention (table 2). The low number of 
eosinophils indicates that COPD was stable in nature (2). 
Table 2. Characteristics ofbronchoalveolar lavage (mean ±SD). 
Fluticasone Placebo 'Healthy' 
propionate smokers 
Start 6 months Start 6 months 
Fluid recovery, % 55 ±14 57 ±14 55 ±15 50±19 69 ±2.2 
Cell number, xl 06 49±24 47 ±31 44±27 40±23 53 ±27 
Cell viability, % 62 ±12 66±12 70±13 67 ±12 66±14 
CD68+ macrophages, % 93 ±8 94±4 94±4 91 ±7 93 ±7 
CD15+ granulocytes, % 2.9 ±2.5 2.8 ±2.7 2.8 ±2.7 3.6 ±6A L7±L6 
BMKI3+ eosinophils, % 0.6 ±OA 0.5 ±OA 0.5 ±OA LO±L3 0.9 ±0.1 
CD3+T-cells, % L3±L9 0.7 ±O.6 3.8±4.8 5.9 ±5.2 L8±L9 
Arachidonic Acid metabolites 
Table 3 shows the levels of protein, albumin and AA metabolites at the start and after 
six months of intervention, which consisted of either FP inhalation or placebo. The 
results of the initial measurements in the FP treated patients and the placebo group are 
comparatively equal (p>.05, Mann-Whitney test). There are also no significant 
differences when companng the COPD patients with the controls. 
77 
Statistical significant differences (comparing post- and pre-intervention results) were 
found in the FP treated patients with regard to PGE" 6kPGF1(l and PGF,(l (p<.05, 
Wilcoxon signed rank test). After correction for protein levels, the results from the 
statistical tests were similar and also significant for the same three mediators (data not 
shown). The change of levels of 6kPGF1(l and PGF,(l differed significantly from that 
in the placebo group [treatroent effect] (p<0.05, Wilcoxon signed rank test). 
Discussion 
In a subgroup of COPD patients, particularly those with bronchial 
hyperresponsiveness, we were able to measure levels of cyclooxygenase and 5-
lipoxygenase products in BAL fluid. We observed significant decreases of three out of 
six mediators after inhaled fluticasone propionate therapy, in a placebo controlled trial 
that lasted for six months (table 3). 
Arachidonic acid metabolites have gained attention in asthma, in which they play an 
important role as mediators of inflammation with bronchoconstriction as the most 
important clinical effect. In a previous study in our institution concerning asthma 
patients we have used the same techniques for collecting BAL fluid and measuring 
levels of AA metabolites (9). These patients had a similar degree of BHR (as 
expressed by PC,o) compared to the COPD patients in the present study. However, 
these asthma patients had a history consistent with asthma, they had allergic reactions 
for common inhaled allergens and were non-smokers. LTCJDJE4 levels were 
comparable, whereas levels of TxB" PGE, and 6kPGF1(l were, respectively, 
approximately 10-, 5- and 15-fold higher in COPD as compared to asthma The 
number of cells in the BAL fluid was, however, about five times higher in COPD as 
compared to asthma. Taking this in account, it appears that cell secretory activity with 
regard to LTCJDJE4 is higher in asthma This is feasible because asthma is an allergic 
inflammatory disease, whereas in COPD there is a nonspecific inflammatory infiltrate. 
The production of LTCJDJE. is almost exclusively attributed to mast cells, which are 
numerous in the airway walls of asthma patients, whereas they are hardly detectable in 
COPD. On the other hand, inflammatory cells in COPD seem to produce higher 
amounts of TxB, and 6kPGF 1 (l. The most obvious explanation seems to be that this is 
induced by cigarette smoking. In one other study we have shown that levels of TxB, 
and PGFp in BAL fluid were significantly elevated in smokers as compared to non-
smokers, and this correlated with packyears (8). Smoking also increased the 
pentagastrin-stimulated gastric luminal release ofTxB2 and PGF,(l (10). 
In the present study, we have compared levels of these mediators in smoking COPD 
patients with the levels in a control group, which consisted of asymptomatic smokers 
with normal lung function and negative allergy tests. There were no significant 
differences. These results indicate that smoking (and not some mechanism specific for 
COPD) could be the single or most important stimulus for an inflammatory infiltrate 
with high levels of certain cyclooxygenase products (11). 
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Table 3. Concentrations of protein (~g/ ml), albumin (~g/ml) and AA metabolites (pg/ml), before and after intervention, 
and in the control group (asymptomatic smokers). Data are expressed as median (range). * data incomplete. 
Fluticasone Placebo Asymptomatic 
Prol'ionate smokers 
n Stali Post- p n Start Post- p !n 
intervention intervention i 
Protein !8 1I8.l 111.3 .6 10 105.4 84.l .3 16 * (13.l-201.9) (18.0-205.4) (33.0-213.7) 31.4-122.8) f 
Albumin !9 23.9 20.6 .3 12 32.6 24.6 .1 6 16.4 
(14.6-55.2) (14.7-74.1) (20.8-47.0) (14.7 -48.l) (1O.l-27.6) 
LTB4 /9 131.2 110.6 .3 12 282.5 212.7 .3 6 244.1 
(54.8-1167) (11.4-920.5) (41.0-1108) (1.7-773.9) (199.1-326.3) 
LTC4/DJE4 ! 9 8.05 5.46 .055 12 9.31 9.32 .1 6 8.26 
(4.68-68.3) (4.11-11.0) (4.3-27.7) (0.01-31.8) 
I: 
(6.49-9.0) 
PGE, 19 43.0 30.0 .01 12 62.0 48.5 .3 37.0 
(35.0-141.0) (12.0-61.0) (15.0-166.0) (3.0-75.0) (32.0-60.0) 
6kPGF,Cl 19 69.0 41.0 .008 12 56.5 54.5 .7 49.0 
(44.0-184) (33.0-65.0) (41.0-78.0) (27.0-81.0) (40.0-67.0) 
PGF,Cl 19 98.0 45.0 .028 II 100.0 107.0 .6 6 37.0 
(47.0-193.0) (27.0-135.0) (36.0-228.0) (0.0-347.0) (28.0-172.0) 
TxB, 19 136.0 141.0 .1 12 201.5 182.5 .3 6 170.0 
(73.0-1269) (69.0-350.0) (54.0-421 ) (0.0-369.0) (96.0-318.0) 
Fluticasone propionate (FP) had no significant effect on BAL cellularity, and also not 
on protein and albumin levels (table 2). Apparently, the influx and the survival of cells 
were not affected by this potent topical glucocorticoid. FP also did not influence the 
levels of the leukotrienes. However, cell secretory activity, particularly the production 
of PGE2, 6kPGF!u and PGF2u, was inhibited as their levels were decreased after 6 
months exposure to FP (table 3). 
In the above-mentioned previous study of asthma patients the same dose of FP was 
used (9). From the AA metabolites in asthma, only PGD2 decreased significantly. 
Levels ofPGF2u were not measured in that study. One other study in asthma patients 
also showed lower levels of PGD2 in BAL fluid after inhaled glucocorticoid therapy 
(12). It was concluded that, in asthma, FP downregulated the capability of mast cells, 
and perhaps also of alveolar macrophages, to produce PGD2. From our present study in 
COPD patients we conclude that FP causes downregulation of the capability of 
alveolar macrophages to produce certain prostaglandins. 
In the present study, the statistically significant clinical effect ofFP treatment in COPD 
patients with BRR was not a reduction of any parameter related to BRR, but the 
course of the FEV!: it decreased in the placebo group, whereas it remained stable in 
the FP treated patients. So, in the placebo group the ongoing inflammation made 
airways obstruction worse. Anti-inflammatory therapy with FP obliterated FEV! 
decline, and one of the mechanisms underlying this effect could be the reduction of 
levels of AA metabolites, particularly PGF2u. PGF2u has strong bronchoconstrictor 
activity through a direct effect on airway receptors and indirectly through cholinergic-
mediated bronchoconstriction (13). Reduction of its level could diminish 
bronchomoter tone. We also observed significant decreases of the levels of 6kPGF! u 
and PGE2• 6kPGF! U is derived from PGI2, which is, like PGE2, a mediator with, 
amongst others, a bronchodilatory effect. Apparently, the activity of these PGs in 
COPD is less as compared to the activity of PGF2u. In murine lower airways PGF2u 
was the most potent bronchial muscle constrictor (14). Alternatively, other 
inflammatory mechanisms could be more important for explaining the clinical effect of 
FP, which we observed in this particular group ofCOPD patients. 
In conclusion, the ongoing inflammation with, amongst others, high concentrations of 
PGF;!l made airways obstruction worse, whereas inhibition of PGF2u production by 
FP seems to be one of the mechanisms leading to preservation oflung function. 
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Abstract 
Oxidative stress in the lung is important in the pathogenesis of COPD. Published 
data indicate that glucocorticoids inhibit blood cells in their capability of producing 
reactive oxygen species (ROS). We investigated the effect of Fluticasone 
propionate (FP) on the ROS production capability of pulmonary cells. 
Bronchoalveolar lavage (BAL) was performed in smoking COPD patients, before 
and after a six month, placebo-controlled treatment with FP. BAL cells were 
stimulated with phorbol myristrate acetate (PMA) alone, and together with 
superoxide dismutase (SOD). From kinetic plots of ferricytochrome-c conversion 
we calculated the maximal rate of superoxide production (V max). Also, we examined 
BAL cell subsets and performed correlation analyses on ROS production and 
relevant clinical determinants. 
Paired results were obtained from 6 FP and 9 placebo treated patients. No 
significant change of V mox was found in both patients groups. Also BAL cellularity 
was unchanged. Correlation analyses showed a significant (inverse) association of 
V max with the number of cigarettes smoked per day. 
We concluded that a potent inhaled glucocorticoid had no effect on the ROS 
production capability of BAL cells from smoking COPD patients. Apparently, 
heavy smoking impaired the ability of alveolar macrophages to produce ROS, 
which was not further decreased by FP. 
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Introduction 
The airways and alveoli of patients with chronic obstructive airways disease 
(COPD) are invaded with numerous inflanunatory cells, which have the ability of 
producing reactive oxygen species (ROS) (1). It has been established that an 
increased oxidative stress is one of the major pathogenic mechanisms (2,3). Oxida-
tive stress may occur either by an increased exposure to ROS or by a decreased 
capability of the involved tissue to neutralise the ever-emerging production ofROS. 
Both mechanisms seem to be involved in the development of COPD. The smoking 
of cigarettes is clearly related to COPD. Cigarette smoke contains several molecu-
les, which are ROS by themselves, and it contains molecules and particulates, 
which generate chemical reactions and inflanunation, with subsequent ROS 
production (4). 
A major goal in the treatment of COPD is the reduction of the number and/or the 
activity of inflanunatory cells. In asthma patients, glucocorticoids have been applied 
successfully with this intention. In the present study, we have investigated if a 
potent inhaled glucocorticoid (Fluticasone propionate, FP) could reduce the ROS 
production in COPD patients. We have selected COPD patients with bronchial 
hyperresponsiveness (BHR) because these patients have an exaggerated decline of 
their lung function. We hypothesized that inflanunation and ROS production in this 
subgroup of COPD patients were severe, and could be influenced by an inhaled 
glucocorticoid. Inflanunatory cells were collected by means of bronchoalveolar 
lavage (BAL), before and after treatment with inhaled FP or placebo. Besides cell 
counts, the ROS production capability was determined in vitro. Furthermore, we 
analyzed the association of ROS production capability with smoking behaviour, 
airways obstruction and BHR. 
Material and methods 
Patients 
COPD patients were selected according to the clinical and functional criteria, which 
are generally accepted (5). Inclusion criteria were: age between 40 and 70 years, 
current smoker, FEV!/iVC ratio 70% of predicted normal values (pred), 
reversibility of FEV! <1O%pred after 750 ~g terbutaline, non-specific BHR -
defined by a PC20 histamine 8 mglml - and negative skin tests for standard inhaled 
allergens. Reference values were obtained from ECCS standards (6). The main 
exclusion criteria were a history of asthma and recent respiratory tract infection. 
Any anti-inflanunatory drugs, including steroids and NSAIDs, and theophyllines 
were discontinued. Potential candidates for this study were informed about the 
negative effects of smoking, and we offered them the opportunity to participate in a 
smoking-cessation program. The Hospital's Medical Ethics Committee approved 
the study. Written informed consent was obtained from all participants. 
83 
Design of the intervention study 
We perfonned a double blind, placebo-controlled study that lasted for six months. 
Patients were randomly assigned to either twice-daily 500 ~g FP or placebo, which 
were delivered via a similar diskhaler. The start of treatment was immediately after 
the first bronchoscopy. Bronchoscopy was repeated at the end of the study. At 
intervals of four weeks, the study participants had a check-up. 
Bronchoscopy 
The procedure was carried out according to international guidelines (7). For local 
anaesthesia we used lidocaine spray and aerosolised oxybuprocaine. The broncho-
scope (Olympus BF I Tl 0) was advanced into the lateral segment of the middle 
lobe, in wedge position. Lavage was perfonned successively with 1 x 40 ml and 4 x 
50 ml sterile phosphate-buffered saline (PBS) solution (Organon Teknika, Boxtel, 
The Netherlands) at body temperature (37°Celsius) and pH 7.4. Aliquots were 
aspirated in two siliconized specimen traps, one for the first 'bronchoalveolar 
fraction' after 40 ml PBS and the second 'alveolar fraction' for the recovery of the 4 
x 50 ml PBS. The lavage fluid was transported to the laboratory on ice and 
processed immediately. The recovery of the first, bronchoalveolar fraction appeared 
to be low and insufficient for perfonning the desired experiments. 
Processing ofBALfluid 
After measurement of volume, the BAL fluid was filtered through sterile nylon 
gauzes and centrifuged at 400xg at 4°Celsius for 5 minutes. The cell pellet was 
washed in PBS supplemented with 0.5% bovine serum albumin. The total cell 
number in the BAL cell suspension was counted in a Coulter Counter Model ZM 
(Coulter Electronics, Hialeah, FL, USA) and viability was assessed by cellular 
exclusion of trypan blue. With F ACScan flow-cytometry (Becton Dickinson, San 
Jose, CA, USA) we analyzed CD3+T-cells. Immunocytochemistry ofcytospins was 
carried out with the APAAP (alkaline phosphatase anti-alkaline phosphatase) 
method and the monoclonal antibodies CD68 (alveolar macrophages), CDl5 (VIM-
D5, neutrophils), BMK-13 (eosinophils). Two independent observers counted at 
least 300 cells in each cytospin. 
Superoxide production assay 
ROS production of BAL cells was detennined by the kinetic microplate assay of 
superoxide dismutase (SOD)-inhibitable ferricytochrome-c (0.16 mM horse heart 
cytochrome-c, Sigma) reduction in a 96-well microplate (Falcon 3072, Becton 
Bickinson, Lincoln Park, NJ). The cells, at a density of IxI05/well, were stimulated, 
in the absence and the presence of SOD, with 8 nM and 80 nM phorbol 12-
myristate 13-acetate (PMA) at 37°C. At 18 seconds intervals the change in 
absorbance at 550 nm (I nm bandwith) was read during 20 minutes in a Thenno-
max microplate reader (Molecular Devices, Sopachem, Lunteren, The Netherlands), 
using 540 nm (10 nm bandwith) as a reference wavelength. All measurements were 
perfonned in duplo. Using the software programme SOFTmax PRO the maximum 
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velocity (V max) of ferricytochrome-c reduction was determined by calculating the 
first derivative of the absorbance time course in each well, and next expressed as 
nmol of superoxide/minll 06 cells, using the difference in V",,", in the presence and 
absence of SOD, the reduced minus oxidized cytochrome-c extinction coefficient of 
21.1 mM·lcm·l, and the empirically determined light path length. Since we found 
the V",,", upon stimulation with 80 nM PMA did not increase further as compared to 
8 nM PMA, apparently the cells were already maximally stimulated at the lowest 
PMA concentration. Therefore, we present these data as the mean and do not refer 
to the PMA concentration. 
Statistical analysis 
Pre- and post-intervention data were tested for significant difference with the paired 
t-test. Differences between patient groups were tested with either the (unpaired) 
Student t-test or the Mann-Whitney test, depending upon distribution of data. Cor-
relation studies were performed with the Spearman rank test Statistical significance 
was considered at p < 0.05. 
Results 
From the initial 23 partIcIpants in the intervention study, paired results were 
obtained from 6 FP patients and from 9 patients with placebo. The reasons for 
missing paired data were insufficient recovery of either BAL fluid or BAL cells. 
The patient characteristics (n= 15), listed in table 1, show that on average these 
patients had moderately severe obstructive airways disease and severe BRR. Com-
pliance with study medication was high: the percentage of returned used blisters 
was 92.5 in the FP and 92.7 in the placebo group. 
Table 1. Patient characteristics (mean ±SD). 
Fluticasone propionate Placebo 
N 6 9 
Age 56±7 57 ±9 
Cigarettes/day 17 ±8 15 ±5 
Packyears 25 ±12 27 ±10 
FEVl %predicted 72 ±12 68 ±13 
FEVl reversibility 4.6 ±2.4 5.3 ±2.4 
PC20 for histamine 3.3 ±3.2 0.8 ±0.6 
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Differences of baseline characteristics between the FP and the placebo group were 
not statistically significant. In the placebo group, mean FEV 1 declined from 68.5 
%pred at the start of the trial to 52.0 %pred after 6 months. However, lung function 
remained unchanged in the FP group (mean FEV j : 72.4 and 69.1 %pred, 
respectively). This treatment effect was statistically significant, and considered as a 
beneficial effect ofFP treatment. 
Immunocytology 
Mean total cell number of the BAL at the start of the trial was 53.0 x 106 for FP 
treated patients and 45.3 x 106 in the placebo group (table 2). Small changes were 
noticed in the BAL cell numbers at the end of the trial, which were not significant 
(table 2). The percentages of fluid recovery, cell viability and cells types were not 
statistically different between both patient groups, before intervention, and did not 
change significantly after 6 months of intervention (table 2). The low number of 
eosinophils indicates that COPD was stable in nature. 
Table 2. Characteristics ofbronchoalveolar lavage (mean ±SD). 
Fluticasone propionate Pacebo 
Start 6 months Start 6 months 
Fluid recovery, % 60 ±13 62 ±ll 54±16 51 ±19 
Cell number, x I 06 53 ±13.5 59 ±31 45.3 ±22.7 36.4 ±18 
Cell viability, % 62 ±12 66 ±12 70±13 67±12 
CD68+ macrophages, % 95 ±3 95±4 95±4 91 ±5 
CD 15+ granulocytes, % 2.4 ±2.8 1.9 ±1.2 3.1 ±2.8 4.2 ±7.5 
BMK13+ eosinophils, % 0.4 ±0.3 0.8 ±0.5 0.4±0.3 0.8 ±1.0 
CD3+ T -cells, % 2.0±2.9 0.7 ±0.9 3.0 ±2.9 3.0 ±6.5 
ROS production capability 
Figure I shows V mox of the patients from the FP and the placebo group, before and 
after intervention. Vrnox ranged from 0.076 to 0.753 (mean 0.35) nmol 
superoxide/minll06 cells in the FP treated patients, and from 0.06 to 0.67 (mean 
0.303) in the placebo group. Statistical analysis showed that there were no signi-
ficant changes after FP or placebo. 
Association of Vmax with airways obstruction, BHR and smoking status 
There were no significant correlations between pre-treatment V rnox on the one hand, 
and FEV j and PC20 on the other. However, the actual number of cigarettes smoked 
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per day correlated significantly with pre-treatment V""", (figure 2, R = -0.67, P = 
0.007, Spearman rank test). There was no significant correlation with packyears of 
smoking. 
Figure 1. Results of the superoxide production assay. 
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Discussion 
In this double blind, placebo controlled trial, we observed no significant effect of a 
potent inhaled glucocorticoid on the ROS production capability (V""",) of BAL cells 
derived from a subgroup of COPD patients, namely those with bronchial 
hyperresponsiveness. At first glance, this result appears to be related to the absence 
of a decrease of the number of inflammatory cells in the BAL. Our correlation 
studies indicated that actual smoking status is an important confounding factor. 
With increasing number of cigarettes smoked per day, V max decreases. 
As there has not been published a similar study in COPD patients before, we 
compared our results with studies concerning the effects of glucocorticoids on ROS 
production capability of blood derived cells, and with studies concerning the effect 
of smoking. 
In one study, the superoxide production by PMA-stimulated blood granulocytes, 
taken from 18 miscellaneous patients on oral glucocorticoid treatment, was 
decreased as compared to healthy controls (8). Superoxide production by blood 
granulocytes of patients with emphysema was decreased after in vivo prednisolone 
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treatment (9). However, dexamethasone, both in vitro and in vivo, did not alter the 
spontaneous superoxide release of blood granulocytes from healthy volunteers (10). 
Figure 2. Correlation of reactive oxygen species production and smoking. 
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Ciglday: number of cigarettes smoked per day. 
The reported studies concerning the effect of smoking on ROS production 
capability are not consistent. Alveolar macrophages (AM) from healthy smokers 
produced more superoxide than AM from nonsmoking control subjects (II - 13). 
Exposure to tobacco smoke in vitro increased the oxidative metabolism of AM (14), 
while it reduced superoxide generation by blood granulocytes (15). Hoidal et al. 
used almost the same lavage method as in our study, and compared young 
asymptomatic smokers with nonsmokers (11). They reported that BAL cells from 
smokers, stimulated with PMA, produced on average 1.93 ronol ROS/minllO' cells, 
while BAL cells from nonsmokers produced 0.945 ronol ROS/minllO' cells. We 
found an average (pre-intervention) ROS production of 0.322 nmol/minllO' cells (n 
= 15). The low ROS production capability in our study could either be due to 
patient selection (COPD), the presence of BHR, different BAL cell counts or to 
smoking. ROS production by BAL cells from smokers without COPD was not 
different from smokers with COPD (16). So, the diagnosis of COPD seems to be 
unimportant. Furthermore, since the level of PC20 was not significantly correlated 
with V mm<, and the cell profile in BAL resembles the reported findings in 'average' 
COPD patients and smokers, the first three options are not likely. However, our 
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correlation analyses indicate that cigarette smoking influences ROS production 
capability. A possible explanation could be that viable macrophages loose their 
ability to release superoxide after repeated stimulation (17). This was attributed to 
ligand-induced desensitisation of specific receptors. This phenomenon might also 
have occurred in our heavy smoking COPD patients. 
In conclusion, the BAL cells from smoking COPD patients with BRR, consisting 
mainly of alveolar macrophages, have a low ROS production capability. This was 
not further decreased by in vivo exposure to a potent inhaled glucocorticoid. The 
low ROS production capability might be one of the causative mechanisms of the 
increased susceptibility of respiratory tract infections and the increased frequency of 
bacterial colonisation of the airways ofCOPD patients. 
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Chapter 7 
Glucocorticoids hamper the ex vivo maturation of lung dendritic cells from their 
low autofluoresceut precursors in the human bronchoalveolar lavage: decreases 
in allostimulatory capacity and expression of CD80 and CD86 
G. T. Verho~e:n1.2, J. M W van Haarst, H J. de Wit, P. J. Simoni, H C. 
Hoogsteden2,H A. Drexhage1 
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Abstract 
Dendritic cells (DCs) were prepared from human bronchoalveolar lavage (BAL) cells. 
We previously reported that in particular the CDla fraction of the low autofluorescent 
(LAF) cells contains the precursors for DCs: after overnight culture, 40% of the LAF 
cells change into functionally and phenotypically prototypic dendritic/veiled cells. 
There are, as yet, no data on the modulatory effects of glucocorticoids (GC) on the 
maturation and function of such DCs isolated from the human lung. 
Functional tests (allogeneic mixed lymphocyte reaction: allo-MLR) were therefore 
performed with CDla+ LAF cells at different stimulator-to-T-cell ratios and after 
preincubation with different dexamethasone (DEX) concentrations. DEX caused 
suppression of the T-cell stimulatory capacity of CDla+ LAF cells, which was dose-
dependent, and more evident at the higher stimulator-to-T-cell ratios. 
Here, we also show that CD80 and CD86 are normally expressed at low levels on 
CDla+ LAF cell-derived DCs as compared to other DC populations. This low-level 
expression of co-stimulatory molecules is discussed here in relation to the previously 
reported low-level expression of CD80 (and CD86) on lung DCs in experimental 
animals. This appears to playa role in a predominant Th2 cell stimulating potential of 
DC from the lung environment. DEX exposure of CDla+ LAF cells prevented the 
upregulation of even this low-level expression of CD80 and CD86. 
The veiled/dendritic morphology and the expression of other relevant cell surface 
markers and adhesion molecules were not affected by DEX exposure. 
It is concluded that DEX hampers the maturation ofCDla+ LAF cells into active lung 
DCs. 
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Introduction 
Dendritic cells (DCs) are professional antigen-presenting cells (APC) and, as such, the 
most potent accessory cells for the stimulation of T cells (I). This function makes the 
pulmonary DC a target cell for studying the initiation and regulation of the immune 
processes underlying various lung diseases (2,3). In humans and in experimental 
animals, pulmonary DCs form a contiguous network within - and directly below - the 
airway epithelium and throughout the alveolar interstitium. Pulmonary DCs situated 
just underneath the bronclrial epithelium are often seen in small clusters with T -ceHs 
(4,5). In allergic asthma, increased numbers ofCDla+ DCs have been observed at this 
location (6,7). 
Glucocorticoid (GC) therapy, considered to be the most effective treatment in asthma 
(8), reduces the number of DCs in the bronchial mucosa (6,7,9). Studies in rats have 
suggested that GCs cause this reduction in number by inlribiting the influx of DCs into 
the airway waH (10). Moreover, GCs induce apoptosis of DCs in rat tracheal mucosa 
(11). Studies using human monocytes, monocyte-derived DCs or human epidermal 
Langerhans cells, indicate that GCs can directly affect the maturation of these cells, 
and can downregulate their accessory function (12-17). There are, to our knowledge, 
no data available on the direct effects of a GC on the ex vivo function and marker 
expression ofDCs isolated from the human lung. 
Recently, we described (18) the isolation, via FACS-sorting, oflow autofluorescent 
(LAP) cells from human bronchoalveolar lavage (BAL). These LAP cells matured, 
after being cultured overnight, into veiled/dendritic cells with the morphology and 
the immunophenotype of immature DCs. The cells showed a strong potency to 
stimulate naive T -cells, and both contained and released biologically active IL-l 
and 1L-6. We also described the marked differences between the CDla+ and CDla-
subsets of LAP cells (19). The CD 1 a + subset exhibited a higher accessory capability 
than the CD 1 a-subset. CD 1 a + LAP cells were very poor producers of IL-I, IL-6 
and TNF-a, whereas CDla- LAP cells were potent producers of these cytokines. 
CDla+ LAP cells were - after the overnight maturation period - both positive for 
and producers of SIOO; CDla- LAF cells were negative in this respect. We 
therefore concluded that the CDla+ LAP cells could be regarded as examples of 
typical DCs from the lung environment, because they can rapidly assume all the 
characteristics of Langer hans cell-like immature DCs (19). 
The above-described method of obtaining typical DCs from human BAL enabled us 
to study, ex vivo, the function and phenotype of human pulmonary DCs, with or 
without preincubation with GCs. 
We report an investigation on the effect of various concentrations of GCs on the 
allogeneic T-cell stimulatory capacity of both the LAP cells and the CDla+ LAP ceHs 
isolated from the human BAL. We also studied cell morphology and the expression of 
cell surface markers, adhesion molecules and co-stimulatory molecules in the various 
DC populations, both before and after incubation with GCs. Markers and molecules 
were chosen that are known to be relevant for T cell stimulation (e.g. MHC-c1ass-II, 
CD80, CD86, CDI1, CD54, etc.) and can be affected by GCs (12-17). 
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Materials and methods 
Bronchoalveolar lavage 
After we obtained informed consent, BAL was performed on individuals during 
anesthesia for routine elective surgery. Subjects with a history of pulmonary or serious 
systemic disease were excluded. BAL was carried out with a flexible bronchoscope 
placed in the right middle lobe with the tip in wedge position. Four aliquots of 50ml 
isotonic saline were, subsequently, instilled and aspirated with gentle suction. BAL 
fluid was collected in siliconized bottles. The selected subjects were predominantly 
active smokers (n = 24, smoking 17 ±7 (mean ±SD) cigarettes per day), because the 
yield of cells in smoking individuals is much larger and more workable than in 
nonsmoking individuals. We also studied the BAL cells of a few subjects who had 
never smoked (n = 3). The mean age of the lavaged subjects was 36 years (range 18-53 
years). The procedure was approved by the Medical Ethics Committee of the Erasmus 
University and University Hospital Dijkzigt. 
Isolation and purification of DC 
BAL cells were kept at 4°C, washed twice in phosphate buffered saline (PBS) 
containing 0.5% bovine serum albumin and 0.45% glucose and, subsequently, filtered 
through a 55J.1m and a 30J.1ffi gauze. BAL cells were sorted on a FACS-Vantage 
(Becton-Dickinson, Erembodegem, Belgium) with a 488-nm laser. Sort windows were 
generated on autofluorescence (FU, 530 nm) to create a population of cells with low 
autofluorescence CLAF) in order to exclude alveolar macrophages (AM), on forward 
scatter (FSC) to exclude small cells (lymphocytes) and debris and on sideward scatter 
(SSC) to exclude cells with a high SSC (granulocytes and AMs). As we described 
previously, this procedure yields a population of LAF cells, comprised of DCs and 
their precursors, with small contaminations of AMs (± 10%) and lymphocytes (± 5%) 
(18). 
A further purification was performed in experiments by sequential labeling of LAF 
cells with OKT6 (CD 1 a) conjugated with phycoerythrin and an additional sort window 
on fluorescence channel 2 (FL2, 585 nm). Flow cytometry results were reported in an 
earlier publication (19). This method yields CDla+ DCs with a contamination of AMs 
of:O:2%. 
Blood monocytes were purified according to techniques described in detail elsewhere 
(20). In short, monocytes were isolated from heparin blood or buffy coats by 
subsequent Ficoll-Paque (1.079 glml; Pharmacia, Uppsala, Sweden) and Percoll (1.063 
glml; Pharmacia) density gradient separation. 
Glucocorticoid exposure 
After isolation, the various BAL DC populations and the blood monocytes were 
incubated overnight under non-adherent conditions in RPMI containing 10% FCS (16 
hours, 3rC, 5% CO2, polypropylene tubes, Falcon, Lincoln Park, NJ, USA) with or 
without various concentrations of dexamethasone (DEX) (Sigma, St. Louis, MO, 
USA). To prevent contamination of the MLR with DEX, cells were washed four times 
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after this incubation period. Between each wash, the cells were incubated at 37°C for 
30 min. 
In selected experiments, beclomethasone dipropionate (BDP) or fluticasone propionate 
(FP) replaced DEX. These GCs are widely used as inhalation therapy for asthma 
patients. 
Monoclonal antibodies 
The following monoclonal antibodies (MoAb) were used: OKIa (HLA-DR) and 
OKMI (CDIIb) (Ortho Diagnostics Systems, Beerse, Belgium); LFA-I/2 (CDIIa) 
and LFA-Ill (CDI8) (CLB, Amsterdam, the Netherlands); LeuM5 (CDIIb) (Becton 
& Dickinson, San Jose, CA, USA); My4 (CDI4) and 4B4 (CD29) (Coulter 
Immunology, Hialeah, FL, USA); HP2/I (CD49d) (Immunotech, Marseille, France); 
BBA3 (anti-ICAM-I, CD54) (British Biotechnology, Oxon, UK); OKT6 (CDIa) 
(American Type Culture Collection, Rockville, MD, USA); B7-24 (anti-B7-1, CD80) 
and B701B7-2 (CD86) (pharmingen GmbH, Hamburg, Germany). L25 is a MoAb 
directed against B cells and DC (21,22) and was a generous gift from Dr T. Takami 
(Gifu, Japan); RFDI recognizes a class IT-associated epitope present on activated B 
cells, DC and alveolar macrophages (23) and was kindly provided by Dr L.W. Poulter 
(London, UK). HBI5a (CD83) was provided by T. F. Tedder (Boston, MA, USA). 
TS2/9 (anti-LFA3, CD58) was a gift from T. Schumacher (Amsterdam, the 
Netherlands). 
Immunocytology 
Cytocentrifuge preparations were prepared from the FACS-sorted LAP and CDla+ cell 
fractions, immediately after sorting, as well as after ovemight culturing in RPMIIFCS 
with or without 1O~ DEX. The cytocentrifuge preparations were fIXed in acetone 
(Merck, Darmstadt, Germany) for 10 min, and then incubated with normal rabbit 
serum 10% (Dako, Gostrup, Denmark) in PBS for 10 min. Next, the slides were 
incubated for 1 h with the appropriate MoAb. Subsequently, the slides were either 
incubated with rabbit-anti-mouse antiserum conjugated with horseradish peroxidase 
(RaMHRP; Dako) for diaminobenzidine (Sigma Chemicals, Axel, the Netherlands) 
staining, or with alkaline phosphatase anti-alkaline phosphatase for Fast Blue BB Base 
(Sigma) staining. Most slides were stained for acid phosphatase and selected slides 
were stained for non-specific esterase. Counterstaining was performed with 
hematoxylin. 
Allogeneic T-cell stimulation 
Responder T-cells were isolated from buffy coats of healthy blood donors. Buffy coats 
were diluted 1 : 1 with PBS, and mononuclear cells were obtained by Ficoll-Paque 
(1.079 g/mJ; Pharmacia) density gradient separation (15 min, 1000 g). Monocytes and 
lymphocytes were separated by Percoll (1.063 g/mJ; Pharmacia) density gradient 
centrifugation. B-cells and residual monocytes were removed from the lymphocytes by 
adherence to a nylon wool column (polyscience, Warrington, P A, USA) (I h, 37°C, 
5% CO2). The purified T-cell populations were stored in liquid nitrogen until use. 
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For the allogeneic rnixed lymphocyte reaction (MLR) (18, 19), variable numbers of 
stimulator cells (e.g. 950,1900,3750, and 7500 CDla+ LAF cells) were cultured with 
150000 allogeneic T-cells (giving a stimulator-to-T-cell ratio of ranging from 1 : 160 
to I : 20). Cultures were always performed in triplicate in a flat bottom 96-well plate 
(Falcon) with a total volume of 200 III per well. The culture medium consisted of 
RPMI 1640 (Gibco, Breda, the Netherlands) to which 10% human A+ serum, penicillin 
and streptomycin were added. Before the MLR, the stimulator cell populations had 
been irradiated with 2000 Rad. After 5 days, 0.5 IlCi 3H-thymidine (20 III from a stock 
of250 mC/m! 3H-thymidine, Amersham, Buckinghamshire, UK) was added. The cells 
were harvested 16 h later. Scintillation was counted with an LKB 1205 Betaplate 
liquid scintillation counter (Wallac, Turku, Finland). 3H-thymidine incorporation in T 
cells alone, as well as in the various stimulator cell fractions without T cells, was 
always less than 500 c.p.m. 
Statistical Analysis 
The Wilcoxon matched pairs test was used for the statistical analysis of data which 
were obtained in the DEX dilution series. In order to compare the results of other data 
sets, either Student's-t-test or the Mann-Whitney test were applied, when appropriate. 
P-values < 0.05 were considered significant. 
Results 
Allogeneic T cell stimulation by LAF cells and CD 1 a + pulmonary DC 
With regard to the yields of the various LAF cell populations in smokers: our starting 
population ofBAL cells, after the first washing procedures, ranged from 4.0-7.5 x 106 
cells (n = 24). The yield ofLAF cells after FACS sorting was 1.8% (SD 0.8, range 0.9-
3.5) of the initial population, and that of high autofluorescent (HAF) cells, i.e. alveolar 
macrophages, 13.4% (SD 5.3, range 6.1-23.7). The yield of CDla+ LAF cells was 
0.47% (SD 0.31, range O.I-LO) of the total BAL cells. That of CD 1a- LAF cells was 
1.33% (SD 0.74, range 0.5-2.7). Because the yield of the CDla- LAF cells was so low 
and involved such a cumbersome methodology, we developed a strategy in which 
experiments were first carried out on unseparated LAF cells before verifYing 
interesting data on purified CD I a + LAF cells. 
With regard to nonsmoking subj ects: yields of BAL and LAF cells were found to be 
no more than one tenth of those from smoking subjects. Therefore, only a few 
experiments were carried out in this group (see below). 
In the [lISt series of experiments, the optimal in vitro dosage of DEX for influencing 
BAL DCs was investigated. For this purpose, unseparated LAF cells were exposed to 
graded concentrations of DEX for 16 h (overnight). The cells were then washed 
thoroughly and used as stimulator cells in the MLR. The recovery of the cells after 
overnight DEX exposure was established via simple cell counting; the viability ofLAF 
cells after overnight exposure to DEX was tested via trypan blue exclusion. DEX 
neither affected the cell survival (the recovery with or without DEX was identical: 40-
60%), nor affected the viability of the cells (80-90%). Figure 1 gives the MLR data. 
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1O-1'M DEX had no significant effect on LAF cell-induced T-cell proliferation and T-
cell stimulations were found to be 40-80 x 1000 c.p.m_ in our assay system. 
1O-8M DEX significantly suppressed the LAF cell-induced T-cell response to 69.2 
±192% (mean ±SD) of the value found in the absence of DE X_ Suppression to 65.0 
±23.9% was reached with 10-7 M, suppression to 49.1 ±2LO% with 10-6 M and 
suppression to 44.5 ±1O.5% with 10-5 M DEX (n = 5-7, P < 0.05 for all concentrations 
tested, Wilcoxon matched pairs test). 
Figure 1. Effect of increasing concentrations of dexamethasone (DEX) preincubation 
(16 h) on accessory function oflow-autofluorescent (LAF) cells_ 
Data represent mean ±SD of5-7 experiments of3H-thymidine incorporation expressed 
as percentage of3H-thymidine incorporation of the situation without DEX-exposure_ 
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We checked to see if a DEX contamination, after the washing procedure, had 
influenced these MLR results by directly influencing the responder T-cell population, 
thus accounting for the suppression_ For this purpose, LAF cells were exposed to 10-6 
M 3H-Iabel!ed DEX overnight. 3H-DEX concentrations in the supernatant and in the 
cell pellet, after the above-described washing procedure, was as low as 10-13 M. At 
concentrations lower than 10-10 M, we found that DEX did not affect PHA-driven T-
cel! stimulation. Hence, contaminating quantities of residual DEX, directly influencing 
T-cells, could not have accounted for the described suppression of the LAF cell driven 
MLRs. On the basis of the above-described data using LAF cells, we decided to use 
10-10 through 10-6 M DEX in further experiments with CDla+ and CDla- populations, 
purified from the LAF cell fraction_ 
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Figure 2. Effects of increasing concentrations of dexamethasone (DEX) on the 
allogeneic T cell stimulatory capacity of CDla+ and CDla- LAF cells derived from 
human BAL, and blood monocytes. 
Results are expressed as counts per minute (c.p.m.) of 3H-thymidine incorporation in 
the mixed lymphocyte reaction (MLR) of 5-15 interindividual experiments (mean 
±SD). A few data are from single, duplicate experiments (in this case, SD is not given). 
Intraindividual variation was negligible. Open bars express DEX-free experiments, the 
wide-striped bars 10.10 M DEX, the narrow-striped bars 10.8 M and the closed bars 10-6 
M. Asterisks indicate significance of group results (p < 0.05, Mann-Whitney or 
Student's t-test). 
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Figure 2 shows the results of the MLRs with blood monocytes and CDla+ and CDla-
LAF cells as stimulators at various DC-to-T-cell ratios, as well as with graded 
concentrations of DEX. In the ratios of I : 40 and I : 80, IS individual BAL derived 
CD1a+ and CDla- cells could be used. For the other ratios, fewer BAL isolated cells 
were available (Fig. 2). For all stimulator-to-T-cell ratios, the CDla+ cells were the 
most potent T-cell stimulators. Statistically significant differences between the (non-
GC exposed) CD 1 a + DCs and CD 1 a - LAF cells were found for the stimulator -to-T-cell 
ratios of 1 : 20 through 1 : 60 (p < 0.05, Mann-Whitney test). 
DEX exposure had no effect on the recovery and the survival of the cells, although it 
appeared to have a dose-dependent suppressive effect on CD1a+ LAF cells in the MLR 
when used at various stimulator-to-T-cell ratios. The suppressive effect of DEX on 
CD1a+ DCs was statistically significant for all concentrations used. When compared to 
cultures without DEX, p = 0.044 for 10.10 M; p = 0.004 for 10.8 M; p = 0.031 for 10-6 
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M, Wilcoxon test). Interestingly, DEX exposure had no significant suppressive effect 
on the intrinsically low stimulatory capacity of the CDla- cells. The DEX exposure 
effect on blood monocytes with regard to T-cell stimulatory capacity was limited and 
not significant. In ratios of I : 10 and I : 5 at a concentration of 10-6 M DEX: p = 
0.0625 (n = 6, Wilcoxon test). 
As smoking has a negative effect on the allogeneic T-cell stimulatory capacity of DCs 
(5,IS), we compared the suppressive effect of DE X in smokers and in nonsmokers. We 
found that DEX induced comparable effects on LAF cells isolated from the BAL of 
both smokers and nonsmokers. Preincubation ovemight with 10-6 M DEX suppressed 
the proliferative T-cell response to 52.6% in nonsmokers (n = 3) and to 46.5% in 
smokers (n = 4). We therefore did not extend these experiments to include CDla+ 
fractionated cells, because, among other reasons, it is difficult to obtain sufficient LAF 
cells from the BAL of nonsmoking subjects. 
GCs other than DEX, such as beclomethasone dipropionate (BDP) and fluticasone 
propionate (FP), also suppressed LAF cell-induced T-cell proliferation in the MLR. In 
a limited series of six experiments, mean (±SD) c.p.m. xlOOO was 90.4 (±I 1.0) without 
GC, 71.7 (±3.2) with DEX, 66.7 (±4.5) with BDP and 37.1 (±16.2) with FP. In these 
experiments, we used a LAF-to-T-cell ratio of I : 20 and the concentration of the GCs 
was 10-6 M. This shows that steroids other than DEX also reduce the accessory 
capability of LAF cells, albeit at other potencies. We did not extend these studies on 
the suppressive effects of steroids other than DEX to include CDla+ fractionated cells. 
Immunocytology of unseperated LAP cells 
It was clear that the ovemight DEX-exposure affected the T cell stimulatory capacity 
of the unseparated LAF cells and the CD I a + LAF cells. We, therefore, embarked on a 
study of the effects of DEX exposure on the expression of relevant molecules on the 
pulmonary APCs. Again, we started by studying the effects of DEX on the 
unseparated LAF cells (Table I and Fig. 3). First of all, we confmned our earlier 
observations by demonstrating that 40% of the LAF cells develop a typical veiled 
morphology after an ovemight maturation in the absence of DE X (Table I). 
The DC-like cells are negative for acid phosphatase, and have many typical DC 
markers when studied in immunocytochemistry: the MHC class II molecules are 
expressed by the vast majority of the LAF cells, while the MHC class II related DQ 
molecule L25 is expressed by ± 30% of the cells (Table I). CD I a is expressed by ± 
15%, and CDS3 by ± 7% of the LAF cells (Table I). The monocytic marker CDl4 is 
expressed by ± 50% of the cells, but there was a large variation between experiments 
(SD, Table I). In F ACS analysis the intensity of CDl4 expression decreased after 
ovemight maturation of freshly isolated LAF cells (without veils) to DC-like cells (see 
representative example of three experiments, Fig. 3). 
Noteworthy is the low level of CD80 expression by freshly isolated LAF cells and 
LAF cell derived veiled/dendritic cells: values of 2-5% to ± 12% were found in 
immunocytochemistry, respectively (Table I). Again, there was a large variability 
between experiments. In innnunocytochemistry, the CD80 expression was mainly 
intracellular, thus it is not surprising that in F ACS analysis an even smaller percentage 
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(range 0 - 6 %) of the LAF cell derived veiled/dendritic cells expressed CD80 on their 
cellmembrane (see Fig. 3). CD86 expression was tested in one experiment. The 
expression was low in both freshly isolated LAF cells and their maturation products (± 
20% of the cells) both in immunocytochemistry and FACS analysis (Table I, Fig. 3). 
Table 1. Immunocytochemistry of the LAF cells and the subpopulation ofCDla+ LAF 
cells after ovemight exposure to 10-6 M dexamethasone (DEX). 
Control exposure was ovemight exposure of the cells to the vehiculum only (culture 
fluid without DEX). For the LAF cells, n = 6; for the CDla+ LAF cells, n = 4. Means 
+SD are ~ven. 
Overnight culture Overnight culture 
without dexamethasone with dexamethasone 
Freshly CDla+LAF CDla+LAF 
isolated LAF cell cell LAF cell cell 
LAF cells derived DC Derived DC derived DC derived DC 
DC 
morphology 11.0 ±3.0 39.0±l6.S 36.5 ±15.6 
HLA-DR S6.0 ±II.O 93.0±3.7 95.0±2.6 
RFDI 29.3 ±16.1 25.3 ±16.7 
L25 72.5 ±15.2 74.3 ±l2.2 
CDla 20.0±14.0 14.S ±I 1.7 14.3 ±IO.S 
CDS3 4.0±1.0 7.0±O.S 5.0±2.5 
CDI4 63.0±14.0 52.5 ±30.3 52.0 ±26.2 
CDSO 2.0 -5.0 12.4 ±7.4 14.0 ±3.7 4.2 ±3.9* 11.3 ±3.4* 
CDS6 (17) (23) 29.0 ±2.4 (15) 20.0±3.0* 
CDlla 17.S ±11.7 16.6 ±13.2 
CDllb 45.0 ±17.0 39.3 ±l5.2 31.0 ±I 1.3 16.2 ±10.7 34.6±9.0 
CDllc 57.4±24.5 56.2 ±22.4 
CDlS SI.4 ±IS.3 S9.4±7.6 
CD54 60.0 ±31.0 62.9 ±19.1 64.3 ±15.7 
CD29 S4.2±14.S 92.4±4.1 
CD49d 15.3 ±4.1 13.7±5.6 
* P < 0.05 versus control, Wilcoxon matched pairs test. -, not tested. 
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We also studied the marker expression after overnight maturation of LAF cells in the 
presence of DEX. This exposure affected neither the veiled morphology nor the 
expression ofHLA-DR. The latter was observed both in terms of number of positive 
cells (Table I), and intensity of marker expression (Fig. 3). Such exposure did also not 
affect the expression of the MHC class TI-related molecules RFDI and L25, and the 
expression of the typical DC markers CDla and CDS3. 
In immunohistochemistry, the number of CD 14 positive cells was not affected by 
DEX exposure (Table I). In FACS analysis, the level of CD 14 expression remained 
somewhat higher (for a representative example of three experiments, see Fig. 3). 
Despite the low CDSO expression, DEX prevented the upregulation during the 
ovemight maturation (Table I, immunocytochemistry: 12.4% versus 4.2% positive 
cells, n = 6,p < 0.05; Wilcoxon test). In the one experiment in which CDS6 expression 
was tested on unseperated LAF cells, DEX exposure also prevented the upreguiation 
of this costimulatory molecule both in terms of number of positive cells (Table I) and 
intensity of expression (Fig. 3). 
Although CD 11 b expression on LAF cell-derived DCs was reduced after DEX 
exposure from 39.3 to 16.2% (mean, Table I), it was not statistically significant due to 
large interindividual differences in expression. The expression of the other 
adhesionlcostimulatory molecules CD11a, CD11c, CDlS, CD29, CD49d, CD54 and 
CD5S was not affected by overnight DEX exposure, either in numerical terms (Table 
I), or in terms of expression levels (data not shown). 
CD80 and CD86 expression o/CD] a + LAF cells 
Because of the effects of DEX exposure on the costimulatory molecules CDSO and 
CDS6 on LAF cells, similar studies were performed on the CDla+ and CDla- LAF 
cell populations. The CD80 and CD86 expression was studied by FACS analysis, after 
ovemight culture with or without DEX (10-6 M). We also studied the CD 11 b 
expression of these cells. Table I gives the data, while Fig. 4 gives a representative 
example of a FACS intensity staining used in such an experiment It also appeared that 
the CDla+ LAF cells had a limited expression ofCD80 and CDS6, but slightly higher 
in comparison to the CDla- cells, ie, CDSO: 14 ±4% versus 5 ±3%; CDS6: 29 ±2% 
versus 13 ±5%, bothp < 0.05, n = 4). Exposure ofCDla+ LAF cells to DEX gave a 
significant, but very small, decrease of CDSO expression (Table I). CDS6 expression 
was clearly diminished (Table I). Overnight incubation with DEX had no effect on 
CDllb expression in CDla+ LAF cells (Table I). 
Figure 3. (next page) Flow cytometry results of a representative experiment (from 
three experiments) showing the effect of overnight maturation and the modulatory 
effect of dexamethasone (DEX) during this overnight process on the cell surface 
expression ofHLA-DR, CDSO, CD86 and CDI4 on LAF cell derived dendritic cells. 
Differences in mean fluorescence intensities (MFI) between staining with the specific 
antibody (solid line) and the IgG control (dotted line) are given in the upper left part of 
each graphs. Note that with the IgG control, there is a relatively high background of 
immunofluorescence, ie, autofluorescence. 
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Discussion 
Costimulation via CD80 and CD86 is essential for fuIl T-ceIl activation. The 
costimulaiory molecules CD80 and CD86 expressed in antigen presenting ceIls (APC) 
interact for such activation with CD28 and CTLA-4 on T ceIls, thereby delivering 
essential second signals. CD80 and CD86 expression is also essential for lung and 
other DC populations: there are various reports showing that antiCD80 and/or 
antiCD86 MoAbs interfere with T ceIl stimulation by such DC populations (24-26). 
DCs isolated from the respiratory tract of rats express relatively low levels of the 
costimulatory molecule CD80, which could indicate extreme immaturity (27). Our 
data on human BAL derived DCs agree with these animal data, and show that only a 
small fraction of human BAL-derived CDla+ LAF ceIls express CD80, i.e. 14%. 
CD86 was expressed in a larger number of the CD I a + LAF ceIls, though in no more 
than ± 30% of the ceIls. It is our experience and that of others (28), that 'immature' 
human monocyte-derived DCs (e.g. those generated by a 7-day culture ofmonocytes 
in GM-CSFIIL-4) express CD80 in ± 25% and CD86 in ± 50% of the cells. Mature DC 
populations (e.g. those from the spleen of mice, or after propagation of immature 
monocyte-derived DC in LPS and TNF -a. containing culture fluids) express higher and 
equal levels of CD80 and CD86, i.e. on 50-60% of the ceIls (29). 
CD80 and CD86 expression in APC have, in some models, different roles in 
influencing the commitment of the stimulated T cens to a Thl or Th2 pathway of 
development. For example, according to Kuckroo et al. (30) and Freeman et aJ. (31), 
CD86 more effectively directs the differentiation of T -cens towards a Th2-like 
phenotype, whereas CD80 favours a Thl development. For this reason, the relatively 
low CD80 expression of pulmonary DCs in rats, compared with the CD86 expression, 
could indicate that DCs at this location are in Th2 default; indeed, such pulmonary 
DCs have been proven to stimulate primarily Th2 pathways (27). Upon maturation of 
such rat lung DCs with GM-CSF, the cens flISt increase in CD80 expression up to the 
level ofCD86 expression and then increase in 1L-12 production capacity. At the same 
time, they loose their Th2 default (27). Since our data on human CDla+ BAL-DC are 
analogous to the rat pUlmonary DC with regard to the relatively low CD80 and CD86 
expression, it is tempting to speculate that the T-ceIIs generated by such CDla+ BAL-
DC are skewed towards a Th2 phenotype, but this needs further investigation. 
Figure 4 (next page). Flow cytometry results of a representative experiment (from 
four experiments) showing the modulatory effect of dexamethasone (DEX) on the ceIl 
surface expression of CD80 (top, a), CD86 (middle, b) and CDllb (bottom, c) in 
CDla+ BAL derived dendritic ceIls, after 16 h culture. The expression ofCD86, and to 
a lesser extend CD80, was decreased. Curve a: with addition of 10-6 M DEX, curve b: 
without DEX, and curve c: IgG-control (note with this control the relatively high 
background immunofluorescence, i.e. autofluorescence). 
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Interestingly, the other cell population of the BAL, i.e. the alveolar macrophages, has 
also been described as being defective in its expression of costimulatory cell surface 
molecules (32). This might indicate that the BAL environment is exceptional in that it 
prevents full expression of costimulating molecules on lung APC. It is of interest to 
note that our CDla+ DC population isolated from the BAL was contaminated with less 
than 2% alveolar macrophages. 
This report, moreover, shows that CDla+ DCs, ex vivo, generated from LAP 
precursors in the presence of GCs had a reduced capability to stimulate allogeneic T-
cells. This suppression was dose-dependent and occurred at various stimulator-to-T 
cell ratios (Fig. 2). The exposure to GCs also prevented the, already minor, 
upregulation of the co stimulatory molecules CD80 and CD86 during the overnight 
culture of freshly isolated LAP cells to CDla+ LAP cells. Neither the level of CDl4 
and MHC-class II expression, nor the dendritic morphology was affected significantly 
by GC. Collectively, these data could indicate that GCs force LAP cells to retain 
precursor characteristics during overnight culture. 
There are no earlier reports available on the ex vivo effect of GC exposure on the 
allostimulatory function of human BAL-derived DCs. In a rat model, in vivo DEX 
treatment caused a 50% reduction of the immunostimulatory capacity of pulmonary 
DC (33). In mice, the immunostimulatory properties of splenic DCs were reduced by 
DEX exposure in vitro (34). The mouse DCs also showed that GCs caused a selective 
downregulation of the expression of CD 80 and CD86. 
With regard to human DC populations, GCs were reported to suppress the accessory 
function of epidermal Langerhans cells ex vivo (12). Using human monocyte-derived 
DCs, van den Heuvel et al. (16) and Piemonti et al. (17) reported that GCs affected the 
differentiation and maturation of DCs, resulting in APC populations less able to 
stimulate T cells. Piemonti et al. (17) also reported that a DC-specific marker (CDla) 
and various costimulatory markers (CD40, CD86) were downregulated, while 
macrophage markers were increased (CD14, CDl6). Van den Heuvel et al. (16) could 
not confirm these latter effects. With regard to GC effects on previously differentiated 
immature human monocyte-derived DCs, exposure to GCs inhibited the production of 
IL-l, IL-6, TNF-a and IL-12p70 when the cells were additionally stimulated with LPS 
or other stimuli (14,15). One report (15) indicates that such GC exposure had no effect 
on DC marker expression and T cell stimulatory capacity of the immature DCs. Other 
reports, however, found downregulating effects on the costimulatory molecules CD40, 
CD80 (17) and CD86 (14) on the DCs, and on the T cell stimulatory capacity of the 
cells (17). Collectively, these data indicate that GCs prevent the further maturation and 
function ofDCs. 
Our data on DEX exposure on the relatively immature lung CDla+ DC are by and 
large in agreement with the literature and show a hampering of the maturation ofBAL-
derived LAP cells to DCs due to GC exposure. The overnight DEX exposure had, in 
our hands, no effect on the survival and viability of the CDla+ LAP cells, the MHC-
class II expression or the expression of adhesion molecules such as CDll, CD18 and 
CD54. Other reports indicate that GCs induce apoptosis of pulmonary DC in situ (11), 
as well as in their precursors, the monocytes, in vitro (16). It should be noted that our 
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results do not completely rule out an effect of DE X on apoptosis ofCDla+ lung DCs in 
our system (more appropriate apoptosis assays other than those involving simple 
survival and viability need to be performed for this). It seems, nevertheless, less likely 
that survival problems of the DC would be solely responsible for the reductions in T-
cell stimulatory capacity found here. 
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Chapter 8 
General discussion 
The results of recent large clinical studies (1-4) give argument to those who believe 
that inhaled glucocorticoid therapy offers no beneficial effect to patients with stable 
chronic obstructive pulmonary disease (5). Yet, inhaled glucocorticoid therapy in 
COPD is not and will not be abandoned. There are three conditions which make this 
therapy worth considering in patients with COPD. 
The first is the inconclusive definition of COPD, which makes a clear distinction 
from asthma difficult. Terms like 'asthmatic bronchitis' have been used to fill this 
gap between asthma and COPD. If records of patients with chronic respiratory 
symptoms are presented to experienced clinicians, their choices of asthma or COPD 
diagnoses are not always identical. The differentiation between asthma and COPD 
can be facilitated by additional investigations, such as high-resolution CT -scan and 
bronchial provocation testing, or by trials with oral or inhaled glucocorticoids. All 
these tests have their pros and cons. 
Secondly, the primary outcome parameter in most studies was FEY!, more 
particularly FEY! decline. This was thought to be the most important objective, 
because FEY! decline determines the prognosis of these patients. Nowadays, we are 
inclined to also taking into account other parameters, like quality of life, the 
frequency of exacerbations, and exercise tolerance. There are studies showing 
beneficial effects of inhaled glucocorticoids on one or more of these parameters 
(3,6). Future intervention studies should take into account these outcomes as well. 
The third condition is based on the understanding that COPD is a heterogeneous 
disease. Both reversible and irreversible changes contribute to the pathophysiology 
of COPD. Reversible changes are airway smooth muscle contraction, mucus 
hypersecretion and inflammation. Irreversible changes are remodelling of small 
airways, loss of alveolar attachments and proteolytic destruction of the elastic-
collagen framework. There are subgroups of COPD with asthmatic features, such as 
some degree of bronchodilator responsiveness or an increased eosinophilic airways 
inflammation. Whether the latter findings are caused by a subclinical degree of 
exacerbation is unclear. Eosinophilic granulocytes do not seem to contribute 
substantially to the inflammatory process in stable COPD, but are present in large 
numbers during COPD exacerbation (7-9). These observations have led to the idea 
that there may be subgroups of COPD patients for whom long-term inhaled 
glucocorticoid therapy is beneficial (10-12). 
The Copenhagen City Lung Study (I) included mild, asymptomatic patients with 
COPD (mean FEY! 2.36 L or 86% predicted; only 39% of the participants had an 
FEY! of <80% predicted). Inhaled budesonide at a moderately high dose had no 
effect on FEY! decline, on respiratory symptoms and on the number of 
exacerbations. 
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The EUROSCOP study (2) compared the effects of a moderate dose of inhaled 
budesonide and placebo on lung function in 912 patients with mild COPD (mean 
FEV! of77% predicted). A significant treatment effect on FEV! decline was noticed 
in the first three months. 
The ISOLDE study (3) was conducted in 990 patients with moderate-to-severe 
COPD (mean FEV! of 50% predicted). A high dose of fluticasone (2 x 500 I-'g) was 
compared with placebo. Fluticasone treated subjects showed significantly increased 
FEV! during the entire three year treatment period, improved morning peak 
expiratory flow rate, less patients drop out of the study due to respiratory causes, 
reduced number of exacerbations, and diminished decline in health status. Some of 
the differences between fluticasone and placebo increased over time, in favor of 
fluticasone. The effect of the inhaled glucocorticoid was greater in those patients 
who had deteriorated faster. 
The Lung Health Study Research Group investigated whether inhaled triamcinolone 
could slow down the decline of lung function in patients with mild-to-moderate 
COPD (4). Approximately 90 percent of the 1116 participants were current 
smokers. There appears to be no effect on FEV! decline and also none on quality of 
life scores. In the first six months of therapy, there was a small increase of the 
FEV 1, comparable to the course of the FEV! in the EUROSCOP study. Beneficial 
effects of the inhaled glucocorticoid were fewer respiratory symptoms and fewer 
unscheduled consultations to physicians for respiratory symptoms. Airway 
reactivity to methacholine improved in the triamcinolone treated patients, but this 
could be explained by the presence of patients with a diagnosis of asthma, who 
constituted almost 10 percent of the participants. In this study, the results of the 
bone density measurements showed a significant adverse effect of triamcinolone, as 
compared to placebo, on bone mineral density after three years of therapy. 
The different findings in those four studies are not necessarily contradictory; the 
results provide varying insights. First, a lower dose of anti-inflammatory therapy 
seems to evoke no or lesser effects. Second, a beneficial effect of inhaled 
glucocorticoid therapy seems to occur most likely in patients with more severe 
COPD. Remarkably, the findings of recent inhaled glucocorticoid studies are 
similar to the older oral glucocorticoid trials, because these also showed a better 
effect in those patients with COPD who had a worse lung function (13). Thes 
findings underscore the importance of further research, leading to definitions of 
subgroups of COPD patients in whom inhaled glucocorticoid therapy is likely to be 
beneficiaL 
Design of our trial 
When designing a study on inhaled glucocorticoids in COPD, we chose a subgroup 
of patients with bronchial hyperresponsiveness (BHR). Epidemiological studies 
showed a steeper decline of the FEV! in patients with COPD and BHR, suggesting 
a more severe inflammation (14). A large multicenter study on patients with 
respiratory symptoms and BHR showed a beneficial effect of an inhaled 
glucocorticoid in patients with the worst degree of BHR [expressed by PCzo] (15). 
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We decided to investigate these patients in detail in order to characterize them as 
much as possible and to detect subtle changes after inhaled glucocorticoid therapy 
or placebo. A treatment period of six months was chosen as a compromise between 
a minimal length for obtaining a steady state effect and a maximal treatment period 
for having patients motivated and for the least drop outs due to exacerbations or 
intercurrent diseases. 
Patient recruitment 
Potential candidates were recruited from the University Hospital Dijkzigt, the Sint 
Franciscus Ziekenhuis, Rotterdam, the Holy Ziekenhuis, Schiedam, the 
Zuiderziekenhuis, Rotterdam, and the Schieland Ziekenhuis, Schiedam. 
Approximately 200 patients were considered to fulfill the inclusion criteria of the 
study and received an invitation for participating in our trial. Eventually, there were 
23 patients who completed the trial, having visited our hospital 15 times in the 6 
months study period. There was no patient dropping out of the study after he or she 
was found to be eligible. The reasons for not participating in the study were (in 
order of frequency): concomitant disease or medication (especially NSAIDs and 
anticoagulant medication for heart disease), lack of time, severity of the study and 
exclusion because of lung function results. There was only one patient in whom 
BHR was no longer present at the first visit, after having had a low PC20 several 
years before. In two patients, meeting the clinical criteria for COPD, PCzo for 
histamine was above 8 mg/mL 
Initial characterization of trial participants 
We have started with lung function testing in order to characterize the participants 
of the trial in terms of pathophysiology. The patients had on average moderately 
severe obstruction (mean FEV j 65% predicted) according to ERS criteria (16). The 
degree of BHR was moderate or severe: mean PC20 for methacholine: 3.5 mg/mL 
One of our major interests was the interrelationship of the mechanical behavior of 
the lungs and the different indexes of the methacholine log dose-response curve. 
Estimates of the mechanical behavior of the lungs and of the integrity of the lung 
parenchyma were obtained from pressure-volume curves with the aid of an 
esophageal balloon, and the single-breath carbon monoxide (CO) transfer. In 
accordance with earlier observations, correlations were significant between indexes 
of the pressure-volume curve and CO diffusion. Bronchial provocation tests were 
performed as complete as possible in order to obtain a reliable plateau value. A 
model fit (17) was applied to it for the estimate of the slope of the curve (reactivity) 
and maximal airways constriction (plateau). PC20 was calculated from the 
interpolation of two adjacent points in the log dose-response curve. None of the 
indexes of the bronchial provocation test was correlated with any parameter of lung 
parenchymal destruction. This means that in patients with COPD who continue 
smoking, there is no straightforward influence of loss of elasticity on contractile 
mechanisms. There is one study showing a correlation between lung parenchyma 
destruction and maximal airways constriction in patients with a -l-antitrypsine 
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deficiency who did not smoke (18). The participants in our study were moderate or 
heavy smokers. So, it appears that smoking and the following small-airways 
inflanunation were confounders with respect to the degree of BHR. In other words, 
inflanunation of small airways seems to be the most important mechanism 
contributing to the degree ofBHR in COPD. 
We found a significant correlation of both PCzo and reactivity (the slope of the 
curve) with the starting FEV]. The correlation of the starting FEV] and PC20 is well 
known and predictable from a mathematical point of view. First, the definition of 
PC20 (as a percentage and not an absolute change of FEV]) makes that small 
changes in narrow airways give a greater percent change as compared to similar 
changes in larger airways. Secondly, resistance to airflow depends on airway lumen 
and according to the law of Poisseuille the (laminar) resistance is inversely 
proportional to the radius with power fOUf. From this, large increases of resistance 
result from small decreases of the diameter of the small airways. So, PCzo is not 
only a determinant of airways pathology but is also influenced by physical 
mechanisms, depending on severity of airway obstruction. 
There are several methods of expressing the effect of a bronchodilatory drug on 
airflow, particularly the FEV], by taking into account the starting FEV]. We have, 
in a similar way, made calculations with the bronchoconstrictory responses 
provoked by methacholine. We found that the correlation of PCzo and the starting 
FEV] is lost if the change of FE V] is expressed as percentage of the predicted value: 
"normalized PCzo". When correlating PC20 with eosinophilic airways infiltration, as 
determined by the number of eosinophils in bronchial biopsies, there was no 
significance. However, there was a significant (negative) correlation between 
eosinophil numbers and normalized PCzo. This implies two things: first, the 
normalized PCzo is a better indicator of eosinophilic airways inflanunation, and 
secondly, for predicting a beneficial response of (inhaled) glucocorticoid therapy 
the normalized PCzo appears to be a better tool than the standard PCzo. The last 
statement is based on the observation that a beneficial effect of inhaled 
glucocorticoids in COPD can be expected with increasing numbers of eosinophils in 
sputum (10). 
We have also tested correlations of other cell types with PCzo, the slope and the 
plateau of the methacholine dose-response curve. There were no correlations, 
suggesting that it is not the number of individual inflanunatory cells but perhaps 
cell activity or airway remodeling, such as swelling of the small-airways walls, that 
contributes to BHR in COPD. 
Effects of inhaled fluticasone propionate 
In accordance with earlier studies, there was no significant effect of an inhaled 
glucocorticoid on PC20 (19-21). There was also no significant effect on the slope of 
the curve, the plateau and ECso (= dose of methacholine causing 50% of the 
maximal effect), which has not been published before. The rightward shift of the 
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methacholine dose-response curve and the decrease of the maximal degree of 
bronchoconstriction (plateau), which occur in patients with asthma after inhaled 
glucocorticoid therapy, were not observed in patients with COPD (fig. 3, chapter 4). 
This, again, indicates that BHR in COPD and in asthma are different phenomena. 
In the placebo treated subjects lung function declined fast, which is in accordance 
with the observations from several epidemiological studies (eg. ref. 14). The 
withdrawal of glucocorticoids could also have contributed to this exaggerated 
decline. Similarly, investigators of the ISOLDE trial noticed during the run-in 
period a significant number of exacerbations after discontinuation of inhaled 
corticosteroids (22). The FEV, of the patients with FP therapy remained almost 
unchanged, and this difference between FP and placebo was highly significant. 
When comparing the different maximal expiratory flow rates, the impression arises 
that the treatment effect originates from an effect on the small airways. 
Unfortunately, we were unable to collect small airways for immunopathological 
investigations. A surrogate measurement of the events in the small airways could be 
bronchoalveolar lavage (BAL). We performed BAL at the start and after six months 
of the intervention period, and harvested two fractions: the first as a bronchial 
fraction and the second as a bronchoalveolar fraction. We measured cell numbers 
and cell activation markers in both samples and were unable to find significant 
changes after placebo or FP therapy. So, these results provided us with no clues for 
the effect of fluticasone on lung function. 
Also, we measured cell numbers and cell activation markers in blood. There were 
no significant changes attributable to either glucocorticoid therapy or glucocorticoid 
withholding. 
However, there were significant changes of cell numbers in biopsy specimens taken 
from the larger airways. The most obvious observation was the increase of the 
number of eosinophils in the patients with placebo and the decrease of eosinophils 
in the patients with FP therapy, suggesting a state of exacerbation in the first and a 
glucocorticoid effect in the last ones. Decreased influx of cells and accelerated 
apoptosis of eosinophils in tissue are well known effects of glucocorticoid therapy 
in subjects with asthma and this also seems to happen in our patients with COPD. 
We were unable to detect an effect on symptoms, probably because we used a 
questionnaire (adapted from the questionaire of the Medical Research Council), that 
turned out to be inappropriate for this study. The use of rescue medication was not 
appreciably different between the two groups of patients. Disease related adverse 
events were significantly more often reported by placebo patients as compared to 
FP treated patients. These adverse events included candidiasis of mouth, stomatitis, 
irritation of pharynx, upper respiratory tract infection, acute bronchitis, and (mild) 
increase of airways obstruction. 
Mediators of inflammation 
We measured arachidonic acid metabolites in bronchoalveolar fluid, before and 
after inhaled fluticasone therapy or placebo. We observed significant decreases of 
the concentrations of PGE2, 6kPGF,u and PGF2u after fluticasone therapy. PGF2u 
112 
has strong bronchoconstrictor activity and reduction of its concentration could be 
one of the mechanisms by which FEV, decline was abolished during FP therapy. 
On the other hand, 6kPGF, CI and PGE2 are known in asthma for causing 
bronchodilation and edema. Reduction of edema and decrease of swelling of the 
walls of small airways could have contributed to the observed effect on FEV,. 
There is little information about the relative effects of these mediators on the 
bronchomotor tone, and none about their contribution to airway small muscle tone 
in COPD. The concentrations of the mediators in our COPD patients were 
compared with those of a control group consisting of smokers without symptoms 
and normal lung function, and also with the results of an earlier study of our 
department using the same methodology in asthma patients and in asymptomatic 
smokers. There were clear differences with asthma, in which concentrations of 5-
lipoxygenase products (predominantly leukotrienes) were higher, while in COPD 
and in smokers the concentrations of cyclooxygenase products (predominantly 
prostaglandins) were increased. From this we concluded that the function of 
inflammatory cells in COPD patients with BHR differs in a qualitative manner from 
asthma and resembles the responses induced by smoking. 
Oxygen radicals 
In an attempt to quantify the capability of inflammatory cells to produce reactive 
oxygen species (ROS), bronchoalveolar ceIls were separated in order to perform 
kinetic assays. These cell fractions consisted almost exclusively of alveolar 
macrophages. Cells from the bronchoalveolar lavage were tested for stimulated 
ROS production, before and after the 6-months intervention period with fluticasone 
or placebo. We found neither effect of fluticasone therapy nor placebo on ROS 
production capability. Other studies were also unable to demonstrate a significant 
effect of an inhaled glucocorticoid on ROS production by sputum derived cells 
(23,24). In our study the concentrations of ROS were low as compared to previous 
studies in which macrophages were tested. The correlations of ROS production and 
patient characteristics were therefore calculated. Actual smoking (the number of 
cigarettes being smoked per day) was negatively correlated with ROS production, 
indicating that heavy smoking had either stimulated intraceIlular counter effects 
against excessive ROS production, or had exhausted macrophages after repetitive 
stimulation. While the general feeling tends towards increased capability of ROS 
production as an effect of smoking, the last thought seems to be the most applicable. 
The finding of a decreased ROS production capability in heavy smokers could be an 
attractive explanation for the vulnerability to bacterial infections or bacterial 
colonization. The oxidative processes in the waIls of the smaIl airways and in the 
alveolar walls could however be different (higher?) from what we observed in our 
study. 
Role of dendritic cells 
In asthma, dendritic [or: antigen-presenting] cells are important for the initiation 
and regulation of the characteristic inflammatory response. Dendritic cells are 
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present in the bronchial wall of patients with asthma in significant numbers. After 
glucocorticoid therapy their number decreases, possible due to a decreased influx. 
In bronchial biopsies derived from COPD patients, dendritic cells were hardly 
detectable, whereas phagocytic cells were present in large numbers. It appears, 
Table 1. Overview of the investigated items in the patients with COPD and BHR, 
and the effects of treatment with inhaled fluticasone propionate. No negative effects 
occurred. 
Beneficial No 
effect effect 
Blood Cells .,. 
Cells activation markers 
.,. 
Cortisol 
.,. 
Lung function PC20 
.,. 
Reactivity .,. 
Plateau 
.,. 
.,. 
EC,o 
FEV1 
.,. 
FEV1IFVC 
.,. 
MEF50 
.,. 
.,. 
MEF25 
FVC .,. 
PEF 
.,. 
Broncho- Cellularity .,. 
Alveolar Dendritic cells .,. 
Lavage Reactive oxvgen species .,. 
LTB4 .,. 
LTCJDJE4 
.,. 
TxB2 
.,. 
PGE2 .,. 
6kPGF1u 
.,. 
PGF2C1 
.,. 
Immunostain- CD3 .,. 
positive cells in CD4 
.,. 
bronchial CD15 
.,. 
.,. 
biopsies CDla 
CD8 .,. 
MBP 
.,. 
CD68 
.,. 
.,. 
tryptase 
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therefore, that the inhaled toxic substance, namely cigarette smoke, is handled in a 
different way in COPD, as compared to asthma, in which the causative inhaled 
particles are allergens. Next to particle size, intrinsic factors seem to play an 
important role. In asthma it is the inherited tendency to react with an allergic 
response to allergens and in COPD it is the susceptibility to cigarette smoke and/or 
similar particles that causes the disease. Asthma could be a disorder resulting from 
an abnormal dendritic cell function, while COPD is a macrophage or neutrophil 
driven disease. One of the most intriguing problems to be solved is whether there 
are intrinsic defects in dendritic cells or macrophages or their enviromnent, which 
causes either one disease. 
Effect of glucocorticoids on dendritic cell function 
The collection, selection and sorting of dendritic cells from bronchoalveolar lavage 
cells enabled us to perform ex vivo functional studies of dendritic cells. We have 
started with investigating cells derived from smoking subjects without lung disease. 
Typical dendritic cells, which were sorted with the aid of cell fluorescence 
characteristics and relevant cell surface markers, showed the highest potency for 
activating T -lymphocytes. After incubation with dexamethasone this function was 
decreased in a dose-dependent way, and this decrease was associated with a 
reduction of the expression of cell surface markers involved in co-stimulation. 
These ex vivo studies were performed prior to our in vivo studies with inhaled 
glucocorticoids in both asthma and COPD patients. The results from the patients 
with COPD and BHR indicate that dendritic cells derived from the bronchoalveolar 
lavage fluid are not influenced by inhaled glucocorticoid therapy. 
Conclusion 
Taking the above-mentioned results into account, our study of bronchial 
hyperresponsiveness in patients with COPD has given some intriguing new 
findings. BHR in COPD differs from BHR in asthma in several respects. 
Pathophysiological mechanisms, apart from FEV [, are not responsible for the 
degree of BHR. There is an abundant inflammatory response, which is reflected, for 
instance, by a high number of cells in BAL fluid. The inflammatory characteristics 
of COPD and BHR show greater resemblances to "healthy smokers" than to 
asthma. Heavy smoking influenced several functions of the inflammatory cells from 
the patients with COPD. The finding of high levels of cyclooxygenase products is 
of interest because the release of eicosanoids from various inflammatory cells is 
involved in the observed BHR induced by repeated exposure of airways to cigarette 
smoke. This deserves further attention. Next to the beneficial effects of inhaled 
fluticasone, which we observed, prostaglandin antagonists could be important for 
the long-term management of COPD. The lung function of placebo treated patients 
deteriorated while FEV! remained stable in the patients with fluticasone therapy. 
This was accompanied by changes in cell numbers in bronchial biopsies, of which 
the effect on eosinophils was most significant. BHR appears to be a characteristic of 
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COPD, which predicts a beneficial response to long-tenn inhaled glucocorticoid 
therapy. Future intervention studies in COPD should incorporate the measurement 
ofBHR. 
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Chapter 9 
Summary 
This thesis describes a detailed investigation of a subgroup of smoking COPD 
patients, particularly those with bronchial hyperresponsiveness (BRR). We 
speculated that inhaled fluticasone propionate could have beneficial effects in these 
patients, who suffer from an exaggerated FEV! decline and a worse prognosis. 
In chapter 1 the current knowledge about BRR in patients with COPD is 
summarized in the first section. Clinical studies indicate that BRR in patients with 
COPD differs in several ways from the BRR observed in patients with asthma. 
Next, inflammation in COPD is discussed, especially pathologic changes and the 
contribution of various cell types. In COPD the most prominent cells in the 
peripheral airways are monocytes/macrophages, neutrophils and CD8+ 
lymphocytes. The inflammatory infiltrate in patients with COPD and BRR has 
gained almost no attention. In the last section of chapter 1, the results of previous 
studies with glucocorticoid therapy in patients with stable COPD are summarized. 
One of the conclusions is that g1ucocorticoids appear to have at least some 
beneficial effects in certain patients with COPD. At this moment, the patients 
benefitting from longterm glucocorticoid therapy are those with 'asthmatic 
features', those with severe airways obstruction and those with rapidly declining 
lung function (FEV!). 
In chapter 2 the results of the functional studies of patients with COPD and BRR 
are presented. Our main interest was the interrelationship of the mechanical 
behavior of the lungs with the different indexes of the methacholine log dose-
response curve. In accordance with earlier observations, correlations were 
significant between indexes of the pressure-volume curve and CO diffusion, be it 
exclusively with the CO diffusion after correction for alveolar volume, which is a 
better estimate for the condition of the lung parenchyma than CO transfer as such. 
A model fit was applied to the results of the methacholine dose-response curves for 
the estimate of the slope of the curve, the plateau value, and EC". None of the 
indexes of the bronchial provocation test correlated with any parameter of lung 
parenchymal destruction. This means that, in patients with COPD who smoke, there 
is no straightforward influence of loss of elasticity on contractile mechanisms. It 
appears that inflammation of small airways is the most important mechanism 
contributing to the presence and the degree ofBRR in patients with COPD. 
In chapter 3 we performed calculations on the expression of the most often used 
index of BRR, PC20• We confirmed earlier observations of a correlation between 
PC20 and the baseline FEV!. This correlation is predictable from a mathematical 
point of view. By expressing the FEV! response as percent predicted, we defined 
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the log2nPC2o• The log2nPC2o showed no correlation with the baseline FEV1• Next, 
we compared the levels of iog2PC20 and log2nPC2o with eosinophilic airways 
inflammation, as determined by the number of eosinophils in bronchial biopsies. 
There was a significant (negative) correlation only between eosinophil numbers and 
log2nPC2o • The 10g2nPC2o appeared to be a good indicator of eosinophilic airways 
inflammation. Several studies have shown that (inhaled) glucocorticoid therapy in 
patients with COPD is more likely to be beneficial when increased numbers of 
eosinophils are present in induced sputum. The calculation of iog2nPC20 could 
replace the procedure of sputum induction. 
In chapter 4 the effects of treatment with fluticasone propionate (FP) inhalation on 
lung function and inflammation are shown. At the start of the intervention, the 
inflammatory profile in bronchial biopsies from the patients with COPD and BHR 
was compared to a control group, which consisted of smokers without symptoms 
and with normal lung function. There were no significant differences, which 
indicates that the inflammatory profile of BHR in COPD is similar to smoking-
induced changes. We observed that dendritic cells were hardly detectable in the 
bronchial biopsy specimens, contrary to our previous findings in patients with 
asthma. Dendritic cells do not seem to be involved in the inflammatory process in 
COPO. 
In accord with earlier studies, there was no significant effect of the intervention on 
PC20 • There was also no significant effect on the other derivatives of the 
methacholine dose-response curve (Fig. 3, Chapter 4: the slope of the curve, the 
plateau value and the ECso). 
In the placebo treated patients, lung function declined fast, while FEV 1 of the FP 
treated patients remained almost unchanged. This difference was statistically and 
clinically significant. Comparison of the different maximal expiratory airflows 
suggests that the treatment effect originates from an effect in the small airways. 
This was accompanied by changes in cell numbers in bronchial biopsies, of which 
the effect on eosinophils was most significant: their number increased in placebo 
treated patients and decreased in FP treated subjects. 
We conclude that inhaled fluticasone causes beneficial effects in patients with 
COPD and BHR during a six-month treatment period. 
In chapter 5, results are described of the measurements of arachidonic acid 
metabolites in bronchoalveolar fluid, before and after inhaled FP therapy and 
placebo, in the same group of patients with COPD and BHR. We observed 
significant decreases of the concentrations of PGE2, 6kPGF I U and PGF 2U after FP 
therapy. PGF2u has strong bronchoconstrictor activity and reduction of its 
concentration could be one of the mechanisms by which FEV1 decline was 
abolished during FP therapy (chapter 3). We compared the levels of the mediators 
in our patients with COPD with the results of earlier studies in our institution using 
the same methodology in patients with asthma and in asymptomatic smokers with 
normal lung function. There were clear differences between COPD and asthma. 
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In asthma, concentrations of 5-lipoxygenase products were higher, while in COPD 
and in 'healthy' smokers the levels of cyclooxygenase products were increased. The 
function of inflammatory cells in COPD patients with BHR appears to differ from 
asthma in a qualitative manner, and resembles the changes induced by smoking. 
In chapter 6 we reported the results of an attempt to quantifY the process of 
reactive oxygen species (ROS) production in COPD. Oxidative stress is one of the 
important pathogenic mechanisms in COPD. Bronchoalveolar lavage cells, mainly 
consisting of alveolar macrophages, were tested for PMA-stimulated ROS 
production, before and after the trial with FP and placebo. We found neither FP 
therapy nor placebo had any effect on ROS production. In our patients the 
concentrations ofROS were low compared to previous studies. Actual smoking (the 
number of cigarettes smoked per day) was negatively correlated with ROS 
production, indicating that heavy smoking had either stimulated intracellular 
counter effects against excessive ROS production, or had exhausted macrophages 
after repetitive stimulation. The fmding of a decreased ROS production capability in 
heavy smokers could be an explanation for the vulnerability to bacterial infections 
or bacterial colonization. The oxidative processes in the walls of the small airways 
and in the alveolar walls could nontheless be different from what we observed in 
our assay. 
The last chapter (7) describes functional studies of ex vivo dendritic cells, derived 
by means of bronchoalveolar lavage from subjects who smoke and have no lung 
disease. Typical dendritic cells, which were sorted with the aid of cell fluorescence 
characteristics and typical cell surface markers, showed the highest potency for 
activating T lymphocytes. After incubation with dexamethasone this function was 
decreased in a dose-dependent way, and this decrease was associated with a 
reduction of the expression of cell surface markers involved in co-stimulation. 
These ex vivo studies were performed prior to our studies with inhaled 
glucocorticoids in patients with asthma and in patients with COPD. The results 
from the patients with COPD and BHR indicate that the appearance and the 
function of dendritic cells derived from bronchoalveolar lavage are not influenced 
by inhaled glucocorticoid therapy which lasted for six months. 
In short, we have investigated in detail a subgroup of smoking COPD patients, 
particularly those with bronchial hyperresponsiveness, because we speculated that 
therapy with inhaled fluticasone propionate could have beneficial effects. We 
observed that the inflammatory infiltrate in bronchial biopsies and the cellularity of 
BAL had characteristics comparable to smoking-induced changes rather than those 
observed in asthma. BHR was not influenced by mechanical factors related to 
reduced elasticity of the lung parenchyma. None of the indexes of BHR were 
affected by fluticasone therapy. The lung function of placebo treated patients 
deteriorated while FEV I remained stable in the patients with fluticasone therapy. 
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This was accompanied by changes in cell numbers in bronchial biopsies, of which 
the effect on eosinophils was most significant. We were unable to find significant 
effects of fluticasone on the ex vivo reactive oxygen species production of BAL 
cells. The concentrations of cyclooxygenase products involved in bronchial 
narrowing were significantly reduced. 
These results indicate that a subgroup of patients with COPD, particularly those 
with bronchial hyperresponsiveness, benefit from therapy with inhaled fluticasone. 
Our results are a strong argument for testing bronchial responsiveness in COPD 
patients, if one is in doubt of prescribing inhaled glucocorticoids. However, this 
policy should be confirmed by a placebo-controlled trial in which bronchial 
responsiveness, among other characteristics, is estimated at the start of the study. 
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Samenvatting 
In dit proefschrift wordt een onderzoek beschreven bij patienten met COPD 
(Chronic Obstructive Pulmonary Disease; chronisch obstructieve longaandoening). 
Onder COPD worden die long- aandoeningen verstaan met een algehele 
vemauwing van de luchtwegen, die in de loop van de tijd geleidelijkaan verslechtert 
en niet duidelijk verbetert na gebruik van medicijnen die de luchtwegen verwijden. 
Algemeen bekend zijn de ziektebeelden 'chronische bronchitis' en 
'emphyseem' !'uitgerekte longen', die vaak samen voorkomen en tegenwoordig 
COPD genoemd worden. Bij patienten met COPD, vooral als zij blijven roken, 
verslechtert de longfimctie sneller dan bij de leeftijd past. Ais patienten met COPD 
ook nog een bronchiale hyperreactiviteit hebben, gaat hun longfimctie nog sneller 
achteruit, wat betekent dat zij meer k1achten hebben en eerder zuHen overlijden. 
Bronchiale hyperreactiviteit is een overrnatige prikkelbaarheid van de luchtwegen. 
Dit kan door de patienten ervaren worden, bijvoorbeeld een scherpe lucht die 
hoesten of kortademigheid geeft. Het kan ook in het longfimctie-laboratorium 
gemeten worden, door de reactie op de uitademing te bepalen na het inademen van 
histamine of methacholine. Bronchiale hyperreactiviteit wordt bij vrijwel aile 
patienten met astma gevonden en bij ongeveer de helft van aile patienten met 
COPD. Het hier beschreven onderzoek richt zich op de kenmerken van bronchiale 
hyperreactiviteit bij patienten met COPD, en op het effect van een zes maanden 
durende, ontstekingsremmende behandeling, namelijk met een glucocorticoid per 
inhalatie: fluticasone propionaat. 
In hoofdstuk 1 wordt de huidige kennis omtrent bronchiale hyperreactiviteit (BHR) 
bij COPD samengevat. Er bestaan verschillen tussen de BHR die bij COPD wordt 
gevonden en de BHR bij astma. Vervolgens wordt het ontstekingsproces in de 
longen van patienten met COPD besproken. Er zijn duide1ijke verschillen tussen het 
ontstekingsproces bij COPD en bij astma. Over het ontstekingsproces bij patienten 
met COPD en BHR is nauwelijks iets bekend. Tenslotte worden in het eerste 
hoofdstuk de effecten beschreven van (inhalatie) glucocorticoiden bij patienten met 
COPD. Deze effecten zijn beduidend minder uitgesproken dan bij astma. Echter bij 
bepaalde patienten met COPD worden wei gunstige effecten waargenomen. Dit zijn 
COPD patienten met astmatische kenmerken, met een emstige luchtweg 
vemauwing en met een snel verslechterende longfimctie. 
In hoofdstuk 2 wordt beschreven wat de relatie is tussen enerzijds BHR en 
anderzijds afwijkingen van de longfunctie die specifiek zijn voor patienten met 
COPD. De meest opvallende daarvan is het verlies van elasticiteit van het 
longweefsel. Wij von den geen relatie tussen de mate van BHR en de ernst van het 
verlies van long elasticiteit. Dit betekent dat BHR bij patienten met COPD 
veroorzaakt wordt door een overrnatige contractiliteit van de gladde spieren in de 
k1eine luchtwegen, onafhankelijk van de elasticiteit van het longweefsel. 
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In hoofdstnk 3 hebben wij onderzocht hoe de relatie is tussen enerzijds BHR en 
anderzijds de ontsteking in de luchtwegen van patienten met COPD. In tegenstelling 
tot bij astma vonden wij geen verband tussen de mate van BHR (de PC20) en 
ontsteking, die uitgedrukt werd in het aantal eosinofiele granulocyten in biopten uit 
de grote luchtwegen. Conform eerdere bevindingen was er een correlatie tussen de 
PC20 en de longfunctie (FEV, bij aanvang van de hyperreactiviteitstest). Daarom 
hebben wij een alternatieve manier van uitdrnkken van de PC20 gedefinieerd: de 
log2nPC2o. Deze waarde was onafhankelijk van de aanvangs-FEV" en wei 
gerelateerd aan het aantal eosinofiele granulocyten in de wand van de luchtwegen. 
De log2nPC2o kan dus als een indicator voor de eosinofiele luchtweg-ontsteking 
worden gebruikt. 
Hoofdstnk 4 handel! over de effecten van fluticasone propionaat, vergeleken met 
placebo behandeling, op ontsteking en longfunctie bij COPD patienten met BHR. 
Eerst werden de uitgangswaarden vergeleken met een controle groep van rokers 
zonder luchtweg-klachten en met een normale longfunctie. Het ontstekingsinfiltraat 
in de grote luchtwegen bij de patienten met COPD was gelijk aan dat in de controle 
groep, dus vooral door het roken bepaald. Fluticasone had geen enkel significant 
effect op de BHR. De FEV, van de placebo groep daalde sterk, terwijl de FEV, bij 
de patienten die fluticasone inhaleerden vrijwel onveranderd bleef. De sterke daling 
van de FEV, werd dus door de actieve behandeling gestopt. Bestudering van de 
overige longfunctie parameters geeft aanwijzingen dat er een effect op de kleine 
luchtwegen is. Er waren kleine, significante veranderingen in het 
ontstekingsinfiltraat, waarvan het meest opvallend was de stijging van het aantal 
eosinofiele granulocyten in de biopten van de grote luchtwegen in de placebo groep, 
terwijl dit aantal daalde in de met fluticasone behandelde patienten. Fluticasone 
heeft dus een beschermend effect op de longfunctie op basis van een afname van het 
aantal ontstekingscellen in de wand van de luchtwegen. 
Hoofdstuk 5 beschrijft de metingen van ontstekingsmediatoren, afkornstig van 
ontstekingscellen. Bij astma spelen deze stoffen een belangrijke rol bij het 
ontstekingsproces, en veroorzaken o.a. vernauwing van de luchtwegen. Bij COPD is 
nog nauwelijks onderzoek gedaan naar het v66rkomen van ontstekingsmediatoren. 
Wij hebben deze stoffen gemeten in de bronchoalveolaire lavage vloeistof van 
patienten met COPD en BHR, v66r en na behandeling gedurende zes maanden met 
fluticasone of placebo. De concentraties van drie van de gemeten stoff en, namelijk 
de prostaglandines E2, F, u en F 2U namen af na behandeling met fluticasone. Van 
deze is prostaglandine F2u een sterke bronchoconstrictor, en de daling in 
concentratie kan dus een van de verklaringen zijn voor de effecten, die wij zagen op 
de FEV, (zie hoofdstuk 4). Bij de patienten met COPD waren de concentraties van 
de mediatoren vergelijkbaar met die gevonden bij rokers zonder luchtweg-klachten 
en een normale longfunctie. Bij patienten met COPD en BHR zijn de concentraties 
van de prostaglandines verhoogd, terwijl bij astma vooral de leucotrienes verhoogd 
aanwezig zijn. 
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In hoofdstuk 6 worden de resultaten besproken van de metingen van de productie 
door ontstekingscellen van zuurstofradicalen. Effecten van zuurstofradicalen spelen 
een belangrijke rol bij het ontstaan van COPD. Wij hebben cellen uit de 
bronchoalveolaire lavage vloeistof (voornamelijk alveolaire macrophagen) 
gestimuleerd tot het produceren van zuurstofradicalen, veer en na een zes maanden 
durende behandeling met fluticasone of placebo. Het bleek dat de aldus verkregen 
cellen betrekkelijk geringe hoeveelheden zuurstofradicalen produceerden, en dat dit 
niet veranderde na fluticasone of placebo. Onderzoek naar correlaties russen 
zuurstofradicaalproductie en klinische kenmerken van de patienten met COPD 
toonde dat (veel) roken een negatieve invloed had op het verrnogen tot productie 
van zuurstofradicalen. Het is mogelijk dat dit een verklaring is voor het feit dat 
COPD patienten een verhoogde vatbaarheid hebben voor bacteriele infecties en 
v~~r bacteriele kolonisatie van de luchtwegen. Een open staande vraag blijfi 
naruurlijk wat er gebeurt in de wanden van de luchtwegen en de alveoli van 
patienten met COPD. 
Het zevende en laatste hoofstuk beschrijfi het onderzoek naar de functies van 
dendritische (of: antigeen-presenterende) cellen bij gezonde proefjJersonen, 
voornamelijk rokers. Dit onderzoek ging vooraf aan onderzoeken bij patienten met 
COPD en BHR, en bij patienten met astrna. Dendritische cellen werden verkregen 
uit de bronchoalveolaire lavage vloeistof door het sorteren op specifieke cel 
eigenschappen. De typische (CDla positieve) dendritische cellen waren de sterkste 
stimulatoren v~~r de deling van T Iymfocyten. Wanneer dexamethason aan het cel-
medium werd toegevoegd, vonden wij een remming van dit stimulerende effect, wat 
afhankelijk was van de dosering van dexamethason. 
Dezelfde onderzoeken werden gedaan bij de eerder beschreven patienten met 
COPD en BHR, veer en na behandeling met fluticasone of placebo per inhalatie. 
Hier werden geen significante effecten gevonden van fluticasone en placebo. 
Conclusie 
In dit proefschrifi worden de resultaten beschreven van het onderzoek van een 
subpopulatie van patienten met COPD, namelijk die met bronchiale hyperreactiviteit 
(BHR). Wij veronderstelden dat deze patienten een emstige mate van ontsteking van 
de luchtwegen hebben waarvoor onderhoudsbehandeling met een inhalatie 
glucocorticoid (fluticasone propionaat) significant guostige effecten heefi. 
Er werd een ontstekingspatroon gevonden wat niet significant verschilde van rokers 
zonder luchtweg-klachten en met een norrnale longfunctie, terwijl er weI verschillen 
waren met eerder gepubliceerde gegevens over ontsteking bij patienten met astrna. 
Behandeling met fluticasone gaf geen verandering van een van de parameters van 
bronchiale hyperreactiviteit. Volgens verwachting was er een sterke daling van de 
longfunctie van de patienten die placebo kregen. De FEV! van de patienten met 
fluticasone bleef echter vrijwel onveranderd. In de biopten van de beide groepen 
patienten werden na behandeling significante veranderingen gezien ten guoste van 
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fluticasone. Ook werden er significant effecten van fluticasone gevonden op bepaalde 
ontstekingsmediatoren. 
Deze resutaten tonen aan dat er een gunstig effect te verwachten is van 
onderhoudsbehandeling met fluticasone propionaat bij COPD patienten met 
bronchiale hyperreactiviteit. Onze resultaten zijn een argument voor het testen van 
bronchiale reactiviteit wanneer men twijfelt over het voorschrijven van een inhalatie 
glucocorticoid bij patienten met COPD. Deze aanpak verdient bevestiging in 
interventie-onderzoeken bij patienten met COPD, waarbij de bronchiale reactiviteit 
als een van de uitkomstpararneters wordt genomen, of minimaal bij aanvang wordt 
gemeten. 
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